Advancing the World
of Veterinary Medicine.
2021 ANNUAL REPORT
NASDAQ: CVET
covetrus.com
There is still much to be done to deliver Covetrus’ full
potential within the attractive and growing animal
health market, and I am proud of all the progress the
team has made over the last two years. In 2021, we
accelerated our pace of innovation, we strengthened
our value proposition to our veterinary practice
customers and their pet owner clients and with our
manufacturer partners, and we grew our technology
footprint. We continue to steadily push forward
towards our end goal of becoming the leading
global technology-enabled veterinary healthcare
solutions company.
Everything Covetrus does is centered on helping
veterinarians thrive and drive better health and
business outcomes. We have the tools needed for
a veterinarian to address their primary day-to-
day challenges, improve their practice workflow,
and continue to grow their business. In 2021, our
technology platform only got stronger, and we
continued to scale our technology solutions and
proprietary brands, strengthening our ability to
support veterinarians’ delivery of animal care.
Looking to 2022, we have exciting product launches,
including: an innovative cloud-based veterinary
operating system in the U.S.; our first international
cloud-based practice management solution, Ascend,
offered in the U.K., Australia and New Zealand;
new features added to our on-premise software
solutions; and a next generation storefront that
will significantly improve the consumer experience
and drive increased revenue for our veterinary
practice customers.
We have a solid foundation in place, a clear plan, and
visibility looking forward to delivering accelerated
growth in 2022. Our end-market is attractive and
durable, and we are aggressively investing in our
platform to enhance our value proposition and
secure new business.
I am confident in our strategy and encouraged by
the momentum we have in the core drivers of our
business. I believe we have a solid blueprint and
the team to execute it, as we drive sustainable
shareholder value creation.
Sincerely,
Ben Wolin
President and Chief Executive Officer
Ben Wolin
President and Chief Executive Officer
Do good.
Be passionate.
Never settle.
Share the customer goal.
Give power.
Driving better
outcomes and
animal care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 10-K
___________________________
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
Commission file number 001-38794
_________________________
COVETRUS, INC.
(Exact name of registrant as specified in its charter)
___________________________
Delaware
83-1448706
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
7 Custom House Street
Portland, ME 04101
(Address of principal executive offices)
(888) 280-2221
(Registrant’s telephone number, including area code)
___________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Ticker Symbol
Name of Exchange on Which Registered
Common Stock, par value $0.01 per share
CVET
Nasdaq Global Select Market
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes
x No
o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes
o
No
x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
Yes
x No
o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).
Yes
x No
o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued
its audit report.
☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐
No
☒
The aggregate market value of the voting common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business
day of the registrant's most recently completed second fiscal quarter, June 30, 2021, was approximately $2.8 billion.
The registrant had 138,136,146 shares of common stock outstanding as of February 18, 2022.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement of Registrant for use in connection with the 2022 Annual Meeting of Shareholders (our “2022 Proxy Statement”), are incorporated
by reference into Part III of this report.
COVETRUS, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2021
TABLE OF CONTENTS
Page
Glossary of Defined Terms and Abbreviations
3
PART I
Item 1.
Business
6
Item 1A. Risk Factors
17
Item 1B. Unresolved Staff Comments
30
Item 2.
Properties
30
Item 3.
Legal Proceedings
31
Item 4.
Mine Safety Disclosures
31
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity
Securities
32
Item 6.
[Reserved]
33
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
34
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
47
Item 8.
Financial Statements and Supplementary Data
48
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
86
Item 9A. Controls and Procedures
86
Item 9B. Other Information
87
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
87
PART III
Item 10. Directors, Executive Officers, and Corporate Governance
87
Item 11. Executive Compensation
87
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
87
Item 13. Certain Relationships and Related Transactions and Director Independence
87
Item 14. Principal Accountant Fees and Services
87
PART IV
Item 15. Exhibits and Financial Statement Schedules
88
Item 16. 10-K Summary
90
SIGNATURES
91
Covetrus, Inc. 2021 Form 10-K
2
AAFCO
Association of American Feed Control Officials
Acquisition*
Our acquisition of Vets First Choice in an all-stock transaction
Adjusted EBITDA*
Adjusted EBITDA is the segment measure of profit or loss reported to the CODM. Adjusted EBITDA
excludes share-based compensation, strategic consulting, transaction costs, formation of Covetrus
expenses, separation programs and executive severance, carve-out operating expenses, certain IT
infrastructure expenses necessary to establish ourselves as a newly public company, goodwill
impairment charges, capital structure-related fees, other impairments, the proportionate share of the
adjustments of consolidated and non-consolidated affiliates where Covetrus ownership is less than
100%, and other income and expense items, net. Non-GAAP Adjusted EBITDA on a total segment
basis is reconciled in Note 2 - Segment Data as required by ASC 280
AIP*
Annual Incentive Plan
AKS
Federal Anti-Kickback Statute
Animal Health Business*
Former Parent's spun-off animal-health business
Animal Owners*
Clients of our Customers
APAC
Asia Pacific
AppointMaster*
AppointMaster, LLC
ASC
Accounting Standards Codification
ASU
Accounting Standards Update
AUD
Australian dollar
CEO
Chief Executive Officer
CARES
Coronavirus Aid, Relief, and Economic Security Act
CCPA
California Consumer Privacy Act
CD&R
CD&R VFC Holdings, L.P.
CFO
Chief Financial Officer
CODM
Chief Operating Decision Maker
COVID-19
Novel Coronavirus Disease 2019
CPR
Cardiopulmonary resuscitation
Credit Facilities*
On February 7, 2019, we entered into a $1.5 billion syndicated credit agreement, comprised of $1.2
billion term loan facility and $300 million revolving line of credit, with a group of lenders for a five-
year term
Customers*
Veterinarians and animal-health practitioners
CVM
Center for Veterinary Medicine
DEA
U.S. Drug Enforcement Administration
DGCL
Delaware General Corporation Law
Defendants*
The Company, our Former Parent, our former Chief Executive Officer and President, and our former
Chief Financial Officer, collectively
Distribution*
All the shares of our common stock that were then owned by our Former Parent were distributed to its
stockholders of record as of January 17, 2019. Concurrent with the Distribution, we paid a cash
dividend of $1.2 billion to our Former Parent from loan proceeds from our newly established term
loan facility
Distrivet*
On April 30, 2020, we combined our subsidiary, SAHS, with Distrivet, S.A. to form a leading animal-
health provider on the Iberian Peninsula. We own 50.01% of the company, called Distrivet, a
Covetrus company
EBITDA
Earnings Before Interest, Taxes, Depreciation, and Amortization
EPA
Environmental Protection Agency
EPS
Basic earnings (loss) per common share
ESPP
Employee Stock Purchase Plan
EU
European Union
EUR
Currency of the European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FCA
Financial regulatory body in the United Kingdom
FDA
U.S. Food and Drug Administration
FDIC
Federal Deposit Insurance Corporation
FOMC
Federal Open Market Committee
Form 10-K
Audited consolidated financial statements and notes included in our Annual Report on Form 10-K for
the year ended December 31, 2021
Glossary of Defined Terms and Abbreviations
Covetrus, Inc. 2021 Form 10-K
3
Form 10-Q or Report
Quarterly Report on Form 10-Q
Former Parent*
Henry Schein, Inc.
FTC
Federal Trade Commission
GAAP
Generally Accepted Accounting Principles in the United States of America
GDPR
General Data Protection Regulation
GFI
Guidance for Industry
GILTI
Global Intangible Low-Taxed Income
Global Technology Solutions
or GTS*
The aggregation of our software services with our prescription management platform and related
pharmacy services
Investment and Shareholders
Agreement*
The Investment and Shareholders Agreement of Distrivet, S.A. executed on January 13, 2020
IS*
Information Systems
ITGC
Information Technology General Controls
LIBOR
London Interbank Offered Rate
MD&A
Management's Discussion and Analysis of Financial Condition and Results of Operations
NM
Not Meaningful
NOL
Net Operating Losses
NZD
New Zealand dollar
OCC
Office of the Comptroller of the Currency
PIMS
Global Technology Solutions practice information management software systems
PPE
Personal protective equipment
PSU
Performance Stock Unit
RSA
Restricted Stock Award
RSU
Restricted Stock Unit
SAHS*
Spain Animal Health Solutions S.L.U.
scil
scil animal-care business
SEC
Securities and Exchange Commission
Separation*
In anticipation of the spin-off, affiliates of Covetrus purchased from certain minority holders their
ownership interests in the applicable operating companies of the Animal Health Business. On
February 7, 2019, our Former Parent completed the spin-off of its Animal Health Business and
transferred the applicable assets, liabilities, and ownership interests to us
Series A Preferred Shares*
7.50% Series A Convertible Preferred Stock
SG&A
Selling, general and administrative expenses
Share Sale*
On February 7, 2019 and prior to the Distribution, we sold $361 million in shares to accredited
institutional investors. The proceeds from the Share Sale were paid to us and distributed to our
Former Parent
SMBs
Small or Medium-Sized Businesses
SOX
Sarbanes-Oxley Act of 2002
Tax Act
U.S. Tax Cuts and Jobs Act of 2017
Transactions*
Collectively the following events, effective February 7, 2019, Vets First Choice became a wholly-
owned subsidiary of Covetrus, Inc. (f/k/a HS Spinco, Inc.), a company formed by our Former Parent
in connection with the spin-off of the Animal Health Business and combination with Vets First
Choice
TSA
Transition Service Agreements
U.K.
United Kingdom
U.S.
United States
USD
U.S. Dollar
USDA
U.S. Department of Agriculture
VCP*
Veterinary Care Plans
Vets First Choice*
Direct Vet Marketing, Inc. (d/b/a Vets First Choice)
VSG*
Veterinary Study Groups, Inc.
Covetrus, Company, we, us,
our, or ourselves
Covetrus, Inc. and its consolidated subsidiaries, collectively
XBRL
eXtensible Business Reporting Language
*Defined term or abbreviation is specific to Covetrus
Covetrus, Inc. 2021 Form 10-K
4
Explanatory Note
As previously disclosed, effective February 7, 2019, Vets First Choice became a wholly-owned subsidiary of Covetrus, Inc., a
company formed by the Former Parent in connection with the Transactions. Covetrus common stock began regular-way trading
under the symbol “CVET” on the Nasdaq Global Select Market on February 8, 2019. Beginning with the Quarterly Report on
Form 10-Q for the quarter ended March 31, 2019, Covetrus began reporting on a consolidated basis, representing the combined
operations of the Animal Health Business and Vets First Choice and their respective subsidiaries.
Rounding adjustments applied to individual numbers and percentages shown in this Report may result in these figures differing
immaterially from their absolute values, and tables may not foot or cross foot.
Forward-looking Statements
Certain matters discussed in this Report, including the information presented in Part II, Item 7, Management’s Discussion
and Analysis of Financial Condition and Results of Operations, contain statements, estimates, and projections that are
“forward-looking statements” as defined under U.S. federal securities laws. These forward-looking statements, which
include statements regarding our business strategy, our expenses and sufficiency of cash, seasonality, deployment of our
platform outside the United States, and the timing and impact of business transactions, involve substantial risks and
uncertainties and include, without limitation, risks regarding our industry, business strategy, plans, goals, and our
expectations concerning our market position, accounting pronouncements, litigation, seasonality of our business, leases,
expenses, interest expense and debt, and sufficiency of cash. When used in this Report, the words “anticipate,” “assume,”
“believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “will,” “future,” and the negative of these or similar terms and phrases are intended to identify forward-looking
statements. Except as required by law, we do not intend to update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise.
These forward-looking statements reflect our current expectations regarding future events, results, or outcomes. Although we
believe the expectations reflected in our forward-looking statements are reasonable, we can give no assurance that these
expectations will prove to have been correct. These expectations may or may not be realized. Some of these expectations
may be based upon assumptions, data, or judgments that prove to be incorrect. Actual events, results, and outcomes may
differ materially from our expectations due to a variety of known and unknown risks, uncertainties, and other factors.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements
include, but are not limited to, those described in this Form 10-K in Part I, Item 1A, Risk Factors.
We operate in a very competitive and rapidly changing market. New risks emerge from time to time, and it is not possible
for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-
looking statements we may make.
Covetrus, Inc. 2021 Form 10-K
5
PART I
We were incorporated in Delaware in April 2018 as a wholly-owned subsidiary of our Former Parent under the name HS Spinco,
Inc., and subsequently changed our name to Covetrus, Inc. We are a global animal-health technology and services company
dedicated to supporting the companion, equine, and large-animal veterinary markets. Our mission is to provide the best products,
services, and technology to our Customers across the globe, so they can deliver exceptional care to their Animal Owners when
and where it is needed.
Transactions that formed Covetrus:
Separation. In anticipation of the spin-off, affiliates of Covetrus purchased from certain minority holders their ownership
interests in the applicable operating companies of the Animal Health Business. On February 7, 2019, Henry Schein completed the
spin-off of its Animal Health Business and transferred the applicable assets, liabilities, and ownership interests to us
Share Sale. Also, on February 7, 2019 and prior to the Distribution, we sold $361 million in shares to accredited institutional
investors. The proceeds from the Share Sale were paid to us and distributed to our Former Parent
Distribution. All the shares of our common stock that were then owned by Henry Schein were distributed to its stockholders of
record as of January 17, 2019. Concurrent with the Distribution, we paid a cash dividend of $1.2 billion to our Former Parent
from loan proceeds from our newly established credit facility (see Note 7 - Long-Term Debt and Other Borrowings, Net)
Acquisition. We then acquired Vets First Choice in an all-stock transaction, and the following day, our shares began trading on
the Nasdaq Global Select Market under the symbol “CVET”
Purpose of founding Covetrus. We combined the complementary capabilities of the Animal Health Business and Vets First
Choice, bringing together innovative practice management software and supply chain and distribution businesses with a
technology-enabled prescription management platform and related pharmacy services.
We are now two years into our three-year strategy, see Our Strategy as discussed below, and we believe our approach to the
market supports the delivery of improved veterinary care and the health of our customers' veterinary practices while driving
increased demand for our products and services. We believe that building lasting relationships between our Customers and
Animal-Owners is an important component to our future success in our three-year stated strategy and beyond.
Item 1.
Business
Overview
Covetrus, Inc. 2021 Form 10-K
6
Acquisitions and Divestitures
Equity Method Investments
In April 2020, we completed the previously announced combination of our subsidiary, SAHS, with Distrivet. See Note 5 -
Divestitures and Equity Method Investments.
Acquisitions
During the year ended December 31, 2021, we completed acquisitions of VCP, a leading platform in veterinary wellness plan
administration, and AppointMaster, a provider of integrated communications solutions for veterinary practices, for an aggregate
purchase price of $85 million. These acquisitions are intended to provide our Customers with new tools to foster stronger
relationships with their Animal Owner clients by delivering better business and healthcare outcomes. See Note 4 - Business
Acquisitions.
Our strategic roadmap to an all-in-one solution for the veterinary market prioritizes providing our supply chain services,
compounding services, PIMS, and the prescription management platform, all through one operating system. In January of 2022,
we announced our veterinary operating system, Covetrus Pulse™, that we expect to launch in our North America segment in the
second quarter of 2022.
Our future success largely depends on our ability to grow and adapt to the changes in the veterinary market. We expect to focus
for 2022 and beyond on the faster-paced growth and higher margin areas of our business in our effort to create a similar product,
service, and technology offerings across our segments.
Segments
We manage our organization geographically in three reportable segments: (i) North America, (ii) Europe, and (iii) Asia Pacific
(APAC) & Emerging Markets. Historically, the business was focused on driving growth through specific product and
service offerings to our Customers; the Transactions allowed us to bring together the different products and service offerings,
along with prescription management, data analytics, and insights through veterinary practice management software, into one
multi-channel veterinary platform. We will continue to focus on delivering this collection of products and services to our
Customers on a geographical basis. We disaggregate our net sales based on our major product categories: supply chain services,
software services, and prescription management. See below, Item 7- Management’s Discussion and Analysis of Financial
Condition and Results of Operations - Segments, Note 3 - Revenue from Contracts with Customers, and Note 2 - Segment Data.
Covetrus, Inc. 2021 Form 10-K
7
Our current product and service offerings across our segments:
North America Segment: Has the most expansive collection of products, services, and technologies for our Customers and
Animal-Owners. In broad categories, we offer supply chain services, software services, and prescription management.
Europe Segment: We offer supply chain services and software services to our Customers and Animal-Owners.
Asia-Pacific and Emerging Markets Segment: We offer supply chain services and software services to our Customers and
Animal-Owners.
Our major products and services categories are described below. See Note 3 - Revenue from Contracts with Customers for a
breakdown of our net sales by segment and product or service categories.
Supply Chain Services
Logistics and in-clinic supply
Proprietary Brands
Membership Organizations
In October 2020, we announced a strategic investment in VSG which was consolidated during the fourth quarter of 2020. This
relationship brings together two highly complementary organizations each dedicated to veterinary practices and committed to
driving enhanced patient care, empowering veterinarians to run better businesses, and advocating for the veterinary profession.
This investment is an opportunity to accelerate our strategic initiative on driving increased customer alignment. See Note 4 -
Business Acquisitions.
Divestitures
In April 2020, we completed the divestiture of our scil business to Heska for approximately $100 million, net of deal-related fees
and other transaction items. See Note 5 - Divestitures and Equity Method Investments.
Our Products, Services, and Technologies
Covetrus exists to help our Customers drive better health for animals and their Animal-Owners as well as business outcomes. We
believe the integration of our products, programs, services, and technologies will provide an all-in-one platform for our Customers
to utilize across their practices.
Covetrus, Inc. 2021 Form 10-K
8
Software and e-commerce
Wellness Plans
We develop, provide, and support veterinary practices with a wide range of veterinary software systems. These technology
solutions include practice management software, data-driven applications, client communications tools, and related services,
which are designed to increase staff efficiency and improve business health, allowing veterinarians and their staff more time to
provide patient care. We also offer solutions that integrate with our software platforms, including client communication services,
reminders, data backup services, hardware sales and support, and credit card processing. These integrated veterinary marketing
services leverage practice-level data and consumer insights to deliver highly personal, relevant, and timely communications,
strengthening the veterinary-client patient relationship and improving Animal Owners' loyalty to their veterinarian. Our payment
solutions also help veterinarians save time and money with credit card processing services, which are integrated into our
veterinary software systems to streamline workflow.
Prescription Management (currently in our North America Segment only)
Prescription Management
Through the integrated product and service offerings available on our prescription management platform, we seek to enable our
Customers to manage the lifecycle of a prescription to create new revenue opportunities, adapt to changing Animal-Owner
purchasing behaviors, and strengthen their client relationships through the convenience of our e-commerce, auto-ship services,
and access to accredited veterinary pharmacies for standard prescriptions, preventatives, diets, and custom-compounded
medications. These products and services ultimately allow our Customers to improve the quality of animal care that is provided.
Our Customers can access our accredited veterinary pharmacies to fulfill compounded, specialty, patient-specific customized
medications, and in-clinic use medications through our prescription management platform. As discussed below, our strategy
includes investing to further develop the capabilities of our prescription management platform and to grow our high margin
custom-compounding medications.
We offer a comprehensive portfolio of products, services, and value-added solutions to our Customers for enhancing practice
revenue, operating efficient practices, and delivering high-quality animal care. By combining our global scale and logistical
expertise with robust software and ordering tools, a broad product offering at competitive prices, and a strong commitment to
customer service, we strive to be an indispensable and trusted partner for our Customers’ evolving needs. We are also continuing
to grow our portfolio of Covetrus-branded and proprietary-branded products. These are products and solutions we develop and
manufacture, both in-house and using third party contract to manufacturers, that we market and sell under Covetrus-owned
branding. Currently, our main proprietary brands are Vi, Kruuse, SmartPak, and Calibra, along with Covetrus-branded products.
Software Services
Covetrus, Inc. 2021 Form 10-K
9
•
Supply chain customers in North America, Europe, and APAC & Emerging Markets
•
Software services customers in the U.S., U.K., Australia, New Zealand, and certain other countries
•
Prescription management and pharmacy services customers in the U.S
COVID-19 and Our Return to Work
To protect the health and safety of our employees, we implemented workplace regulations and guidelines recommended from
government and public health authorities related to COVID-19. In March 2020, we transitioned a large portion of our teams to
working remotely and implemented staggered schedules in our distribution facilities. We created a COVID-19 information portal
on our intranet that provides best practices for working at home and staying connected, communications from our leadership
team, internal contacts for any COVID-19 questions, and helpful external reference links.
We adhere to regulations and guidelines instituted by local authorities in our areas of operations and make judgments with the
best available information at the time. For example, in the U.S., we issued safety protocols for our employees based on their
vaccination status. These protocols are applicable for our employees who are working in our offices and facilities as well our
employees who are working remotely.
In our effort to return to work in our offices in 2022, we will be offering hybrid work schedules, to reduce the number of
employees in a facility at any given time. The hybrid work arrangement allows employees to split the workweek between remote
work on certain days and onsite work on certain days. To support our managers in this hybrid environment, we will provide
online training on how to manage remote workers, implement a telecommuting policy, and develop etiquette guidelines for hybrid
meetings.
We are continuing to actively monitor how COVID-19 and related variants are impacting our business operation and the industry
and may take further actions to alter our business operations in the best interests of our employees, Customers, partners, suppliers,
and other stakeholders, or as required by federal, state, or local authorities.
We are building the infrastructure in the U.S. necessary to support growth of our pharmacy presence. As of December 31, 2021,
we own or lease properties which are integral to our global operations as well as necessary infrastructure for our future growth.
We also have 503A pharmacies as well as an FDA registered outsourcing facility under section 503B of the Federal Food, Drug,
and Cosmetic Act. We initiated a legal-entity rationalization in 2021 that was completed in the first quarter of 2022, and as a
result of that process we are re-licensing our pharmacies and facility under one legal-entity, Covetrus North America, LLC.
Certain of our pharmacies have completed the re-licensing process for all 50 states and the District of Columbia. We currently
anticipate to complete this re-licensing process in all 50 states in the first half of 2022. Obtaining licensure for our pharmacies is
an important factor in our strategic focus for expanding our pharmacy infrastructure.
Our Customers
Our customer base for our products, programs, services, and technologies is comprised principally of animal-health and veterinary
practices and clinics in the companion-animal, equine, and large-animal markets in North America, Europe, and APAC &
Emerging Markets. These veterinary practices consist of both small, privately owned businesses and an increasing number of
corporate-owned practices. We also serve animal-health providers and producers and pet specialty retail stores. Our major product
categories service customers in the following markets:
Covetrus, Inc. 2021 Form 10-K
10
Our Strategy
Our current three-year strategic plan prioritizes the following:
2020
2021
2022
Streamline
Synchronize
Accelerate
Focus
Our Business
Harmonize
Our Capabilities
Expand
Our Offering
Technology Roadmap
Our offerings to our Customers are centered on helping them drive better health and business outcomes in their practices. During
2021, our primary technology focus was on the development of an all-in-one cloud-based veterinary operating system, Covetrus
Pulse™, which was announced at the 2022 Veterinary Meeting & Expo and is expected to be released in our North America
segment during the second quarter of 2022. Covetrus Pulse™ is intended to unite the applications veterinary practices rely on into
one secure cloud platform driving improved efficiencies in business operations, animal health, and client experiences. With
Covetrus Pulse™, we expect to enable our Customers to create, renew, and approve prescriptions, communicate with Animal
Owners and coworkers, personalize dashboards used in practice management, and customize in-clinic and Animal Owner
experiences using a suite of preferred third-party applications. Included within the Covetrus Pulse™ launch for the second quarter
of 2022 in our North America segment, are the offerings from our 2021 acquisitions, VCP and AppointMaster.
Covetrus Pulse™ combines our previously separate offerings in a cloud solution for an easier to use experience for our
Customers. For example, an Animal-Owner can book an appointment via our online booking tool. This appointment is followed
up with text and email reminders from our communication platform. Once at a Customers' practice, a veterinarian manages this
patient using our PIMS which provide medical record storage, treatment paths and workflow solutions. From within the veterinary
operating system, at the point of care, veterinarians can proactively prescribe medication and have those medications delivered via
our prescription management solution straight to the Animal-Owners home. Through our prescription management solution,
Animal-Owners can sign up for auto-ship programs and receive personalized medication from our compounding pharmacy. To
drive compliance and provide financial visibility to pet parents, a Customer can enable care plans via our wellness plan
administration solution creating a subscription relationship with the Animal-Owner. Then the Animal-Owner can shop online with
their veterinarian, our Customer, and manage their prescriptions and communicate with their veterinarian via our telehealth
platform.
2021 Organization Harmonization
In order to create “one face to our customer”, we combined our commercial organizations within our North America segment in
late 2020, and we completed the integration of these organizations during 2021. We also took similar actions to combine our
commercial organizations in our Europe segment, with particular focus on our U.K. and Germany regions during 2021. In
addition, we created a global operations enablement function to drive continuous improvement, consistent performance, and
improved efficiencies across our segments.
Accelerating in 2022:
Our strategic priorities in 2022 build on the foundational capabilities we have developed to accelerate our ability to serve
Customers through improved and expanded offerings. These key priorities are expected to also drive growth in revenues and
operating margin and include:
Covetrus, Inc. 2021 Form 10-K
11
•
Optimizing our integrated value proposition, including Covetrus Pulse™, to drive sales growth
•
Developing offerings to expand consumer marketing and technology solutions on behalf of
veterinarians
•
Driving proprietary brand growth across our segments through introduction of new products and a
more focused management structure
•
Improving profitability in our Europe segment through more focused growth initiatives and cost
structure changes in the UK and Germany
•
Maintaining a stable corporate cost base to drive improved operating margin through growth in our
segments
Human Capital
At the core of our strategy exists a commitment to build a strong culture and strong teams, enable scale, effectiveness and
efficiency, and have the right capabilities and talent to drive business success.
Who Are We?
In 2021
Full-time Covetrians
Part-Time Covetrians
In North America
1,603
1,424
In Europe
1,771
116
In APAC & EM
661
135
Total Covetrians
4,035
1,675
For the year ended December 31, 2021, we had voluntary turnover of 20% as compared to voluntary turnover of 16% for the year
ended December 31, 2020. In 2021, we also internally promoted 478 people of our workforce and 756 moved laterally within our
organization.
In 2020, we created a global diversity, equity, and inclusion program, which includes a global advisory board and a number of
global, business unit, and regional diversity and inclusion leads dedicated to driving our commitments and strategic focus areas as
well as to ensure local support. The executive sponsors of program are Sharon Wienbar (member of our Board of Directors) and
Ben Wolin (President and Chief Executive Officer). We identified five diversity and inclusion commitments to drive lasting
change within five years: (i) diversity-focused recruitment, (ii) diversify the animal-health industry, (iii) employee education and
training, (iv) inclusion & employee resource groups, (v) transparency. We are one year into our 5 year diversity and inclusion
commitment; and in line with our expectation for public accountability we have disclosed our workforce by gender to drive
increased accountability and comparability in future periods.
Our Executive Leadership Team
Ben Wolin
President & CEO
Direct Reports to our CEO are 40% female
Matt Malenfant
Chief Commercial
Officer
Matthew Foulston
Chief Financial Officer
Georgia Wraight
President, Global
Technology Solutions
Bekki Kidd
Head of Global
Operations
Dustin Finer
Chief Administrative
Officer
% of function that is female by organizational level
Senior Vice President and
Vice President
30%
8%
50%
17%
53%
Senior Director and
Director
33%
37%
41%
21%
50%
Senior Manager, Manager,
and Supervisor
62%
59%
47%
29%
34%
Individual Contributor (1)
61%
71%
57%
44%
44%
(1) Employees without management responsibility
Covetrus, Inc. 2021 Form 10-K
12
•
Animal Health Divisions of Traditional Distribution Companies: the MWI Animal Health division of
AmerisourceBergen Corporation and the Patterson Veterinary division of Patterson Companies, Inc., and other national,
regional, and local full-service distributors
•
Animal Health Practice Management Service Providers: IDEXX Laboratories, Inc. and several regional and local
veterinary software vendors, including those offering cloud-based solutions
•
Animal Health-focused E-Commerce Companies: Amazon.com, Inc. and zooplus AG, retail and online pharmacy
providers such as Chewy, Inc., PetMed Express, Inc., and Strategic Pharmaceutical Solutions, Inc. (d/b/a Vetsource), as
well as manufacturers of animal-health products that sell directly to veterinary practices and retailers, thereby eliminating
or reducing the role of distributors
Additionally, the growth in online and brick-and-mortar retailers offering certain animal-health products and services directly to
Animal Owners continues to impact our Customers and, in turn, our business given our strategic alignment with the veterinary
community. COVID-19 has accelerated this trend. Our operating results may be materially adversely affected should this trend
continue to accelerate.
Occupational Health & Safety
At our facilities, first aid and CPR training is held annually on a volunteer basis to address the safety of employees in the case of
emergencies. All Covetrus facilities have standard operating procedures created by dedicated safety committees that address
industry best practice, cleaning procedures, site security, equipment, material handling, and use of PPE.
Throughout the COVID-19 pandemic, we have created subcommittees to review and reinforce PPE use and safety protocols.
While health, safety, and quality have always been priorities, an emphasis on hygiene has helped keep our employees safe while
at work and at home. Any employee who is re-entering Covetrus office space is required to complete a return-to-work training
and COVID safety protocol.
Talent Attraction and Retention
We design our benefits on the basis of creating rewards programs that support a high-performance culture and attract and retain
talent. We also prioritize aligning our high-performance culture with a focus on health. We are driving a clear intention on
wellness throughout our organization. Our goal for our employees well-being is that their lives are improved, their lives are
healthier, life spans are longer, productivity is increased, and medical claims cost is reduced.
Our offerings to our employees, depending on location, also includes: resilience and wellness training, employee assistance
programs, dog-friendly office environments, ESPP, identity theft, and pet insurance. In 2022, we started offering legal insurance
to our employees.
We believe we maintain positive relations with our employees. In certain countries, we are bound by union agreements negotiated
by the employer's association with the respective union representatives. We are also party to shop agreements on workplace-
related issues, negotiated with works councils at individual facilities that relate to those facilities.
Our Competition
The market for providing products, services, and technology to the global animal-health industry is highly competitive and
fragmented. Competitive factors include price, product offerings, value-added services, service and delivery levels, credit terms,
and customer support. Substantially all of the products we sell are available to Customers from a number of distributors,
manufacturers and suppliers and, increasingly, some are being sold directly to Animal Owners and, as a result, significant price
reductions by our competitors or changes in how products are ultimately procured by Animal Owners could result in competitive
harm.
Our principal competitors include:
Covetrus, Inc. 2021 Form 10-K
13
Buying patterns can also be affected by manufacturers’ and distributors’ marketing programs or price increase announcements,
which can cause veterinarians to purchase animal-health products earlier than when those products are needed. This kind of early
purchasing may reduce our sales in the quarters these purchases would have otherwise been made. The sales of animal products
can also vary due to changes in the price of commodities used in manufacturing the products and weather patterns, which may
also affect period-over-period financial results. We expect our historical seasonality trends to continue in the foreseeable future.
Working Capital
Our principal capital requirements include the funding of working capital needs, debt service, strategic investments, and capital
expenditures. We require substantial working capital, which is susceptible to fluctuations in the level of accounts receivables and
inventory purchase patterns and seasonal demands throughout the year. We extend credit to many of our customers globally in the
ordinary course of business, which increases accounts receivable balances within our business segments and is dependent, to an
extent, on seasonal demand. Our sales terms vary from due immediately for credit card payments to significantly longer periods
generally offered to larger customers. Inventory purchase activity and stock levels are also dependent on sales activity and
seasonal demand, however, on occasion, we consider special inventory buy-in opportunities to achieve better purchase terms and
earn larger rebates.
Laws and Regulations
The sale of certain animal-health products is also governed by the laws and regulations specific to each country in which we sell
our products.
Our prescription management and pharmacy services business, which currently operates only in the U.S., is regulated by federal
and state laws governing, among other things, the purchase, distribution, management, compounding, dispensing, marketing, and
labeling of prescription and non-prescription drugs and related services. In addition, we are subject to FDA, DEA, and
comparable state regulations affecting the pharmacy and pharmaceutical industries, including state pharmacy licensure,
registration or permit standards, state and federal controlled substance laws, and statutes and regulations related to FDA approval
Seasonality
Our quarterly sales and operating results have varied from period to period in the past and will likely continue to do so in the
future. In the companion-animal market, sales of parasite protection products have historically tended to be stronger during the
spring and summer months, primarily due to an increase in vector-borne diseases during that time, which correlates with our
second and third quarters given that most of our business is in the northern hemisphere. Parasite protection products represented
23% of our net sales in 2021. The following chart reflects our quarterly parasite protection product sales compared to our net sales
in 2021.
Covetrus, Inc. 2021 Form 10-K
14
•
Generally, all animal-health pharmaceuticals are subject to pre-market review and must be shown to be safe, effective,
and produced by a consistent method of manufacture as defined under the Federal Food, Drug, and Cosmetic Act
•
If the drug is for food-producing animals, potential consequences for humans are also considered
•
Animal supplements generally are not required to obtain pre-market approval from the CVM, although they may be
treated as a food. Any substance that is added to, or is expected to become a component of, animal food must be used in
accordance with a food-additive regulations, unless it is generally recognized as safe, under the conditions of its intended
use. Alternatively, the FDA may consider animal supplements to be drugs. The FDA has agreed to exercise enforcement
discretion for such supplements if each such supplement meets certain conditions
USDA - the regulatory body in the U.S. for veterinary biologics, such as vaccines, is the USDA.
•
The USDA’s Center for Veterinary Biologics is responsible for the regulation of animal-health vaccines, including
immunotherapeutics. Marketing of imported veterinary biological products in the U.S. requires a U.S. Veterinary
Biological Product Permit. Veterinary biologics are subject to pre-market review and must be shown to be pure, safe,
potent, and efficacious, as defined under the Virus Serum Toxin Act. The USDA requires post-licensing monitoring of
these products
EPA - the main regulatory body in the U.S. for veterinary pesticides is the EPA.
•
The EPA’s Office of Pesticide Programs is responsible for the regulation of pesticide products applied to animals
•
Animal-health pesticides are subject to pre-market review and must not cause “unreasonable adverse effects to man or
the environment” as stated in the Federal Insecticide, Fungicide, and Rodenticide Act
•
Within the U.S., pesticide products that are approved by the EPA must also be approved by individual state pesticide
authorities before distribution in that state. Post-approval monitoring of products is required, with reports provided to the
EPA and some state regulatory agencies
DEA - under the Controlled Substances Act, distributors of controlled substances are required to obtain, and renew annually,
registrations for their facilities from the DEA.
•
Distributors are also subject to other statutory and regulatory requirements relating to the storage, sale, marketing,
handling, and distribution of such drugs, in accordance with the Controlled Substances Act and its implementing
regulations, and these requirements have been subject to heightened enforcement activity in recent times
•
Distributors are subject to inspection by the DEA
FTC - the FTC regulates advertising pursuant to its authority to prevent “unfair or deceptive acts or practices in or affecting
commerce” under the Federal Trade Commission Act
•
Advertising and promotion of animal-health products that are not subject to approval by the CVM may be challenged by
the FTC, as well as by state attorneys general and by consumers under state consumer protection laws
•
The FTC will find an advertisement to be deceptive if it contains a representation or omission of fact that is likely to
mislead consumers acting reasonably under the circumstances, and the representation or omission is material, and if the
advertiser does not possess and rely upon a reasonable basis, such as competent and reliable evidence, substantiating the
claim
•
The FTC may address unfair or deceptive advertising practices through either an administrative adjudication or judicial
enforcement action, including preliminary or permanent injunction
•
The FTC may also seek consumer redress from the advertiser in instances of dishonest or fraudulent conduct
of the sale and marketing of new pharmaceuticals. State pharmacy laws require pharmacies to be licensed or otherwise authorized
to dispense prescription medications.
We are authorized to dispense prescription medication in all 50 states and the District of Columbia. As we expand our pharmacy
infrastructure, obtaining licensure in all 50 states and the District of Columbia is an important aspect of our growth strategy for
higher-margin aspects of our business and delays or failures to obtain licenses may disrupt our near-term strategic objectives.
Non-resident pharmacies are licensed similar to resident pharmacies. As such, each prescription for a medication that is fulfilled
by one of our pharmacies is generally covered by the laws of the state where the Animal Owner is located. The laws and
regulations relating to the sale and delivery of prescription medications vary from state to state but generally require that
prescription medications be dispensed with the authorization from a prescribing veterinarian.
U.S.
FDA - the regulatory body that is responsible for the regulation of animal-health pharmaceuticals in the U.S. is the CVM housed
within the FDA.
Covetrus, Inc. 2021 Form 10-K
15
State Registration - states may require registration of animal-drug distributors and wholesalers.
•
Additional requirements may apply when the product is also a controlled substance. States work closely with the
AAFCO in their regulation of animal food
•
The AAFCO’s annual Official Publication contains model animal and pet-food labeling regulations that states may adopt
•
The publication is treated deferentially by the federal and state government agencies that regulate animal food. Many
states require registration or licensing of animal-food distributors
•
States may also review and approve animal-food labels prior to sale of the product in their state
Rest of world
Country-specific laws have provisions that include requirements for licensing, regulatory approvals, certain labeling, safety,
efficacy, and manufacturers’ quality control procedures (to assure the consistency of the products), as well as company records
and reports. Many other countries’ regulatory agencies will generally refer to the FDA, USDA, European Union regulatory
agencies, and other international animal-health entities, including the World Organization for Animal Health and the Codex
Alimentarius Commission, in establishing standards and regulations for veterinary pharmaceuticals and vaccines.
Other regulations
Through our 503A and 503B compounding pharmacies, we are subject to U.S. anti-kickback statutes. Anti-kickback statutes
prohibit among other things the exchange of anything of value, in an effort to induce the referral of business reimbursable by
federal health care programs and state health programs. We maintain an annual compliance program to educate our employees on
these risks.
Veterinary compounding pharmacies must remain mindful of compliance with state and federal laws that govern the relationship
between pharmacies and referral sources. The AKS imposes criminal penalties against individuals and entities that pay or receive
remuneration in return for referring an individual for service paid under a federal health care program. Veterinary compounding
pharmacies have historically avoided scrutiny under the AKS because no federal programs are involved in veterinary
compounding funding. However, most states have enacted statutes and regulations that mirror the AKS and, in some cases, are
even broader than the AKS.
Various states have enacted business and insurance regulations prohibiting referral arrangements that result in the offer or
acceptance of any rebate, refund, commission, discount or other consideration as compensation or inducement for referring
patients, clients or customers. These regulations often encompass all health-care related professions, including pharmacies and
veterinary practices. Penalties for violations of these state anti-kickback regulations may include imprisonment as well as
substantial fines.
We are subject to various federal, state, local and foreign environmental, health and safety laws and regulations. These laws and
regulations govern matters such as the emission and discharge of hazardous materials into the ground, air or water; the generation,
use, storage, handling, treatment, packaging, transportation, exposure to and disposal of hazardous and biological materials,
including recordkeeping, reporting and registration requirements; and the health and safety of our employees. See Risk Factors -
We are subject to complex environmental, health and safety laws and regulations.
Where You Can Find Important Information
We are subject to the informational requirements of the Exchange Act and, in accordance with the Exchange Act, we file annual,
quarterly, and current reports, proxy statements, and other information with the SEC. The SEC maintains an Internet web site that
contains reports, proxy statements, and other information about issuers, like us, who file electronically with the SEC. The address
of the site is http://www.sec.gov. The reports and other information, including any related amendments, filed by us with, or
furnished by us to, the SEC are also available free of charge at our Internet web site as soon as reasonably practicable after such
material is electronically filed with, or furnished to, the SEC. Our principal executive offices are located at 7 Custom House
Street, Portland, ME 04101, and our telephone number is (888) 280-2221. Our website is https://covetrus.com/. We may disclose
important information through one or more of the following channels: SEC filings, public conference calls and webcasts, press
releases, and the social media channels identified on the Newsroom page of our website https://covetrus.com/news-room/.
Covetrus, Inc. 2021 Form 10-K
16
Item 1A. Risk Factors
Prospective investors should carefully consider the risks described in this section, together with all of the other information in this
Annual Report on Form 10-K. These risks may not be the only risks we face but are risks we believe may be material at this time.
Additional risks and uncertainties that we do not yet know of, or that we currently think are not material, may also impair our
business operations or financial results. If any of the events or circumstances described in this section occur, our business,
financial condition or results of operations, and the trading price of our securities, could decline. Investors and prospective
investors should consider these risks, the information contained under the heading Forward-Looking Statements and the risks
described in this Annual Report on Form 10-K before deciding whether to invest in our securities. We may update these risk
factors in our future periodic reports.
Risks Relating to Our Business
We face risk related to health epidemics, including the COVID-19 pandemic, which could have a material adverse effect on
our business and results of operations, and could also have an effect on our ability to maintain effective internal controls.
Our business has been and could continue to be adversely affected by a widespread outbreak of contagious disease, including the
recent pandemic of respiratory illness caused by a novel coronavirus known as COVID-19. Global health concerns relating to the
COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased
economic volatility and uncertainty.
The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel
bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. The spread of COVID-19
caused us to modify our business practices in fiscal years 2020 and 2021, particularly with respect to our liquidity position and
near-term cost structure. For example, to increase our cash position in 2020, we issued 250,000 shares of 7.50% Series A
Convertible Preferred Stock for an aggregate purchase of $250 million in a private placement, we also made incremental
borrowings under our revolving credit facility that were subsequently repaid. In 2020, we also reduced non-critical capital
expenditures, temporarily lowered executive, board and senior-level employee compensation, and enacted employee furloughs
and hiring freezes, deferral of payroll taxes under the CARES Act; and a temporary suspension of our 401(k) employer match,
which was later reinstated, among other actions. In 2021, we continued to carefully manage spending, including through controls
on hiring. To date, the majority of these actions have been eased. In addition, we continue to manage our inventory levels to
ensure we hold appropriate stock for market conditions, and we have negotiated to extend payment terms on certain contracts. We
may take further actions as may be required by government authorities or that we determine are in the best interests of our
employees, customers, and business partners. There is no certainty that such actions will be sufficient to mitigate the risks posed
by the virus or will otherwise be satisfactory to government authorities. If significant portions of our workforce are unable to work
effectively, including due to illness, quarantines, social distancing, government actions, including the vaccine mandate, or other
restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted, and our stock price could
decline.
The extent to which the COVID-19 pandemic may impact our business, results of operations, financial condition, and potentially
our control procedures is highly uncertain and cannot be predicted. Such impact will depend on a number of factors including, but
not limited to, the duration and spread of the pandemic, its severity, the actions to contain the virus or treat its impact, including
with respect to government- or employer- imposed vaccine mandates, the spread of variants of COVID-19 and efficiency of
vaccines to prevent or mitigate such spread, and how quickly, and to what extent, normal economic and operating activities
resume. In the first quarter of 2020, the COVID-19 pandemic led to increased volatility in our stock price and a sustained decline
in our market capitalization which required us to perform an interim impairment review, which could reoccur. In addition, due to
current internal policies, many of our employees continue to work remotely, which could have an adverse effect on our internal
control over financial reporting. The COVID-19 pandemic could also limit the ability of our customers, suppliers, and business
partners to perform, including our customers' ability to make timely payments to us during and following the pandemic. In
addition, our supply chain has experienced certain disruptions as a result of the COVID-19 pandemic which, together with other
factors, has resulted and in the future could result in longer delivery lead times, increased cost and inventory shortages. We may
also experience a suspension of services from third parties. Even after the COVID-19 pandemic has subsided, we may experience
an adverse impact to our business as a result of its global economic impact, including increased inflation rates and the effect of
those rates on the actions of Animal-Owners as well as any recession that has occurred or that may occur in the future.
Covetrus, Inc. 2021 Form 10-K
17
•
The security capabilities, reliability, and availability of on-demand services
•
Concerns with entrusting a third party to maintain and manage data, especially confidential or sensitive data
•
Our ability to minimize the time and resources required to implement our services, maintain high levels of Customer
satisfaction, and implement upgrades and other changes to our software without disrupting services we provide
•
The level of customization or configuration we offer
•
The ability to provide rapid response time during periods of intense activity on Customer websites
•
The price, performance and availability of competing products and services
The market for these services may develop more slowly than we expect, which would have a material adverse effect on our
business, financial condition, results of operations and cash flows.
The animal-health market is highly competitive, and we may not be able to compete effectively.
The animal-health market is highly competitive and rapidly changing, and we expect competition to intensify in the future. Our
competitors include the animal-health businesses of large pharmaceutical and distribution companies, specialty animal-health
businesses, animal-health focused businesses, practice management service providers, and Internet-based businesses, such as
Chewy, Inc. and PetMed Express, Inc., (1-800-PetMeds), and may, in the future, include new market entrants. Some of our
competitors have access to greater financial, marketing, technical, and other resources than us that could allow them to compete
more effectively.
Specifically, difficult macroeconomic conditions, such as decreases in per capita income and level of disposable income,
increased and prolonged unemployment, or a decline in consumer confidence as a result of the COVID-19 pandemic could have a
material adverse effect on the demand for our products and services. Under difficult economic conditions, that could also become
inflationary, consumers may seek to reduce discretionary spending by forgoing our services or choosing not to purchase our
products. Decreased demand for our products and services could negatively affect our overall financial performance.
There are no comparable recent events that provide guidance as to the effect of the spread of COVID-19 and, as a result, the
ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet
know the full extent of COVID-19’s impact on our business, our operations, control procedures, or the global economy as a
whole. However, the effects could have a material adverse impact on our results of operations and could cause volatility in our
stock price. We will continue to monitor the situation closely.
We may not successfully implement our business strategies.
We are pursuing, and will continue to pursue, strategic initiatives that management considers critical to our long-term success,
including: optimizing our integrated go-to-market strategy, driving significant adoption of our veterinary operating system within
our North America segment in 2022, investing more in our consumer marketing and technology capabilities to further strengthen
the vet-to-pet relationship; rationalizing our operations in the U.K. and Germany; restoring profitable growth in Europe,
enhancing our proprietary brand strategy through talent acquisition and new product development; and leveraging our fixed
Corporate infrastructure as we now have the established cost base to support the business moving forward. The strategic
initiatives may result in our pursuing synergistic investments or acquisitions.
There are significant risks involved with the execution of these initiatives, including significant business, economic and
competitive uncertainties, many of which are outside of our control. Accordingly, we cannot predict whether we will succeed in
implementing these strategic initiatives. It could take several years to realize the anticipated benefits from these initiatives, if any
benefits are achieved at all. Additionally, our business strategy may change from time to time, which could delay our ability to
implement initiatives that we believe are important to our business.
Many veterinary practices have invested substantial effort and financial resources into the information systems and
procedures that support their business and, as a result, Customers may be reluctant to migrate or integrate their systems to
those that we provide.
Our success depends, in part, on the willingness of Customers to adopt new technologies and services. Many veterinary practices
have invested substantial effort and financial resources into the information systems and procedures that support their businesses
today and may be reluctant or unwilling to migrate or integrate these systems with online or cloud-based, on-demand services.
Other factors that may affect market acceptance of our services include:
Covetrus, Inc. 2021 Form 10-K
18
If any of our competitors are more successful with respect to any key competitive factor such as technological advances or newer
low-cost business models with the ability to operate at higher gross margins, our sales and profitability could be adversely
affected. Additional competitive pressure could arise from, among other things, limited demand growth or a significant number of
additional competitive products or services being introduced into a particular market, price reductions by competitors, or the
ability of competitors to capitalize on their economies of scale.
Changes in manufacturer sales channels and the increase in e-commerce options for companion animal products could
negatively impact our market share, margins, and distribution of our products.
In most markets, companion Animal Owners typically purchase their animal-health products directly from veterinarians.
Companion Animal Owners increasingly have the option to purchase animal-health products from sources other than
veterinarians, such as online retailers, “big-box” retail stores or other over-the-counter distribution channels. This trend has been
demonstrated, for example, by the significant shift away from the veterinarian distribution channel in the sale of flea and tick
products in recent years. Additionally, major U.S. online e-commerce retailers such as Amazon and Chewy.com are becoming
licensed as veterinary mail order pharmacies to offer pharmacy products directly to consumers in all 50 US states. Even where
prescriptions must be written by a veterinarian, companion Animal Owners may shift to these services for home delivery of
prescription medications and diets. Decreased emphasis on veterinary visits, and increased consumer choice through familiar e-
commerce retailers could reduce demand for veterinarian-based e-commerce services and have a material adverse impact on our
business. We market our companion animal prescription products through the veterinarian channel, both in-office and through our
online platform, any decrease in reliance on, and visits to, veterinarians by companion Animal Owners could reduce our market
share for such products and have a material adverse effect on our business. Companion Animal Owners may further choose to
substitute human health products for animal-health products if human health products are deemed to be lower-cost alternatives.
Because the majority of all the products that we distribute and sell are not manufactured by us, we are dependent on third
parties for the manufacture and supply of substantially all our products.
We obtain substantially all our products from third parties. Generally, we do not have long-term contracts with our suppliers
committing them to supply products to us. Therefore, suppliers may not provide the products we need in the quantities we request
or at all. Additionally, certain key suppliers, in the aggregate, supply a significant portion of the products we sell. As a result,
these suppliers may have increased bargaining power and we may be required to accept less favorable purchasing terms in the
future, which could erode our margins. In addition, we currently purchase many products and materials from single sources. Some
of the products that we purchase from these sources are proprietary and, therefore, cannot be readily or easily replaced by
alternative sources. These products include branded and patented products from major pharmaceutical manufacturers, including
Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Merck & Co., Inc., Vedco, Inc., and Zoetis, Inc.,
among others. These five suppliers accounted for approximately 48% of our purchases for the year ended December 31, 2021.
Effective January 1, 2021, we no longer are partnered with Merck & Co. in the U.K. has which resulted in reduced net sales and
the loss of customers in that region. Additionally, if we are unable to obtain adequate quantities of products in the future from
single-source suppliers, we may be unable to supply the market, which could have a material adverse effect on our results of
operations.
Additionally, because we generally do not control the actual production of the products we sell, we may be subject to delays
caused by interruption in production based on conditions outside of our control, including interruption due to physical loss of the
manufacturers' or their suppliers' facilities and the manufacturers’ failure to comply with applicable government requirements.
The failure of manufacturers of products regulated by the FDA, the DEA, or other governmental agencies to meet these
requirements could result in product recall, cessation of sales or other market disruptions. If any of our third-party suppliers were
to become unable or unwilling to continue to provide the products in our required volumes, we would need to identify and obtain
acceptable replacement sources on a timely basis. There is no guarantee that we would be able to obtain such alternative sources
of supply on a timely basis, if at all. In 2021, our supply chain has experienced certain disruptions which has resulted and in the
future could result in longer delivery lead times, increased cost and inventory shortages which may affect our ability to meet
Customer demand in the short term. Suppliers may also limit their partnership options based on competitive pricing that may not
be achievable with our current margin profile which may create more single source suppliers in the veterinary channel. An
extended interruption in the supply of our products, especially any high-sales volume product or single source supplier product
could have a material adverse effect on our business, financial condition, results of operations and cash flows.
Covetrus, Inc. 2021 Form 10-K
19
Turnover of key personnel, including executive officers, could disrupt our operations and any inability to attract and retain
qualified personnel could harm our business.
Any unplanned turnover or our failure to develop an adequate succession plan for key positions could deplete our institutional
knowledge base and erode our competitive advantage. The loss or limited availability of the services of key personnel, or our
inability to recruit and retain key personnel in the future, could, at least temporarily, have a material adverse effect on our
business, financial condition, results of operations and cash flows. Additionally, factors including reduced employment pools,
federal subsidies offered in response to the COVID-19 pandemic, and other government regulations including the vaccine
mandate, have contributed to increased labor shortages and employee turnover within our organization. These trends have led to,
and could in the future lead to, increased costs, such as increased overtime to meet demand and increased wage rates to attract and
retain employees. An overall or prolonged labor shortage, lack of skilled labor, increased turnover or labor inflation could have a
material adverse impact on our operations, results of operations, liquidity or cash flows.
Our future success also depends on our ability to attract, retain, and motivate talented technical, managerial, sales, marketing, and
service and support personnel. Competition for sales, marketing, and technology development personnel is particularly intense in
the software and technology industries. As a result, we may be unable to successfully attract or retain qualified personnel, which
could have a material adverse effect on our business, financial condition, results of operations and cash flows.
Disruptive innovations and advances in medical practices and technologies could negatively affect the market for our
products.
The market for our products could be impacted negatively by the introduction and broad market acceptance of newly-developed
or alternative products that address the diseases and conditions for which we sell products, including “green” or “holistic” health
products or specially bred disease-resistant animals. In addition, technological breakthroughs by others may obviate our
technology and reduce or eliminate the market for our products. Introduction or acceptance of such products or technologies could
materially adversely affect our operating results and financial condition.
Animal health products are subject to unanticipated safety, quality or efficacy concerns, which may expose us to liabilities or
harm our reputation.
Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not
scientifically or clinically supported, leading to product recalls, withdrawals or suspended or declining sales, as well as product
liability and other claims.
Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a
product’s sales and could, depending on the circumstances, materially adversely affect our results of operations.
In addition, since we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health
products generally, by veterinarians and pet owners, any concern as to the safety, quality or efficacy of our products, whether
actual or perceived, may harm our reputation. In addition, the success of our compounding pharmacy services is dependent on
perceptions of us and the safety and quality of our products and services. We could be adversely affected if we or any other
compounding pharmacies or our formulations and technologies are subject to negative publicity. We could also be adversely
affected if any of our formulations or technologies, any similar products sold by other companies, or any products sold by other
veterinary compounding pharmacies prove to be, or are asserted to be, harmful. For instance, to the extent any of the components
of approved drugs or other ingredients used to produce our compounded formulations have quality or other problems that
adversely affect the finished compounded preparations, our business could be adversely affected. These concerns and the related
harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of
whether such reports are accurate.
Many of our Customers and Animal Owners are price sensitive, and if the prices for our products and services are
unacceptable to them, it could have a material adverse effect on our business, financial condition, results of operations and
cash flows.
As the market for our services matures, or as new competitors introduce new products or services that compete with us, we may
be unable to retain our existing Customers or attract new customers based on the same pricing model as previously used. As a
result, it is possible that competitive dynamics in our market may require us to change our pricing model or reduce our prices,
which could have a material adverse effect on our business, financial condition, results of operations and cash flows.
Covetrus, Inc. 2021 Form 10-K
20
•
Maintain and manage systems to facilitate the purchase and distribution of thousands of inventory items from numerous
distribution centers
•
Receive, process and ship orders on a timely basis
•
Manage the accurate billing and collections for thousands of Customers and
•
Process payments to suppliers
Information security risks have generally increased in recent years, and a third-party action, employee error, malfeasance or other
events that bypass our IS security systems causing an IS security breach may lead to a material disruption of our IS business
systems and the loss of business, customer or client information resulting in a material adverse effect on our business. Because
techniques used to obtain unauthorized access to, or to sabotage, IS security systems change frequently and generally are not
recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventive
measures. Although we maintain insurance coverage for various cybersecurity risks, there can be no guarantee that all costs or
losses incurred will be fully insured.
In addition, we develop products and provide services to our Customers that are technology-based, and a cyberattack that
bypasses the IS security of our products or services causing a security breach and perceived security vulnerabilities in our
products or services could also cause significant reputational harm, and actual or perceived vulnerabilities may lead to claims
against us by our Customers, their clients and governmental agencies. Perceived or actual security vulnerabilities in our products
or services, or the perceived or actual failure by us or our Customers who use our products to comply with applicable legal
requirements, may not only cause us significant reputational harm, but may also lead to claims against us by our Customers, their
clients and governmental agencies and involve fines and penalties, costs for remediation, and substantial defense and settlement
expenses.
In addition, we market and sell many of our services to veterinary practices and clinics, which are typically small-to-medium
sized businesses, or SMBs. Selling to and retaining SMBs can be more difficult than selling to and retaining large enterprises
because SMBs are more price sensitive, more difficult to reach with broad marketing campaigns, and often require higher sales,
marketing and support expenditures by vendors that sell to them per revenue dollar generated for those vendors.
We may lose Customers and have difficulty attracting new customers if we have defects, disruptions, or poor service in our
technology product offerings.
Because we deliver online and cloud-based applications as a service, errors or defects in the software applications underlying the
service, or a failure of our hosting infrastructure, may render the service unavailable to Customers. Since our Customers will use
our platform to manage critical aspects of their businesses, any errors, defects, disruptions in service or other performance
problems with the platform, whether in connection with the day-to-day operation of the platform, upgrades or otherwise, could
damage the Customers’ businesses. If we experience any errors, defects, disruptions in service or other performance problems
with our online and cloud-based services, Customers could delay or withhold payment or stop doing business with us, and our
business, results of operations and reputation could be harmed.
Consolidation of our customers and suppliers could negatively affect the pricing of our products.
Veterinarians are our primary customers. In recent years, there has been a trend towards the concentration of veterinarians in large
clinics and hospitals. In addition, our suppliers have seen consolidation in their industries. Furthermore, we have seen the
expansion of corporate customers, including larger cross-border ones, and an increase in the consolidation of buying groups
(cooperatives of veterinary practices that leverage volume to pursue discounts from manufacturers). The pace of consolidation and
structure of markets varies greatly across geographies. If these trends towards consolidation continue, these customers and
distributors could attempt to improve their profitability by leveraging their buying power to obtain favorable pricing and payment
terms. These impacts could have a material adverse effect on our operating results and financial condition.
When our information systems (or third-party systems we rely on) are interrupted, damaged by unforeseen events, are subject
to cyberattacks or fail for any extended period of time or unauthorized access is obtained to a Customer’s or their Client’s
data, we may incur significant liabilities, our service may be perceived as not being secure, Customers may curtail or stop
using our products or services and our results of operations could be materially adversely affected.
The services we offer involve the maintenance of our Customers’ and Animal Owners sensitive information. In addition, we rely
on IS in our business to obtain, rapidly process, analyze, manage, and store data to, among other things:
Covetrus, Inc. 2021 Form 10-K
21
•
The theft, destruction, loss, misappropriation or release of confidential data or intellectual property
•
Operational or business delays resulting from the disruption of information systems and subsequent clean-up and
mitigation activities
•
The need to continually evolve procedures and safeguards to meet new IS challenges, and enhancing protections, and
conducting investigations and remediation, may impose additional costs on us
•
Claims, fines and penalties, and costs for remediation, or substantial defense and settlement expenses and
•
Negative publicity resulting in reputation or brand damage with our Customers or Animal Owners, suppliers or industry
peers or the loss of sales or Customers
We store, process and use information collected from or about our Customers and Animal Owners that subjects us to
legislative and regulatory burdens and may expose us to liability and potential objections from such Customers and Animal
Owners, and our actual or perceived failure to adequately protect or appropriately use data could harm our brand, our
reputation in the marketplace and our business.
Because we collect, store, process and use data, some of which contains personal information, we are subject to complex and
evolving laws and regulations relating to privacy, data protection and other matters related to personal information. Failure to
abide by these laws, regulations and standards could expose us to breach of contract claims, investigations, substantial fines,
penalties and other liabilities and expenses, costs for remediation and harm to our reputation. Our Customers and Animal Owners
may also object to or opt out of the collection and use of their data, which may harm our business.
Certain states in which we operate, including California, and countries outside of the United States have adopted or may in the
future adopt new regulations governing handling, storage, use and protection of personal information. The CCPA is a state statute
intended to enhance privacy rights and consumer protection for residents of California, U.S. Both in the United States and abroad,
these laws and regulations continue to evolve and remain subject to significant change. In addition, the application and
interpretation of these laws and regulations are often uncertain. If we fail to comply with such laws and regulations, we could be
required to make significant changes to our products or services, or incur substantial fines, penalties, or other liabilities. For
example, if legislation or regulations are adopted, interpreted or implemented in a manner that is inconsistent with our current
business practices and that require changes to these practices, the design of our products and services or privacy practices, it could
have a material adverse effect on our business, financial condition, results of operations and cash flows. The costs of compliance
with, and the other burdens imposed by, new or existing laws or regulatory actions may prevent us from selling our products or
services, or increase the costs of doing so, and may affect our ability to invest in or develop products or services. In addition, a
determination by a court or government agency that any of our practices do not meet these standards could result in liability or
negative publicity and could have a material adverse effect on our business, financial condition, results of operations and cash
flows.
In addition, the European Parliament and the Council of the European Union have adopted the EU GDPR effective from May 25,
2018, which increases privacy rights for individuals in Europe, extends the scope or responsibilities for data controllers and data
processors and imposes increased requirements and potential penalties on companies offering goods or services to individuals
who are located in Europe, or Data Subjects, or monitoring the behavior of such individuals (including by companies based
outside of Europe). Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of total company
revenues. Individual member states may impose additional requirements and penalties as they relate to certain things such as
employee personal data. Among other things, the GDPR requires, with respect to personal data concerning Data Subjects,
company accountability, consents from Data Subjects or other acceptable legal basis needed to process the personal data, prompt
breach notifications within 72 hours, fairness and transparency in how the personal data is stored, used or otherwise processed,
and data integrity and security, and provides rights to Data Subjects relating to modification, erasure and transporting of the
personal data. Our efforts to implement programs and controls that comply with the GDPR are likely to impose additional costs
on us, and we cannot predict whether the interpretations of the requirements, or changes in our products or services in response to
new requirements or interpretations of the requirements, will be accepted as compliant by applicable regulatory authorities.
Successful claims for misappropriation or release of confidential or personal data brought against us or fines or other penalties
assessed or any claim that results in significant adverse publicity against us could have a material adverse effect on our business
and reputation.
Additionally, changes in the legislative or regulatory action related to cybersecurity may increase our costs to develop or
implement new technology-based products and services. In addition, changes in the regulatory environment could increase our
compliance related costs.
Risks associated with these and other actual or perceived IS security breaches may include, among other things:
Covetrus, Inc. 2021 Form 10-K
22
•
Management, communication, and integration problems resulting from language barriers, cultural differences and
geographic dispersion of our customers and personnel
•
Compliance with foreign laws, including laws regarding online disclaimers, advertising, liability of online service
providers for activities of customers especially with respect to hosted content, and more stringent laws in foreign
jurisdictions relating to consumer privacy and protection of data collected from individuals and other third parties
•
Accreditation and other regulatory requirements to do business and to provide domain name registration, web-hosting
and other products in foreign jurisdictions
•
Greater difficulty in enforcing contracts, including our universal terms of service and other agreements
•
Increased expenses incurred in establishing and maintaining office space and equipment for our international operations
•
Greater costs and expenses associated with international marketing and operations
•
Greater risk of unexpected changes in regulatory practices, tariffs, trade disputes and tax laws and treaties, as well
multiple and possibly overlapping tax regimes
•
Different or lesser degrees of protection for our or our customers' intellectual property and free speech rights in certain
markets
•
Increased exposure to foreign currency risks
•
Increased risk of a failure of employees to comply with both U.S. and foreign laws, including export and antitrust
regulations, anti-bribery regulations and any trade regulations ensuring fair trade practices
•
Heightened risk of unfair or corrupt business practices in certain geographies and
Our business is subject to risk based on global economic conditions.
Macroeconomic, business, and financial disruptions could have a material adverse effect on our business, financial condition,
results of operations and cash flows. Certain of our Customers, Animal Owners and our suppliers could be affected directly by an
economic downturn, including as a result of the COVID-19 pandemic or political instability, war, uprisings, or hostilities and
associated broad-reaching economic sanctions, and could face credit issues or cash flow problems that could give rise to payment
delays, increased credit risk, bankruptcies and other financial hardships that could decrease the demand for our products or hinder
our ability to collect amounts due from Customers. If one or more of our large Customers discontinue their relationship with us
because of economic conditions or otherwise, our operating results and financial condition may be materially adversely affected.
Furthermore, our exposure to credit and collectability risk is higher in certain international markets and our ability to mitigate
such risks may be limited. While we have procedures to monitor and limit exposure to credit and collectability risk, there can be
no assurances such procedures will effectively limit such risk and avoid losses. In addition, since Animal Owners typically utilize
discretionary income to purchase services or products for their pets, economic concerns may cause some Animal Owners to forgo
or defer visits to veterinary practices or could reduce their willingness to treat pet health conditions or even to continue to own a
pet.
Our business is exposed to domestic and foreign currency fluctuations that could have a material adverse effect on our
business, financial condition, results of operations and cash flows.
As a percentage of our consolidated net sales, net sales outside of the U.S. were approximately 41% in 2021, 45% in 2020, and
47% in 2019. Changes in non-U.S. currencies relative to the U.S. dollar impact our sales, profits, assets, and liabilities. In
addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable effects when the
operating results of our non-U.S. business activity are translated into U.S. dollars and could cause our results of operations to
differ from our expectations and the expectations of our investors. For our international sales denominated in U.S. dollars, an
increase in the value of the U.S. dollar relative to foreign currencies could make our products and services less competitive in
international markets. Alternately, a weakening of the currencies in which transactional sales are generated relative to the
currencies in which costs are denominated would decrease operating profits and cash flow. Changes in currency exchange rates
may also affect the relative prices at which we purchase materials and services in foreign markets. In addition, the impact of
currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively
impact our operating results. While we may use financial instruments to mitigate the impact of fluctuations in currency exchange
rates on our cash flows, unhedged exposures would continue to be subject to currency fluctuations.
The future growth of our business depends in significant part on increasing our global sales.
Conducting and expanding international operations could negatively impact our financial condition, results of operations, and
cash flow and subjects us to risks we generally do not face in the U.S., including:
Covetrus, Inc. 2021 Form 10-K
23
•
The potential for political, social, or economic unrest, terrorism, hostilities or war, including the conflict between Russia
and Ukraine and the potential impact of financial and economic sanctions on the regional and global economy
We may require financing to fund our ongoing operations and capital expenditures, the availability of which is uncertain.
The capital and credit markets can experience volatility and disruption. Such markets can exert extreme downward pressure on
stock prices and upward pressure on the cost of new debt capital and can severely restrict credit availability for most issuers. We
may seek financing to refinance current debt and to fund our ongoing operations that require expenditures to develop
enhancements to our platforms, expand capacity, and add new businesses complementary to our product lines. In the future we
may engage in transactions that depend on our ability to obtain financing.
Depending on conditions in the financial markets and our financial performance, we may not be able to raise additional capital on
favorable terms, or at all. If we are unable to pursue our current and future spending programs, we may be forced to cancel or
scale back those programs. Failure to successfully pursue our capital expenditure and other spending plans could negatively affect
our ability to compete effectively and have a material negative effect on our business and results of operations.
Assertions by a third party that we are infringing its intellectual property, whether successful or not, could subject us to costly
and time-consuming litigation or expensive licenses.
The software and technology industries are characterized by the existence of many patents, copyrights, trademarks, and trade
secrets and by frequent litigation based on allegations of infringement or other violations of intellectual property rights. The
preparation or sale of our products may infringe on the patent rights of others. As we face increasing competition, the possibility
of intellectual property rights claims against us may grow. Our technology may not be able to withstand any third-party claims or
rights against their use. Additionally, although we have licensed from other party's proprietary technology covered by patents, we
cannot be certain that any such patents will not be challenged, invalidated, or circumvented. These types of claims could harm our
relationships with our Customers, may deter future Customers from using our services or could expose us to litigation for such
claims.
Any intellectual property rights claim against us, with or without merit, could be time-consuming, expensive to litigate or settle
and could divert management attention and financial resources. An adverse determination also could prevent us from offering our
services to Customers and may require the procurement or development of substitute services that do not infringe. As a result of
intellectual property rights claims against us, we may have to pay damages or stop using technology or formulation found to be in
violation of a third party’s rights. We may have to seek a license for the intellectual property, which may not be available on
reasonable terms, if at all, and may significantly increase our operating expenses or may require us to restrict our business
activities in one or more respects. As a result, we may also be required to develop alternative non-infringing technology, which
could require significant effort and expense.
In addition, we use open source software in our platform and will use open source software in the future. From time to time, we
may face claims from companies that incorporate open source software into their products, claiming ownership of, or demanding
release of, the source code, the open source software, or derivative works that were developed using such software, or otherwise
seeking to enforce the terms of the applicable open source license. These claims could also result in litigation, require us to
purchase a costly license or require us to devote additional product, technology, and development resources to change our
platform or services, any of which would have a material adverse effect on our business, financial condition, results of operations
and cash flows.
Our business and operations are subject to risks related to climate change.
The long-term effects of global climate change present both physical risks (such as extreme weather conditions or rising sea
levels) and transition risks (such as regulatory or technology changes), which are expected to be widespread and unpredictable.
These changes could over time affect, for example, the availability and cost of products, commodities and energy (including
utilities), which in turn may impact our ability to procure goods or services required for the operation of our business at the
quantities and levels we require. In addition, many of our operations and facilities around the world are in locations that may be
impacted by the physical risks of climate change, and we face the risk of losses incurred as a result of physical damage to
distribution or fulfillment centers, loss or spoilage of inventory and business interruption caused by such events and insurance
may not be available or cost effective for the coverage limits needed.
Covetrus, Inc. 2021 Form 10-K
24
•
Limiting our ability to obtain additional debt or equity financing needed for working capital, capital expenditures, debt
service requirements, acquisitions and general corporate or other purposes,
•
Requiring a substantial portion of our cash flows from operations be dedicated to payments on our indebtedness instead
of other purposes, including working capital, capital expenditures and future business growth opportunities,
•
Limiting our ability to make continuous improvements to our business model and adjust to changing market conditions
that may place us at a competitive disadvantage compared to our competitors with less debt, and
•
Increasing our vulnerability to a downturn in general economic conditions or in our business
The agreements governing our Credit Facilities contain restrictive covenants, which restrict our operational flexibility.
The agreements governing our Credit Facilities contain restrictions and limitations on our ability to engage in activities that may
be in our long-term best interests, including financial and other restrictive covenants that will limit our ability to:
•
Incur additional indebtedness,
•
Make dividends and other restricted payments,
•
Incur additional liens,
•
Consolidate, merge, sell, or otherwise dispose of all or substantially all assets,
•
Make investments,
•
Transfer or sell assets,
•
Enter into restrictive agreements,
•
Change the nature of the business, and
•
Enter certain transactions with affiliates
The agreements governing our Credit Facilities also contain other restrictions customary for facilities of this nature.
Our ability to borrow additional amounts or avoid acceleration of borrowed amounts under these agreements will depend on
satisfaction of these covenants, including two financial covenants: (i) a maximum consolidated net total leverage ratio and (ii) a
minimum consolidated net interest coverage ratio. Events beyond our control could affect our ability to meet these covenants. Our
failure to comply with obligations under these agreements may result in an event of default under those agreements. A default, if
not cured or waived, may permit acceleration of our indebtedness. If our indebtedness is accelerated, we cannot be certain that we
will have sufficient funds available to pay the accelerated indebtedness or that we will have the ability to refinance the accelerated
indebtedness on terms favorable to us or at all. This could have a material adverse effect on our business, financial condition,
results of operations and cash flows and could cause us to become bankrupt or insolvent.
We also use natural gas, diesel fuel, gasoline and electricity in our operations, all of which could face increased regulation as a
result of climate change or other environmental concerns. Regulations limiting greenhouse gas emissions and energy inputs may
also increase in coming years, which may increase our costs associated with compliance. These events and their impacts could
otherwise disrupt and adversely affect our operations and could materially adversely affect our financial performance.
Risks Relating to Indebtedness
Our substantial indebtedness could adversely affect our financial condition and impair our ability to operate our business. We
may incur substantial additional indebtedness, which could further exacerbate the risks to our financial condition.
On February 7, 2019, we entered into a $1.5 billion syndicated credit agreement with a group of lenders for a five-year term (the
“Credit Facilities”). The Credit Facilities included a $1.2 billion term loan facility, which was fully funded and primarily used to
pay a dividend to Henry Schein, and a $300 million revolving line of credit for working capital and general corporate purposes.
As of December 31, 2021, there was $1.1 billion outstanding under the term loan facility and there were no borrowings under the
revolving line of credit, although we do utilize the revolving line of credit from time to time.
We may incur significant additional indebtedness in the future, including secured indebtedness. Although the agreements
governing our current Credit Facilities contain restrictions on the incurrence of additional indebtedness, these restrictions are
subject to qualifications and exceptions, and the additional indebtedness incurred in compliance with these restrictions could be
substantial.
Our current level of indebtedness, and any additional indebtedness, could have a material adverse effect on our business, financial
condition, results of operations and cash flows, including the following:
Covetrus, Inc. 2021 Form 10-K
25
We require a significant amount of cash to service our indebtedness. Our ability to generate such cash depends on many
factors, some beyond our control.
Our ability to make payments on and to refinance our indebtedness, and to fund capital expenditures, will depend on our ability to
generate cash. This ability, to a certain extent, is subject to economic, financial, competitive, legislative, regulatory, and other
factors that are beyond our control. We have substantial indebtedness with significant debt service requirements, and we may
incur additional indebtedness that would lead to increased interest expense and require additional cash flows to fund. In addition,
borrowings under the Credit Facilities bear interest at variable interest rates. During the year ended December 31, 2021, our
interest rate swap contracts with notional amounts aggregating $500 million, which fixed a portion of future interest payments
associated with our variable-rate term loan facility, matured on July 31, 2021. Interest rate increases could result in larger debt
service requirements. Such an increase in our debt service obligations would adversely affect our cash flows. We cannot
guarantee that our business will generate sufficient cash flows from operations or that future borrowings will be available to us
under our Credit Facilities or any subsequent credit agreement, or that we can obtain alternative financing proceeds in an amount
sufficient to enable us to pay our indebtedness or to fund our other liquidity needs. We may need to refinance all or a portion of
our indebtedness at or before maturity. We cannot provide assurance that we will be able to refinance any of our indebtedness on
commercially reasonable terms or at all.
The debt service obligations under our Credit Facilities could also reduce funds available for working capital, capital expenditures
and other general corporate purposes and may create competitive disadvantages relative to other companies with greater liquidity.
Risks Relating to Regulation and Governmental Action
We are subject to substantial regulation in our business and operations and failure to comply with, or material changes to
such regulations, could have a material adverse effect on our business and results of operations.
Our pharmacy and supply chain businesses are impacted by federal and state laws and regulations governing, among other things:
the purchase, distribution, management, compounding, dispensing, marketing and labeling of prescription drugs and related
services; DEA and state regulation affecting the sale and distribution of controlled substances; and statutes and regulations related
to the sale and marketing of animal drugs, pet food, insecticides and devices. Our failure to comply with any of these laws and
regulations could severely limit or curtail our pharmacy and supply chain operations, which would materially harm our business
and prospects. Our business could be affected by changes in these or any newly enacted laws and regulations, as well as federal
and state agency interpretations of such statutes and regulations. Such statutory or regulatory changes could require that we make
changes to our business model and operations and could require that we incur significantly increased costs to comply with such
regulations. Further, we are required to comply with the laws of, and regulations promulgated by, various states, including the
pharmacy boards of such states. State pharmacy boards regulate the dispensing and marketing of our pharmaceutical products and
may take action, including fines, against companies for violations of their rules and regulations.
The FDA issued proposed guidance titled Guidance for Industry #256: Compounding Animal Drugs from Bulk Drug Substances
(“GFI #256”) on November 18, 2019. The comment period for this proposed guidance ended on October 15, 2020. If adopted,
GFI #256 would strictly limit the circumstances under which the FDA would permit compounding of veterinary drug products. It
is uncertain whether GFI #256 will be adopted in the form proposed, or at all. The proposed guidance is similar to guidance
proposed by the FDA in 2015 and ultimately withdrawn in November 2017. These and other restrictions that may be imposed on
the activities of compounding pharmacies may limit the available market for compounded formulations from bulk substances for
animal use, as compared to the market available for the FDA-approved animal drugs. The FDA was expected to issue its final
guidance in January 2022. However, several members of Congress recommended the FDA delay this action. As of the February
25, 2022, the industry has not received final guidance.
The marketing and sale of compounded formulations is subject to and must comply with state statutes and regulations governing
compounding pharmacies. These statutes and regulations include, among other things, restrictions on compounding in advance of
receiving an animal-specific prescription, restrictions on compounding drugs that are essentially copies of FDA-approved drugs,
restrictions on compounding drug products for office use, and restrictions on wholesaling. These and other restrictions on the
activities of compounding pharmacies may significantly limit the market available for compounded formulations, as compared to
the market available for FDA-approved drugs.
Covetrus, Inc. 2021 Form 10-K
26
•
Compliance with governmental controls, trade restrictions, restrictions on direct investments, quotas, embargoes, import
and export restrictions, tariffs, duties, and regulatory and licensing requirements by domestic or foreign entities,
including restrictions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the
U.K. Office of Financial Sanctions Implementation, United Nations Security Council, and Australia's Department of
Foreign Affairs and Trade,
•
Difficulties in building, staffing, and managing foreign operations (including a geographically dispersed workforce) and
maintaining compliance with foreign labor laws,
•
Burdens to comply with, and different levels of protection offered by, multiple and potentially conflicting foreign laws
and regulations, including those relating to environmental, health and safety requirements and intellectual property,
•
Changes in laws, regulations, government controls or enforcement practices with respect to our business and the
businesses of our Customers,
•
Political and social instability, including crime, civil disturbance, terrorist activities, armed conflicts, outbreak of disease,
and natural and other disasters,
•
Ongoing instability or changes in a country’s or region’s regulatory, economic, or political conditions, including as a
result of the United Kingdom’s leaving the European Union, or Brexit, and any other similar referenda or actions by
other European Union member countries,
•
Local business and cultural factors that differ from our normal standards and practices, including business practices
prohibited by the U.S. Foreign Corrupt Practices Act, U.K. Bribery Act, and other anti-corruption laws and regulations,
•
Longer payment cycles and increased exposure to counterparty risk,
•
Disruptions in transportation of our products or our supply chain, and
•
The differing product and service needs of foreign Customers.
The multinational nature of our business subjects us to potential risks that various taxing authorities may challenge the pricing of
our cross-border arrangements and subject us to additional tax, adversely impacting our effective tax rate and our tax liability. In
addition, international transactions may involve increased financial and legal risks due to differing legal systems and customs.
Compliance with these requirements may prohibit the import or export of certain products and technologies or may require us to
obtain a license before importing or exporting certain products or technology. A failure to comply with any of these laws,
regulations or requirements could result in civil or criminal legal proceedings, monetary or non-monetary penalties, or both,
disruptions to our business, limitations on our ability to import and export products and services, and damage to our reputation.
While the impact of these factors is difficult to predict, any of them could have a material adverse effect on our business, financial
condition, results of operations and cash flows. Changes in any of these laws, regulations or requirements, or the political
environment in a particular country, may affect our ability to engage in business transactions in certain markets, including
investment, procurement, and repatriation of earnings.
Legislation may be proposed in the United States or other jurisdictions in the future that could impact the distribution channels for
our companion animal products. For example, such legislation may require veterinarians to provide Animal Owners with written
prescriptions and disclosure that the Animal Owner may fill prescriptions through a third party, which may further reduce the
number of Animal Owners who purchase their animal-health products directly from veterinarians. Such requirements may lead to
increased use of generic alternatives to our products or the increased substitution of our products with other animal-health
products or human health products if such other products are deemed to be lower-cost alternatives. Any of these events could have
a material adverse effect on our business, financial condition, results of operations and cash flows.
The sale and distribution of our products is also regulated in most or all jurisdictions outside the United States where our business
operates. Local regulations on sale and distribution may be tightened, for example regarding labeling, quality, or transportation,
which may increase our costs of doing business. In the European Union, a revision of legislation on veterinary medicinal products
became effective January 28, 2022 throughout the European Union that limits the use of antibiotics, tightens importation rules,
and imposes stricter pharmacovigilance standards. This regulation must still be implemented at the member state level and as
such, additional requirements may be adopted by individual member states which would have the effect of increasing the
compliance requirements for our business in the European Union with resulting costs.
A significant portion of our operations is conducted in foreign jurisdictions and is subject to the economic, political, legal,
regulatory, and business environments of the countries in which we do business. Risks associated with such international
operations could negatively affect our business, financial condition, results of operations and cash flows.
We have significant operations outside of the United States. We expect that we will continue to expand our international
operations in the future. International operations inherently subject us to several risks and uncertainties, including:
Covetrus, Inc. 2021 Form 10-K
27
•
Quarterly variations in our revenues, operating expenses, and earnings
•
Developments in the financial markets and worldwide or regional economies,
•
Announcements of innovations or new products or services by us or our competitors,
•
Announcements by the government relating to regulations that govern our industry,
•
Significant sales of our common stock or other securities in the open market,
•
Variations in interest rates,
•
Changes in the market valuations of other comparable companies, and
•
Changes in accounting principles
In addition, as reported in the Schedule 13D/A filed by CD&R on November 20, 2020, CD&R beneficially owns 33,670,541
shares, or approximately 24.4% of our outstanding shares of common stock, based on 138,011,969 shares issued and outstanding
as of December 31, 2021. We have granted CD&R customary registration rights with respect to its shares of our common stock. If
CD&R or another large institutional shareholder were to sell a substantial number of shares of our common stock at once or in
large blocks, the market price of our common stock could decline.
Our business could be materially adversely affected by a negative outcome in significant litigation or other legal proceedings.
We are currently involved in a shareholder securities litigation, and may be subject to future litigation matters, claims, and
demands. These matters may divert financial and management resources that would otherwise be used to benefit our operations.
No assurances can be given that the results of these matters will be favorable to us. An adverse resolution or outcome of any of
these lawsuits, claims, demands or investigations, in excess of related insurance coverage, could have a negative impact on our
results of operations, financial condition, and liquidity.
We are subject to complex environmental, health and safety laws and regulations.
We are subject to various federal, state, local and foreign environmental, health and safety laws and regulations. These laws and
regulations govern matters such as the emission and discharge of hazardous materials into the ground, air or water; the generation,
use, storage, handling, treatment, packaging, transportation, exposure to and disposal of hazardous and biological materials,
including recordkeeping, reporting and registration requirements; and the health and safety of our employees. Due to our
operations, these laws and regulations also require us to obtain, and comply with, permits, registrations or other authorizations
issued by governmental authorities. These authorities can modify or revoke our permits, registrations or other authorizations and
can enforce compliance through fines and injunctions.
Furthermore, regulatory agencies are showing increasing concern over the impact of animal health products on the environment.
This increased regulatory scrutiny has in the past and may in the future necessitate that additional time and resources be spent to
address these concerns in both new and existing products.
Our failure to comply with the environmental, health and safety laws and regulations to which we are subject, including any
permits issued thereunder, may result in environmental remediation costs, loss of permits, fines, penalties or other adverse
governmental or private actions, including regulatory or judicial orders enjoining or curtailing operations or requiring corrective
measures, installation of pollution control equipment or remedial measures. Environmental laws and regulations are complex,
change frequently, have tended to become more stringent and stringently enforced over time and may be subject to new
interpretation. It is possible that our costs of complying with current and future environmental, health and safety laws, and our
liabilities arising from past or future releases of, or exposure to, hazardous materials could materially adversely affect our
business, financial condition and results of operations.
Risks Relating to Our Common Stock
The market price of our common stock is likely to be highly volatile and subject to wide fluctuations, and you may be unable to
resell your shares at or above the price at which you acquired them, or at all.
The market price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to many
factors that are beyond our control, including, but not limited to:
Covetrus, Inc. 2021 Form 10-K
28
•
Authorize the issuance of “blank check” preferred stock that could be issued by our Board without approval of
stockholders,
•
For the first three years following the Merger until the 2022 annual meeting of stockholders, divide our Board into three
classes, serving staggered terms of one, two and three years, respectively,
•
Provide that vacancies on our Board may be filled only by a majority vote of directors then in office,
•
Prohibit stockholders from calling special meetings of stockholders,
•
Prohibit stockholder action by written consent,
•
Establish advance notice requirements for stockholder nominations of candidates for election as directors before an
annual or special meeting of our stockholders or to bring other business before an annual meeting of our stockholders,
and
•
Subject us to Section 203 of the DGCL, which will prohibit us from engaging in business combinations with certain
“interested stockholders” for three years following the date such stockholder became interested unless certain criteria are
met.
These provisions may prevent our stockholders from receiving the benefit from any premium to the market price of the common
stock offered by a bidder in a takeover context. Even in the absence of a takeover attempt, the existence of these provisions may
adversely affect the prevailing market price of the common stock if the provisions are viewed as discouraging takeover attempts
in the future. The amended and restated by-laws also make it difficult for stockholders to replace or remove management by
giving our Board the sole ability to elect and remove officers. These provisions may facilitate management entrenchment that may
delay, deter, render more difficult or prevent a change in our control, which may not be in the best interests of the stockholders.
Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware, or if the Court
of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of
Delaware (each such court, as applicable, the “Selected Forum”), as the exclusive forum for certain litigation that may be initiated
by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
Failure to establish and maintain effective internal controls could have a material adverse effect on our ability to report our
financial condition, results of operations, or cash flows accurately and on a timely basis and could harm our reputation.
As a publicly traded company, we are subject to the Exchange Act and SOX. SOX requires that we maintain effective disclosure
controls and procedures and internal control over financial reporting.
To comply with these requirements, we have and will need to continue to upgrade and implement additional internal controls,
reporting systems, information technology systems and procedures, and hire additional accounting, legal, compliance, and finance
staff. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting that results in
a more than reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or
detected on a timely basis.
During the quarter ended December 31, 2019, management identified a material weakness in our internal controls over financial
reporting relating to our accounting for income taxes. We remediated the material weakness as of December 31, 2021. For a
discussion of our internal controls over financial reporting and a description of the identified material weakness, see Part II, Item
9A. Controls and Procedures of this Report.
Under our amended and restated certificate of incorporation, our non-employee directors generally have no obligation to offer
us corporate opportunities.
Our amended and restated certificate of incorporation addresses potential conflicts of interest with respect to corporate
opportunities and transactions that are presented to, or which otherwise come into the possession of, any of our directors who is
not also one of our employees or an employee of any of our subsidiaries. Under our amended and restated certificate of
incorporation, we renounce any interest or expectancy in such corporate opportunities unless they were presented to a non-
employee director expressly and solely in such person’s capacity as one of our directors.
Anti-takeover provisions in our amended and restated certificate of incorporation and amended and restated by-laws could
discourage, delay, or prevent a change of control and may affect the trading price of our common stock.
Our amended and restated certificate of incorporation and amended and restated by-laws include a number of provisions that may
discourage, delay, or prevent a change in our management or control over us that stockholders may consider favorable. For
example, the amended and restated certificate of incorporation and amended and restated by-laws, collectively:
Covetrus, Inc. 2021 Form 10-K
29
Our amended and restated certificate of incorporation provides that the Selected Forum will be the sole and exclusive forum for
(i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed
to us or our stockholders by any of our current or former directors, officers, employees or stockholders, (iii) any action asserting a
claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated by-
laws or as to which the DGCL confers jurisdiction on a Selected Forum, (iv) any action asserting a claim against us that is
governed by the internal affairs doctrine, (v) any action to interpret, apply, enforce or determine the validity of our amended and
restated certificate of incorporation or our amended and restated by-laws, or (vi) any other action asserting an “internal corporate
claim” under Section 115 of the DGCL. If a stockholder files any of the preceding actions in a court other than a court located
within the State of Delaware (a “Foreign Action”), such stockholder shall be deemed to have consented to (x) the personal
jurisdiction of the Selected Forum in connection with any action brought in such court to enforce the choice of forum provision
and (y) having service of process made on such stockholder in any such enforcement action by service on the stockholder’s
counsel (as such stockholder’s agent) in the foreign action. By becoming a holder of our common stock, a person will be deemed
to have notice of and have consented to the provisions of our amended and restated certificate of incorporation related to choice of
forum. The choice of forum provision in our amended and restated certificate of incorporation may limit our stockholders’ ability
to obtain a favorable judicial forum for disputes with us.
General Risk Factors
If securities or industry analysts publish unfavorable research about us or cease to provide coverage of us, our stock price and
trading volume could decline.
The trading market for our common stock will depend in part on the research reports that securities or industry analysts publish
about us and our business. If one or more of the securities and industry analysts who cover our stock downgrades the stock or
publishes unfavorable research about us, the stock price would likely decline. If one or more of these analysts ceases coverage of
us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause the stock price or trading
volume to decline.
Changes in our tax rates or exposure to additional income tax liabilities could adversely affect our financial results.
Our future effective income tax rates could be unfavorably affected by various factors including, among others, changes in the tax
rates, rules and regulations in jurisdictions in which we generate income. Such taxes could also impact our ability to manage
liquidity globally, invest capital where and when needed, or return capital if so desired. In addition, the amount of income taxes
we pay is subject to ongoing audits by U.S. federal, state and local tax authorities and by non-U.S. tax authorities. If these audits
result in assessments different from amounts recorded, our future financial results may include unfavorable tax adjustments.
Item 1B. Unresolved Staff Comments
None
Item 2.
Properties
Our corporate headquarters consists of two facilities located in Portland, Maine. We utilize distribution centers and offices
throughout the world and across all segments as well as pharmacies in North America, with global square footage of over 3
million.
We have 503A pharmacies for animal health care, that are fully licensed in all 50 states and the District of Columbia, as well as an
FDA registered outsourcing facility under section 503B, for human health care, of the Federal Food, Drug, and Cosmetic Act. We
have pharmacies and an outsourcing facility in Omaha, Nebraska; Portland, Maine; Houston, Texas; and Phoenix, Arizona which
in the aggregate, comprise approximately 190,000 square feet of compounding space for our operations.
Our significant distribution centers are strategically located which helps to reduce transportation costs and facilitate the
distribution of products to our Customers. Our national distribution service centers in Ohio have approximately 350,000 of square
feet. Our distribution centers, which are leased, in Fort Worth, Texas; Albany, New York; Duluth, Georgia; Denver, Colorado;
Des Moines, Iowa; Elizabethtown, Pennsylvania;; Lexington, Kentucky; Ocala, Florida; Colonial Heights, Virginia; Southaven,
Mississippi; Tualatin, Oregon; Visalia, California; Dumfries, Scotland provide approximately 690,000 of square feet for our
operations.
Covetrus, Inc. 2021 Form 10-K
30
We believe that our existing facilities are adequate for our needs, and while all of our global properties are not material, the
constellation of our properties throughout the world is significant to us and our continued success. In 2021, leases we believe are
necessary to grow our operations commenced, including our new 503A pharmacy in Portland, Maine as well as our second
national distribution service center in Ohio, which are both discussed above. See Note 10 - Leases. We believe that our properties
are in good condition, are well maintained, and are suitable and adequate to carry on our business. We have additional operating
capacity at certain distribution center facilities.
Item 3.
Legal Proceedings
Refer to Note 8 - Commitments and Contingencies included in notes to the consolidated financial statements.
Item 4.
Mine Safety Disclosures
Not applicable
Covetrus, Inc. 2021 Form 10-K
31
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity
Securities
Our common stock has been listed on the Nasdaq Global Select Market under the symbol “CVET” since February 8, 2019. Prior
to that date, there was no public trading market for our common stock. A “when-issued” trading market for our common stock
existed between February 4, 2019 and February 7, 2019 under the symbol “CVETV”.
Holders of Common Stock
As of February 18, 2022, there were 461 holders of record of our common stock. This number does not reflect beneficial owners
whose shares are held in street name.
Securities Authorized for Issuance Under Equity Compensation Plans
Information regarding our equity compensation plans and the securities authorized for issuance thereunder is set forth herein
under Part III, Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
below.
Dividend Policy
We have never declared or paid any cash dividends on our common stock. We anticipate that we will retain all available funds
and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the
foreseeable future. In addition, our debt instruments materially restrict our ability to pay dividends on our common stock.
Payment of future cash dividends, if any, will be at the discretion of the Board of Directors after taking into account various
factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or
then-existing debt instruments, and other factors the Board of Directors deems relevant.
Stock Performance Graph
The graph below compares the cumulative total shareholder return of our common stock to the Nasdaq Global Market Composite
Index and the S&P 600 Health Care Index. An investment of $100 and reinvestment of all dividends are assumed on February 7,
2019, the effective date of the registration of our common stock. The graph shows the value for each of these investments through
December 31, 2021.
Covetrus, Inc. 2021 Form 10-K
32
February 7,
2019
December 31,
2020
March 31,
2021
June 30,
2021
September 30,
2021
December 31,
2021
Covetrus Inc
$100
$67
$70
$63
$42
$46
Nasdaq Global Market Composite
$100
$196
$195
$204
$180
$166
S&P 600 Health Care
$100
$146
$158
$167
$157
$155
Recent Sales of Unregistered Securities
Not applicable
Issuer Purchases of Equity Securities
The following table sets forth information about our purchases of our outstanding common stock during the quarter ended
December 31, 2021:
Period
Total Number of
Shares Purchased (a)
Average Price Paid
Per Share (a)
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans or
Programs
Approximate Dollar
Value of Shares that
May Yet be
Purchased Under
Plans or Programs
October 2021
20,414 $
19.35
— $
—
November 2021
2,346 $
19.81
— $
—
December 2021
5,448 $
17.25
— $
—
28,208 $
18.98
—
—
(a) Shares of common stock we purchased were solely for the cancellation of shares of stock withheld for related tax obligations that occurs upon vesting of
restricted shares
Item 6.
[Reserved]
Covetrus, Inc. 2021 Form 10-K
33
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Our financial information is summarized in this MD&A and is intended to help the reader better understand Covetrus, our
operations, financial results, and current business environment for the year ended December 31, 2021 compared to December 31,
2020. This MD&A should be read in conjunction with our consolidated financial statements and accompanying notes in Item 8.
Financial Statements and Supplementary Data of this Report.
The discussion of our financial condition and results of operations for the year ended December 31, 2020 as compared to the year
ended December 31, 2019 included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of
Operations in our Annual Report on Form 10-K for the year ended December 31, 2020 is incorporated by reference into this
MD&A.
Overview
We are organized based upon geographic region and focus on delivering our platform of products and services to our Customers
on a geographical basis. Our reportable segments are (i) North America, (ii) Europe, and (iii) APAC & Emerging Markets. Our
major product groups that we disaggregate within our reportable segments are (i) supply chain services, (ii) software services, and
(iii) prescription management. See Note 2 - Segment Data and Note 3 - Revenue from Contracts with Customers.
Across our segments and major product groups, the willingness of Animal Owners to spend with their veterinarians on
preventative and therapeutic treatments and procedures is critical to our financial performance. In the companion-animal market
specifically, there is an ongoing trend of owners humanizing, or providing the best possible lives for their pets. Across the
companion animal, equine, and large animal markets, we anticipate that for us to succeed on our strategic roadmap, we should
prioritize value creation with our Customers so that we can seek to strengthen the relationship between Customers and Animal
Owners as well as enable our Customers to provide proactive healthcare options to Animal Owners, including our investment in
Covetrus Pulse™, our veterinary operating system, higher margin proprietary brand products and compounding.
See Item 1. Business for a detailed discussion of our corporate mission and strategy that should be read in conjunction with our
discussion and analysis of financial condition and results of operations.
Key Factors and Trends Affecting our Results
Growth continues following the onset of the COVID-19 pandemic
In an effort to contain COVID-19 or slow its spread, particularly in 2020, governments around the world enacted various
measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence,
and practice social distancing when engaging in essential activities. The determination of what was an “essential” business was
mandated by local authorities. Operationally, all of our distribution centers and pharmacies remained open as veterinary medicine
has been deemed an essential service in most geographies across the globe. During 2020, the animal-health market largely
benefited from the lockdowns instituted in response to the COVID-19 pandemic, including the benefit to veterinary practices,
including our Customers, from an increase in visits driven by people adopting more pets during 2020 as well as companion
Animal Owners increasing their per-visit spend with their veterinarians. This is expected to be a multi-year effect as these Animal
Owners seek care from veterinary practices for their newly adopted pets. Additionally, the required responses to mitigate the
spread of the COVID-19 pandemic shifted Customer and Animal-Owner demand to our prescription management and online
pharmacy services. During 2020, we undertook certain temporary cost-containment measures to help us manage the uncertainty
created by the COVID-19 pandemic, which are no longer in place. Additionally, we experienced a beneficial effect on SG&A in
2020 and 2021, relative to pre-pandemic levels, from decreased travel and in-person trade shows and conferences as a result of the
COVID-19 pandemic.
The net sales growth for the year ended December 31, 2021 reflects the continued strength of the companion-animal market, our
improved sales execution which was furthered by our commercial organization realignment, and elevated purchasing patterns
from our prescription management and online pharmacy service users. Our prescription management and online pharmacy service
are currently available in our North America segment and as the economy re-opens, which remains unpredictable due to the
volatility of COVID-19 variant infection rates, users’ behavior may change.
Covetrus, Inc. 2021 Form 10-K
34
However, we believe the retention of Customers and their Animal-Owner clients brought to us during the COVID-19 pandemic in
2020 and beyond, our continued market penetration, and the introduction of product and service offerings aimed at driving greater
utilization of our online pharmacy services could lead to long-term net sales growth.
We adhere to the regulations and guidelines instituted by local authorities in our area of operations and make judgments with the
best available information at the time. We are continuing to actively monitor how COVID-19 and related variants are impacting
our business operation and the industry and may take further actions to alter our business operations in the best interests of our
employees, Customers, partners, suppliers, and other stakeholders, or as required by federal, state, or local authorities.
Foreign Currency Effects
Our performance was impacted by the appreciation of other currencies as compared to USD for the year ended December 31,
2021 as compared to the same period of 2020. However, this effect may be temporary and reverse. In December of 2021, we
entered foreign currency forward exchange contracts, that are not designated as hedges, to offset our exposure to foreign exchange
fluctuations driven by certain intercompany loans with foreign subsidiaries. For the year ended December 31, 2021, these
intercompany loans resulted in foreign exchange losses of $5 million. In future periods we expect by the income statement foreign
exchange gains or losses on these intercompany loans to be offset by gains or losses on forward exchange contracts, which we
intend to renew on a monthly basis beginning from December 31, 2021. Because these forward contracts must be settled in cash
each month, they may have a positive or negative impact on our cash balances and cash flows from operating activities.
Investing in Innovation
Our strategic initiatives in the near and long-term are focused on transforming our offerings into an all-in operating system
solution across our segments. Our current priorities focus on accelerating the contribution provided by our higher margin
technology, e-commerce, and proprietary products and solutions, including aligning our organization structure to harmonize and
advance these offerings in a coordinated go-to-market strategy. SmartPak and Covetrus-branded products and proprietary brands
like Kruuse, Vi, and Calibra are included within our supply chain services major product category. Our prescription management
platform and compounding services are included within our prescription management major product category. To support these
strategic initiatives, our spending will likely further increase to support our continued acquisitive and organic growth in the
animal-health market. We also expect to invest in internal initiatives to develop technology to be used across our business to drive
greater efficiency as well as coordination of our global employee base. However, we closely monitor the expenses we deem
necessary for growth and maintain ongoing cost management practices to align expenses with expected volumes and provide
long-term flexibility for our transformation.
Cost Inflation and Labor Availability
We are also closely tracking macroeconomic factors, including rising inflation, that could lead to increased costs for our
operations, which our expense management practices may or may not be able to offset. For example, costs have risen related to
elevated labor turnover beginning in the spring of 2021, worker shortages and increased competition for a diminished labor pool,
employee retention programs, global supply chain disruptions, and transportation rate increases.
Terms with Key Suppliers, Customers, and Partners
Each year, suppliers engage in negotiations with us regarding pricing terms, including performance rebates and other growth
incentives. Our supply chain services are dependent upon third-party suppliers, and the results of these negotiations, including
whether the contractual relationship remains in place, can have a material impact on the financial performance of our business.
Effective January 1, 2021, we no longer are partnered with Merck & Co., in the U.K., which contributed to a decrease in our U.K.
Net sales for the year ended December 31, 2021. We also are no longer partnered with one of our customers in the U.K., which
further depressed our U.K. net sales throughout 2021. For the year ended December 31, 2021 as compared to the year ended
December 31, 2020, we experienced a 6% decline relative to consolidated net sales, or $193 million excluding foreign exchange
gains, in our consolidated net sales attributable to the decreasing net sales in the U.K. On gross profit, the U.K.'s contribution
declined to 2% of consolidated gross profit for the year ended December 31, 2021 as compared to 4% for the year ended
December 31, 2020.
The transition of our supply chain operations in Germany to a third-party logistics provider in late 2020 has resulted in disruption
to our supply chain and a reduction in customer sales volumes. Although we are making progress on stabilizing our customer base
and improving service levels in this market, we continue to experience lower sales volumes following the transition.
Covetrus, Inc. 2021 Form 10-K
35
(In millions)
Years Ended
Location
December 31, 2021
December 31, 2020
Cost of sales
$
7 $
5
Selling, general and administrative
129
130
Total amortization expense
$
136 $
135
Definition of Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (“Adjusted EBITDA”)
Adjusted EBITDA is a non-GAAP financial measure used to (i) aid management and investors with year-over-year comparability,
(ii) determine management performance under our compensation plans, (iii) plan and forecast, (iv) communicate our financial
performance to our Board of Directors, shareholders, and investment analysts, and (v) understand our operating performance
without regard to items we do not consider a component of our core ongoing operating performance. Adjusted EBITDA has
certain limitations in that it does not consider the impact of certain expenses to our consolidated statements of operations.
Adjusted EBITDA excludes share-based compensation, strategic consulting, transaction costs, formation of Covetrus expenses,
separation programs and executive severance, carve-out operating expenses, certain IT infrastructure expenses necessary to
establish ourselves as a newly public company, goodwill impairment charges, other impairments, capital structure-related fees, the
proportionate share of the adjustments to EBITDA of consolidated and non-consolidated affiliates where Covetrus ownership is
less than 100%, and other income and expense items, net. Currently, we do not allocate expenses managed at the corporate level,
such as corporate wages and related benefits, corporate occupancy costs, professional services utilized at the corporate level, and
non-recurring expenses to our operating segments. Other companies may not define or calculate Adjusted EBITDA in the same
way. We provide Adjusted EBITDA by segment as a supplemental measure to GAAP as well as on a consolidated, non-GAAP
basis. Non-GAAP Adjusted EBITDA on a total segment basis is reconciled in Note 2 - Segment Data as required by ASC 280.
For the year ended December 31, 2021 compared to the year ended December 31, 2020 there was an 18% reduction in net sales in
Germany. However, these customer losses are not expected to have a significant effect on us as our German operations represent
approximately 1% of our consolidated net sales for the for the year ended December 31, 2021 as compared to 2% for the year
ended December 31, 2020. During the fourth quarter of 2021, we announced a number of actions that are expected to improve
operational efficiency and better position our commercial teams in these geographies to service our Customers. We believe these
actions will help to improve revenue trends and drive improved profitability in both countries.
Our supplier relationships are concentrated with five suppliers accounting for approximately 48% and 50% of our purchases for
the years ended December 31, 2021 and December 31, 2020, respectively. If we were to lose one of these five major
manufacturing relationships, our global financial performance could be materially affected. Our ability to exercise influence over
the terms with these suppliers has historically been limited, resulting in pressure on our ability to grow our gross profit margins.
We are focused on developing stronger relationships with our manufacturers and suppliers, and we expect to utilize our strategic
growth initiatives to influence Customer and Animal-Owner brand loyalty in our efforts to drive value for our suppliers. However,
if a competitor is able to obtain better terms with suppliers in the veterinary channel or obtain exclusivity on products we typically
sell to our Customers within the global animal-health market or if a supplier decides to go directly to the Customer or Animal
Owner and bypass our services, our business could be impacted beyond the short-term.
Acquisition-driven Amortization
As we pursue a growth strategy through acquisitions, we are likely to acquire intangible assets, such as customer relationships,
trademarks, patents, product development (including formulas), and non-compete agreements. Our intangibles are predominately
composed of intangibles acquired through our acquisition of Vets First Choice. These acquired intangibles have useful lives of 5
years for trademarks and trade names, 11 years for product formulas, 11 years for customer relationships, and 5 years for
developed technologies.
The amortization of these intangibles has a long-term effect on our expense recognition. Product formulas are amortized to cost of
sales as these formulas are directly tied to the production of compounded products as alternatives to back-ordered solutions,
patient-specific customized medications, and in-clinic use medications. Amortization expense for our other intangible assets not
directly related to sales-generating activities, is included in SG&A. The following table summarizes our amortization expense:
Covetrus, Inc. 2021 Form 10-K
36
Results of Operations
Years Ended
(In millions)
December 31, 2021
December 31, 2020
Net sales
$
4,575
$
4,339
Cost of sales
3,717
3,541
Gross profit
858
798
Gross margin %
18.8 %
18.4 %
Operating expenses:
Selling, general and administrative
881
867
Operating income (loss)
$
(23)
$
(69)
Interest expense, net
$
(32)
$
(46)
Other, net
$
1
$
91
Net income (loss)
$
(54)
$
(17)
Net income (loss) attributable to Covetrus
$
(54)
$
(19)
Year Ended December 31, 2021 Compared to Year Ended December 31, 2020
Net Sales
(In millions)
December 31, 2021
% of
Total
December 31, 2020
% of
Total
$ Change
% Change
North America
$
2,719
59 % $
2,377
55 % $
342
14 %
Europe
1,412
31
1,571
36
(159)
(10)
APAC & Emerging Markets
461
10
402
9
59
15
Eliminations
(17)
—
(11)
—
(6)
(55)
Total net sales
$
4,575
100 % $
4,339
100 % $
236
5 %
North America net sales +$342 million І +14%
Year Ended 2021 v 2020
↑
Primarily due to $241 million in net supply chain organic growth driven by strong end market demand and market share
gains in the companion-animal market, which is our largest market, and $97 million from prescription management
growth as well as net sales from acquisitions contributed for all or part of 2021 and 2020
↓
Largely due to $(3) million from net sales that are no longer being contributed following our disposition of scil in the
second quarter of 2020
Europe net sales $(159) million І (10)%
Year Ended 2021 v 2020
↓
Largely due to $(209) million driven by the loss of Merck & Co. as a supply partner as well as a loss of a customer, both
in the U.K., and disruption in our supply chain operations resulting from our transition to a third-party logistics provider
in Germany and $(82) million from the disposition of scil, the deconsolidation of a subsidiary in Spain and the managed
exit of our French distribution business that occurred in 2020 as the divested businesses contributed net sales for all or
part of 2020
↑
Primarily due to $77 million in organic growth including the strong performance in the Netherlands, Ireland, Belgium and
in our proprietary brands, Kruuse and Vi and $61 million in favorable foreign exchange rate impact
APAC & Emerging Markets net sales +$59 million І +15%
Year Ended 2021 v 2020
↑
Primarily due to $31 million from strong underlying supply chain organic growth and $28 million in favorable foreign
exchange rate impact
Covetrus, Inc. 2021 Form 10-K
37
Consolidated net sales +$236 million І +5%
Year Ended 2021 v 2020
↑
Primarily due to net supply chain organic growth in North America and APAC & Emerging Markets as well as certain
markets within Europe, including growth in proprietary brands, prescription management growth, and favorable foreign
exchange rate impacts
↓
Largely driven by the loss of Merck & Co. as a supply partner as well as a loss of a customer, both in the U.K., and
disruption in our supply chain operations resulting from our transition to a third-party logistics provider in Germany, our
disposition of scil and the deconsolidation of a subsidiary in Spain in the second quarter of 2020, and the managed exit of
our French distribution business in the fourth quarter of 2020
Gross Profit and Gross Margin
(In millions)
December 31, 2021
Gross
Margin %
December 31, 2020
Gross
Margin %
$ Change
Gross Profit
% Change
North America
$
559
20.6 % $
500
21.0 % $
59
12 %
Europe
206
14.6
219
13.9
(13)
(6)
APAC & Emerging Markets
93
20.2
79
19.7
14
18
Total gross profit
$
858
18.8 % $
798
18.4 % $
60
8 %
North America gross profit +$59 million І +12%
Year Ended 2021 v 2020
↑
Primarily due to $28 million from prescription management growth, $23 million from supply chain organic growth and $8
million from acquisitions
Europe gross profit $(13) million І (6)%
Year Ended 2021 v 2020
↓
Largely due to $(25) million from a decrease in supply chain gross profit driven by the loss of Merck & Co. as a supply
partner as well as a loss of a customer, both in the U.K., and disruption in our supply chain operations resulting from our
transition to a third-party logistics provider in Germany and $(12) million from our disposition of scil, the deconsolidation
of a subsidiary in Spain, and the managed exit of our French distribution business that occurred in 2020 as the businesses
contributed gross profit for all or part of 2020
↑
Primarily due to $8 million from favorable foreign exchange rate impacts, $8 million from organic growth in several
markets, including the Netherlands, Czech Republic, Poland, and Romania, and $8 million in strong performance in our
proprietary brands Kruuse and Vi
APAC & Emerging Markets gross profit +$14 million І +18%
Year Ended 2021 v 2020
↑
Primarily due to $9 million from organic growth related to supply chain, and $5 million from favorable foreign exchange
rate impacts
Consolidated gross profit +$60 million І +8%
Year Ended 2021 v 2020
↑
Primarily due to prescription management growth, supply chain organic growth in North America, favorable foreign
exchange rate impacts, net supply chain organic growth within certain markets in Europe as well as growth in proprietary
brands, APAC & Emerging markets net supply chain organic growth, and acquisitions
↓
Largely driven by the loss of Merck & Co. as a supply partner as well as a loss of a customer, both in the U.K., and
disruption in our supply chain operations resulting from our transition to a third-party logistics provider in Germany, our
disposition of scil and the deconsolidation of a subsidiary in Spain in the second quarter of 2020, and the managed exit of
our French distribution business in the fourth quarter of 2020
Covetrus, Inc. 2021 Form 10-K
38
SG&A
(In millions)
December 31, 2021
% of
Respective
Net Sales
December 31, 2020
% of
Respective
Net Sales
$ Change
% Change
North America
$
512
19 % $
495
21 % $
17
3 %
Europe
175
12
184
12
(9)
(5)
APAC & Emerging Markets
62
13
55
14
7
13
Corporate
132
—
133
—
(1)
(1)
Total SG&A
$
881
19 % $
867
20 % $
14
2 %
North America SG&A +$17 million І +3%
Year Ended 2021 v 2020
↑
Largely due to increased costs to support the growth in our supply chain and prescription management services businesses
of $14 million and $7 million, respectively, and $10 million of expenses from acquisitions in the fourth quarter of 2020
and the third quarter of 2021
↓
Primarily due to an $(8) million operating lease right-of-use asset impairment in the prior year, reduced separation
program and executive severance of $(4) million, and a $(3) million decrease in share-based compensation expense
Acquisition-related intangible amortization was 23% of North America SG&A in 2021 and 24% in 2020
Europe SG&A $(9) million І (5)%
Year Ended 2021 v 2020
↓
Primarily due to a decrease of $(20) million due to our disposition of scil, the deconsolidation of a subsidiary in Spain,
and the managed exit of our French distribution business that occurred in 2020 and $(5) million decrease in expenses
related to the formation of Covetrus
↑
Largely due to an $8 million increase in separation programs and executive severance, a $6 million unfavorable foreign
exchange rate impacts and $2 million from increased share-based compensation expense
APAC & Emerging Markets SG&A +$7 million І +13%
Year Ended 2021 v 2020
↑
Largely due to $3 million in unfavorable foreign exchange rate impacts, $2 million from increased share-based
compensation expense, and a $2 million increase in separation programs and executive severance
Corporate SG&A $(1) million І (1)%
Year Ended 2021 v 2020
↓
Primarily due to $(11) million in decreased expenses related to the formation of Covetrus, a $(4) million decrease in
transaction costs, $(3) million in decreased IT infrastructure costs, a $(2) million decrease in separation programs and
executive severance, and a $(1) million decrease in capital structure related costs
↑
Largely due to $8 million in increased costs incurred as we continued to invest in our corporate infrastructure to enable
our growth, $7 million in increased legal costs related to on-going litigation, and $5 million from increased share-based
compensation
Consolidated SG&A +$14 million І +2%
Year Ended 2021 v 2020
↑
Largely due to increased costs to support growth in our North America supply chain and prescription management
services, expenses from acquisitions in the fourth quarter of 2020 and the third quarter of 2021, unfavorable foreign
exchange rate impacts, increased costs incurred as we continued to invest in our corporate infrastructure to enable our
growth, increased legal costs related to on-going litigation, increased share-based compensation, and an increase in
separation programs and executive severance
↓
Primarily due to a decrease in expenses that are no longer being incurred following our disposition of scil, the
deconsolidation of a subsidiary in Spain, and the managed exit of our French distribution business, decreased expense
related to the formation of Covetrus, operating lease right-of-use asset impairment in the prior year, decreased transaction
costs, decreased IT infrastructure costs, and decreased capital structure related costs
Covetrus, Inc. 2021 Form 10-K
39
Other Income (Expense)
(In millions)
December 31, 2021
December 31, 2020
$ Change
% Change
Interest expense, net
$
(32) $
(46) $
14
30 %
Other, net
1
91
(90)
(99)
Other (expense) income, net
$
(31) $
45 $
(76)
(169) %
For the year ended December 31, 2021, the change in other income, net as compared to the year ended December 31, 2020 is
primarily due to the gain on the divestiture of scil and a gain on the deconsolidation of our subsidiary, SAHS, in Spain in the prior
year. See Note 2 - Segment Data.
Income Taxes
Year Ended 2021 v 2020
Income tax expense of $0 million on a loss before income taxes of $(54) million
For the year ended December 31, 2021, our effective tax rate was 1.1% compared to 28.9% for the prior year period. The decrease
in our effective tax rate is primarily related to valuation allowances in 2021 due to uncertainty regarding the realization of future
tax benefits from certain U.S. and non-U.S. deferred tax assets.
The valuation allowance on deferred tax assets was $27 million as of December 31, 2021 and $11 million as of December 31,
2020. The change in valuation allowance for the year ended December 31, 2021 was $16 million and was attributable primarily to
an increase related to the uncertainty regarding the realization of future tax benefits based on significant negative evidence in the
U.S. and certain non-U.S jurisdictions. See Note 13 - Income Taxes.
Adjusted EBITDA
(In millions)
December 31, 2021
% of
Respective Net
Sales
December 31, 2020
% of
Respective Net
Sales
$ Change
% Change
North America
$
223
8 % $
187
8 % $
36
19 %
Europe
71
5
72
5
(1)
(1)
APAC & Emerging Markets
40
9
28
7
12
43
Corporate
(90)
NM
(61)
NM
(29)
NM
Total adjusted EBITDA
$
244
5 % $
226
5 % $
18
8 %
North America Adjusted EBITDA +$36 million І +19%
Year Ended 2021 v 2020
↑
Primarily due to prescription management growth of $21 million, $10 million of supply chain organic growth, and $5
million additional contribution from acquisitions
Europe Adjusted EBITDA $(1) million І (1)%
Year Ended 2021 v 2020
↓
Largely due to a $(19) million decrease composed of the loss of Merck & Co. as a supply partner and a loss of a customer,
both in the U.K., and the disruption from our transition to a third-party logistics provider in Germany
↑
Primarily due to $7 million of positive organic growth in several markets, including the Netherlands and Belgium, as well
as our proportionate share of growth in our equity method investment in Spain, a $7 million increase in contribution from
our higher margin proprietary brands, and $3 million from favorable foreign exchange rate impacts
APAC & Emerging Markets Adjusted EBITDA +$12 million І +43%
Year Ended 2021 v 2020
↑
Primarily due to a $9 million increase from organic growth mainly related to supply chain and $2 million from favorable
foreign exchange rate impacts
Covetrus, Inc. 2021 Form 10-K
40
Corporate Adjusted EBITDA $(29) million
Year Ended 2021 v 2020
↓
Largely due to foreign exchange transaction effects associated with intercompany notes of $(14) million resulting from a
loss in 2021 as compared to a gain in 2020, $(8) million in increased costs incurred as we continued to invest in our
corporate infrastructure to enable our growth, and $(7) million in increased legal costs related to on-going litigation
Consolidated Adjusted EBITDA +$18 million І +8%
Year Ended 2021 v 2020
↑
Primarily due to improved performance across certain of our markets, including an increased contribution from higher
margin products and services, a favorable foreign exchange rate impact, and additional contributions from acquisitions
↓
Largely due to the loss of Merck & Co. as a supply partner and a loss of a customer, both in the U.K., and the disruption
from our transition to a third-party logistics provider in Germany, unfavorable foreign exchange transaction effects
associated with intercompany notes, increased costs incurred as we continue to invest in innovation and our corporate
infrastructure to enable our growth, and increased legal costs
Adjusted EBITDA is our primary segment performance metric. We do not allocate expenses managed at the corporate level to our
segments. See Note 2 - Segment Data for additional information on corporate allocations and for a reconciliation of total adjusted
EBITDA to net income (loss) in accordance with ASC 280.
Liquidity and Capital Resources
Overview
Our primary sources of liquidity are cash and cash equivalents, cash flows from the operations of our business, and available
borrowing capacity under our Credit Facilities. Our principal uses of cash include working capital-related items, capital
expenditures, debt service, and strategic investments.
Credit Facilities
The Credit Facilities include a term loan facility and a revolving line of credit. There were no borrowings from the revolving line
of credit as of December 31, 2021 and December 31, 2020.
Short-Term
Our liquidity fluctuates during the year due to sales seasonality. Generally, our sales of parasite protection products in the
companion-animal market peak during the spring and summer months, which are hemisphere dependent, as vector-borne diseases
typically increase during these seasons. This seasonality also affects the timing and amount of our inventory purchases, and
subsequently our accounts payable balances.
We have obligations related to our operations that require the use of cash in both the short and long term:
•
Long-term obligations related to borrowing arrangements, in particular our term loan facility which has required annual
amortization payments of $60 million and covenant limitations on our leverage which may affect our ability to grow
through acquisitions in future periods, see Note 7 - Long-Term Debt and Other Borrowings, Net
•
Leases that we enter into in the normal course of business, we have $177 million in lease obligations from 2022 and
beyond, $22 million of which is payable in 2022, see Note 10 - Leases, and
•
Unconditional purchase obligations, we have a exclusive supply agreement which obligates us to purchase $29 million of
products through September 30, 2025. In 2022, we are obligated to buy $8 million of inventory. see Note 8 -
Commitments and Contingencies)
We also have sources of cash to be used in both the short and long term:
•
Accounts Receivable, which has historically been highly liquid. At December 31, 2021 and December 31, 2020, we had
accounts receivable of $480 million, net of $4 million allowance, and $507 million, net of $5 million allowance, see Note
3 - Revenue from Contracts with Customers
•
Availability under our revolving line of credit, subject to our covenant restrictions, if applicable. At December 31, 2021,
$298 million was available, see Note 7 - Long-Term Debt and Other Borrowings, Net
•
Accessing the capital and credit markets
Covetrus, Inc. 2021 Form 10-K
41
Planned uses of liquidity included in our near-term strategic plan:
•
Completing our pharmacy innovation and operational capacity expansion in Arizona and Maine
•
Enhancing the consumer experience through continuous improvements in e-Commerce, appointment management,
wellness, and veterinarian-to-pet-owner connectivity
•
Expanding our value proposition communication to the market and refinement of our commercial organization go-to
market strategy
•
Developing or acquiring cloud-based practice management software and technology coordination with select existing
service offerings, including our recently acquired software from VCP and AppointMaster
•
Enabling business-to-business ordering capabilities focused on our compounding services, distribution, and inventory
management services
•
Optimizing our distribution network in North America, including investments in the systems and facilities that support
our network
•
Rolling out a European enterprise resource planning system to reduce complexity in our global enterprise resource
planning landscape
•
Investing in external growth opportunities to support our strategic objectives and potentially making acquisitions and
investments earlier or later than we expect
•
Mandatory term loan facility amortization payments
Acquisitions
During the year ended December 31, 2021, we completed acquisitions of VCP, a leading platform in veterinary wellness plan
administration, and AppointMaster a provider of integrated communications solutions for veterinary practices, for an aggregate
purchase price of $85 million, of which $81 million were cash payments. These acquisitions are intended to provide our
Customers with new tools to foster stronger relationships with their Animal Owner clients by delivering better business and
healthcare outcomes and better positions us to help veterinarians deliver proactive healthcare via membership programs integrated
with our practice management and prescription management solutions.
We repatriated $68 million in June 2021 to provide for greater flexibility in how we fund our planned investments, including our
acquisition of VCP as well as toward certain of our planned investments listed above. At December 31, 2020, we determined
certain unremitted earnings existing in foreign subsidiaries located in various jurisdictions were no longer indefinitely reinvested.
Accordingly, our tax liability associated with the repatriation of the undistributed earnings from the applicable subsidiaries located
in these tax jurisdictions was recorded as of December 31, 2020.
Trends
Our operational plans to manage our liquidity continue to involve seeking opportunities to reduce non-critical capital
expenditures, managing opportunistic inventory purchases as we carefully monitor sales forecasts and timing of projected price
increases, reducing our other costs, and maximizing our payment terms wherever possible. We also continue to monitor cash flow
projections and will consider additional borrowings, if needed, based on availability under our Revolving Credit Facility. We
believe we have sufficient sources of funding to meet our business requirements, including our covenants within our Credit
Facilities, for the next 12 months.
In December 2021, we prepaid $30 million of the term loan facility's $60 million mandatory amortization payments for 2022,
which reduced our outstanding balance will lower future interest payments. We are permitted to make optional prepayments at
any time without premium or penalty. The next quarterly mandatory principal amortization payment of $15 million is due on
September 30, 2022.
Our interest rate swap contracts, which effectively fixed the borrowing rates on a portion of our floating rate debt, matured on July
31, 2021. With less outstanding debt and current floating interest rates at which we borrow still historically low, we anticipate
incurring lower interest expense, at least for a period of time until the FOMC decides to increase the Fed Funds Rate. How many
increases, the size of those increases and when the FOMC decides to act will largely determine how long we will incur lower
interest expense.
We were in compliance with the covenants in our Credit Facilities as of December 31, 2021. Based on our expected Credit
Facilities-defined leverage as of December 31, 2021, once the quarterly compliance filing is made, we expect the current
applicable margin on our borrowings outstanding will be 25 basis points lower at least until the next compliance filing is made for
the three months ending March 31, 2022.
Covetrus, Inc. 2021 Form 10-K
42
•
Investing in our expansion of global sales and marketing efforts
•
Launching new products and services
•
Pursuit of strategic, higher-margin acquisition and investment targets
•
Increasing our pharmaceutical compounding operations capacity
•
International expansion
•
Term loan facility debt service
•
Ongoing operating lease payments
•
Capital investments
•
Pursuit and maintenance of appropriate regulatory clearances, approvals for existing products, and any new products that
may be developed
Sources of liquidity:
•
Operations-driven cash generation
•
Borrowings under our revolving line of credit
•
Availability of financing through the capital markets
•
Sales of businesses or assets if those actions align with our strategic objectives
Our term loan facility and revolving credit facility bear interest on a floating rate basis, which are referenced to LIBOR.
Following December 31, 2021, one-week and two-month USD LIBOR, as well as all non-USD LIBOR tenors, ceased publication
immediately, while three-month, six-month, and one-year USD LIBOR will cease publication after June 30, 2023. As a result, in
lieu of amending or waiving any term of the Credit Facility, we notified the administrative agent to the Credit Facility that non-
USD currencies would not be available to us either as a revolving line of credit or term loan facility borrowing, and further we
suspended our rights to borrow at the two-month USD LIBOR tenor until such time as the Credit Facility is amended with an
alternative benchmark rate to USD LIBOR.
Longer term, if we desire to access alternative sources of funding through the capital and credit markets, challenging global
economic conditions, such as steep inflationary effects, long-lasting COVID-19 pandemic or an economic downturn, could
adversely impact our ability to do so.
Cash and Cash Equivalents
We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due
to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value.
Selected Measures of Liquidity and Capital Resources
(In millions)
December 31, 2021
December 31, 2020
Cash and cash equivalents
$
183 $
290
Availability under our revolving line of credit
$
298 $
299
As per the revised schedule contained in the 2020 amendment to our Credit Facilities, we are required to remain compliant with a
Credit Facilities-defined leverage covenant that is currently set at 4.50x as of December 31, 2021, but will decrease to 3.75x as of
June 30, 2022, through maturity of the Credit Facilities in February 2024.
The duration of the COVID-19 pandemic continues to be unknown. Should the severity of variant strains increase and reduce the
effectiveness of vaccines and negatively impacts global economic conditions, then we may experience a negative impact on our
liquidity position. Therefore, we continuously assess steps we can take to improve working capital and increase cash on our
balance sheet and closely monitor the capital markets for additional opportunities to improve our liquidity position.
Long-term
Our long-term liquidity is expected to be aligned with our strategic development, and the needs of our growing business in terms
of investment to fund growth, as well as availability of financing. We currently anticipate the following long-term liquidity trends
for our business, which depend on the short term uses and sources of cash affecting our near term strategic planning as well as
maintenance of our existing obligations:
Uses of liquidity:
Covetrus, Inc. 2021 Form 10-K
43
Cash Flows
The following table summarizes our cash flows from operating, investing, and financing activities:
Year Ended
(In millions)
December 31, 2021
December 31, 2020
Net cash provided by (used for) operating activities
$
102 $
53
Net cash provided by (used for) investing activities
$
(140) $
(5)
Net cash provided by (used for) financing activities
$
(66) $
104
Cash inflows and outflows from changes in operating activities for the year ended December 31, 2021 v December 31,
2020
Net cash provided by operating activities of $102 million as compared to net cash provided by operating activities of $53 million
was:
↑
Primarily driven by increasing accounts payable related to inventory purchases (discussed below), a decrease in accounts
receivable related to the loss of Merck & Co. in the U.K. as a partner effective January 1, 2021 and the subsequent loss of
a customer in the U.K. as well as the effect from our improved collection efforts, and the effect from our improved
profitability from certain markets, in particular the increasing contribution from higher margin products
↓
Largely driven by inventory increases in 2021 due to increased demand, while maintaining our disciplined, global
approach to inventory management as compared to our purposeful reduction in inventory in 2020, which was instituted to
manage the COVID-19 uncertainty
Cash inflows and outflows from changes in investing activities for the year ended December 31, 2021 v December 31,
2020
In 2021, net cash used for investing activities of $(140) million was:
↓
Largely due to payments of $81 million for our VCP and AppointMaster acquisitions and $60 million in purchases of
property and equipment
In 2020, net cash used for operating activities of $(5) million was:
↓
Primarily due to $58 million in purchases of property and equipment and $54 million related to business acquisitions and
payments related to our deconsolidation of a subsidiary in Spain and contribution to our equity method investment in
Spain, called Distrivet, a Covetrus company
↑
Primarily due to $103 million in net proceeds from the divestiture of scil and $4 million in proceeds from the sale of
property and equipment
Cash inflows and outflows from changes in financing activities for the year ended December 31, 2021 v December 31,
2020
In 2021, net cash used for financing activities of $(66) million was:
↓
$30 million in principal payments of debt, $15 million in tax payments related to share-based awards, $14 million to
acquire the remaining minority interests held by our former partners in certain of our Brazilian and North American
entities, $13 million in payments to the former owners of Distrivet S.A. on the one-year anniversary of closing, April 30,
2021, and $2 million in distributions to non-controlling shareholders
↑
Due to $8 million in proceeds from share-based awards
In 2020, net cash provided by financing activities of $104 million was:
↑
Primarily due to proceeds of $250 million from the issuance of Series A preferred stock and proceeds from share-based
awards
↓
Largely due to principal payments, acquisition payments, preferred stock issuance costs, preferred stock dividends, debt
issuance costs, and tax payments related to share-based awards
Critical Accounting Estimates
Preparing financial statements in accordance with GAAP involves us making estimates and assumptions that affect reported
amounts of assets and liabilities, net sales and expenses, and related disclosures in the accompanying notes at the date of our
financial statements. We base our estimates on historical experience, industry and market trends, and on various other
assumptions that we believe to be reasonable under the circumstances. However, by their nature, estimates are subject to various
assumptions and uncertainties, and changes in circumstances could cause actual results to differ from these estimates, sometimes
materially.
Covetrus, Inc. 2021 Form 10-K
44
We believe that our policies and estimates that require our most significant judgments are considered our critical accounting
policies and are discussed below. In addition, refer to Note 1 - Business Overview and Significant Accounting Policies for further
details.
Goodwill
When using the quantitative impairment test for assessing goodwill, determining the fair value of a reporting unit is judgmental in
nature and involves the use of significant estimates and assumptions. Fair values were estimated using both the income approach,
discounting projected future cash flows based on budget projections and growth rates that consider estimated inflation rates, and
the market approach, applying a multiple of earnings based on comparable publicly traded companies. Key estimates include
weighted-average cost of capital, future levels of gross and operating profits, and projected capital expenditures. The rates used to
discount projected future cash flows under the income approach reflect a weighted-average cost of capital in the range of 8.5% to
9.0%, depending on the reporting unit, which considered capital structure and risk premiums, including those reflected in our
current market capitalization.
We completed our annual evaluation for impairment of goodwill during the fourth quarter of 2021. The evaluation indicated that
the fair value estimates of our reporting units exceeded their carrying values by sufficient margins and no impairments were
required. See Note 6 - Goodwill and Other Intangibles, Net for changes in goodwill by reporting unit. A 0.5% increase in the
weighted-average cost of capital in our North America reporting unit, assuming fair values were calculated using 100% of a
discounted cash flows, or income approach, would result in a decrease to the North America reporting unit's fair value of
approximately $200 million, which would not cause the North America reporting unit's carrying value to exceed its fair value.
As of December 31, 2021 and 2020, Goodwill was $1,247 million and $1,187 million, respectively. All goodwill is recorded in
our North America reporting unit.
Income Taxes
We are subject to income taxes in the U.S. and 22 foreign jurisdictions. Significant judgment is required in determining income
tax expense, deferred taxes and uncertain tax positions. The underlying assumptions are also highly susceptible to change from
period to period. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that
some or all the deferred tax assets will be realized. The ultimate realization of deferred taxes assets is dependent upon generation
of future taxable income during the period in which those temporary differences become deductible. Management considers the
scheduled reversal of deferred tax liabilities, projected future taxable income, and taxable income in carryback years and tax-
planning strategies when making this assessment. There is currently significant negative evidence which contributes to our
recording a valuation allowance against our deferred tax assets due to U.S. and non-U.S. cumulative losses over a three year
period ended December 31, 2021. This objective evidence limits our ability to consider other subjective evidence which otherwise
could potentially result in an increase in our deferred tax assets of up to $27 million.
We record a provision for income taxes for the anticipated tax consequences of our reported results of operations using the asset
and liability method. Deferred income taxes are recognized by applying enacted statutory tax rates applicable to future years to
differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax
bases.
Although we believe our assumptions, judgments, and estimates are reasonable, changes in tax laws or our interpretation of tax
laws and the resolution of any tax audits could significantly impact the amounts provided for income taxes in our consolidated
financial statements. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the
period that includes the enactment date. Adjustments to income tax expense, to the extent we establish a valuation allowance or
adjust the allowance in a future period, could have a material impact on our financial condition and results of operations.
The critical accounting estimates below do not represent a material estimate in the preparation of our 2021 financial statements;
however, these estimates have in the past been and are likely in the future to be significant based on our current trends, practices,
and policies.
Covetrus, Inc. 2021 Form 10-K
45
Business Acquisitions
The net assets of businesses acquired are recorded at their fair value and the accounting is based on critical estimates, judgments,
and assumptions derived from analysis of market conditions, discount rate, discounted cash flows, customer retention rates, and
estimated useful lives. We generally allocate the purchase price to identifiable intangible assets, accounts receivable, inventory,
property and equipment, deferred taxes, and other current and long-term assets and liabilities. Any excess of acquisition
consideration over the fair value of identifiable net assets acquired is recorded as goodwill.
Intangible Assets
Intangible assets other than goodwill are evaluated for impairment whenever events or changes in circumstances indicate that the
carrying amount of the asset or asset groups, which represent the lowest level identifiable cash flows that are largely independent
of the cash flows of other groups of assets and liabilities, may not be recoverable through the estimated undiscounted future cash
flows to be derived from such assets.
Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, customer relationships, and intellectual
property, and impairment losses are recorded if the asset’s carrying amount is not recoverable through our undiscounted,
probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount
and the estimated fair value. When an impairment exists, the related assets are written down to fair value.
Loss Contingencies
We are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages,
investigations relating to governmental laws and regulations, and other matters arising out of the normal course of our business.
Certain of these matters include speculative claims for substantial or indeterminate amounts of damages. We record a liability
when we believe that it is probable that a loss has been incurred and the amount can be reasonably estimated. If we determine that
a loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss in the notes to our
financial statements. We regularly evaluate developments in our legal matters and, as appropriate, adjust our accruals and make
changes to our disclosures.
Significant judgment is required to determine both probability and the estimated amounts of loss contingencies. Such claims,
suits, and proceedings are inherently unpredictable and subject to significant uncertainties, some of which are beyond our control.
If any of these estimates and assumptions change, it could have a material impact on our results of operations, financial position,
and cash flows.
Accounting Standards Update
For information on updated accounting standards that we have recently adopted or will adopt in future periods, see Note 1 -
Business Overview and Significant Accounting Policies included under Item 8, Financial Statements and Supplementary Data.
Covetrus, Inc. 2021 Form 10-K
46
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We have exposure to market risks related to changes in foreign currency exchange rates and interest rates as follows:
Foreign Currency Risk
We have foreign currency exposures related to buying, selling, and financing in currencies other than the functional currencies of
our operations. Where appropriate, we enter into foreign exchange spot transactions to manage short term exposures. We use
derivative instruments, such as foreign currency forwards, to economically hedge intercompany loans that are denominated in
foreign currencies. At December 31, 2021 our three most significant foreign currency exposures are the EUR, GBP, and AUD.
We did not enter into any foreign currency hedging arrangements in 2020. See Note 15 - Derivatives
We are exposed to foreign currency risk due to the translation of the results of certain international operations into U.S. Dollars as
part of the consolidation process. Fluctuations in foreign currency exchange rates can therefore create volatility in the results of
operations and may adversely affect our financial position.
As of December 31, 2021, a hypothetical 5% increase in foreign exchange rates, where we conduct our business in local currency,
versus the U.S. dollar would have resulted in a decrease of $3 million in annualized operating income.
Conversely, a hypothetical 5% decrease in foreign exchange rates would have resulted in an improvement of $3 million in
annualized operating income.
Interest Rate Risk
As of December 31, 2021, we had variable-rate borrowings outstanding of $1.1 billion under the Credit Facility. Increases in the
underlying interest rate elections we make will negatively affect interest expense, while decreases to the underlying interest rates
will have a positive influence on our interest expense. We regularly review the projected borrowings under the Credit Facility and
the current interest rate environment.
In 2019, we executed interest rate swap contracts with notional amounts aggregating $500 million that were designated as cash
flow hedges. See Note 15 - Derivatives. Our earnings are affected by changes in interest rates, however, due to our interest rate
swap contracts, the effects were mitigated to an extent, through maturity in July of 2021.
We perform sensitivity analyses on our forecasted exposure to interest rates for the next fiscal year. If market interest rates
increase 1% over the next 12 months, our net interest expense would increase by $11 million.
Conversely, if market interest rates decrease 1% over the next 12 months, our net interest expense would decrease by $6 million.
Among the many actions taken by the Federal Reserve System to reduce the impact of the COVID-19 pandemic, the decision by
its Federal Open Market Committee to lower interest rates has generally benefited us in the form of lower interest expense. As
U.S. inflation increases, the FOMC may reverse course and look to increase interest rates, which would increase our interest
expense. How many increases, the size of those increases and when the FOMC decides to act will largely determine how much
and/or how quickly our interest expense increases in the near term.
Covetrus, Inc. 2021 Form 10-K
47
Item 8.
Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Reports of Independent Registered Public Accounting Firm (BDO USA, LLP, Boston, MA, PCAOB ID: 243)
49
Consolidated Financial Statements:
Balance Sheets as of December 31, 2021 and December 31, 2020
52
Statements of Operations for the years ended December 31, 2021, December 31, 2020, and December 31, 2019
53
Statements of Comprehensive Income (Loss) for the years ended December 31, 2021, December 31, 2020, and
December 31, 2019
54
Statements of Shareholders' Equity for the years ended December 31, 2021, December 31, 2020, and December 31, 2019
55
Statements of Cash Flows for the years ended December 31, 2021, December 31, 2020, and December 31, 2019
56
Notes to Consolidated Financial Statements:
Note 1: Business Overview and Significant Accounting Policies
58
Note 2: Segment Data
66
Note 3: Revenue From Contracts with Customers
69
Note 4: Business Acquisitions
70
Note 5: Divestitures and Equity Method Investments
70
Note 6: Goodwill and Other Intangibles, Net
71
Note 7: Long-Term Debt and Other Borrowings, Net
72
Note 8: Commitments and Contingencies
74
Note 9: Accrued Expenses and Other Current Liabilities
75
Note 10: Leases
75
Note 11: Property and Equipment, Net
76
Note 12: Share-based Compensation and Other Employee Benefits
76
Note 13: Income Taxes
78
Note 14: Fair Value
82
Note 15: Derivatives
83
Note 16: Accumulated Other Comprehensive Income (Loss)
84
Note 17: Earnings (Loss) Per Share
84
Note 18: Related-Party Transactions
85
Note 19: Redeemable Non-controlling Interests
85
Covetrus, Inc. 2021 Form 10-K
48
Report of Independent Registered Public Accounting Firm
Board of Directors and Shareholders
Covetrus, Inc.
Portland, ME
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Covetrus, Inc. (the “Company”) as of December 31, 2021 and
2020, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity, and cash flows for
each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated
financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three
years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of
America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in
Internal Control – Integrated Framework (2013 issued by the Committee of Sponsoring Organizations of the Treadway
Commission (“COSO”) and our report dated February 28, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with
the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to
the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement,
whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a
test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial
statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or
disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or
complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate
opinions on the critical audit matters or on the accounts or disclosures to which it relates.
Realizability of Deferred Tax Assets
As described in Note 13 to the Company’s consolidated financial statements, the Company had deferred tax assets related to
deductible temporary differences and tax attributes of $114 million, net of a $27 million valuation allowance, as of December 31,
2021. The values assigned to deferred tax assets is judgmental, and the realizability of these assets is dependent upon generation
of future taxable income during periods in which temporary differences become deductible. In assessing the realizability of
deferred tax assets, the Company considers the scheduled reversal of existing temporary tax differences, projected future taxable
income, taxable income in carryback years, and changes in tax laws.
Covetrus, Inc. 2021 Form 10-K
49
•
Assessing evidence, both confirming and contradictory, to determine whether it is more likely than not that all or some
portion of deferred tax assets will not be realized; and
•
Assessing the reasonableness of scheduling of the reversal of existing taxable temporary differences;
•
Utilizing professionals with specialized skills and knowledge to assist in evaluating management’s determination of the
realizability of deferred tax assets and the overall reasonableness of tax positions which support the conclusions reached.
/s/ BDO USA, LLP
Boston, MA
February 28, 2022
We have served as the Company’s auditor since 2018.
Report of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Covetrus, Inc.
Portland, ME
Opinion on Internal Control over Financial Reporting
We have audited Covetrus, Inc. (the “Company’s”) internal control over financial reporting as of December 31, 2021, based on
criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of
the Treadway Commission (the “COSO criteria”) In our opinion, the Company maintained, in all material respects, effective
internal control over financial reporting as of December 31, 2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(“PCAOB”), consolidated balance sheets of Covetrus, Inc. (the “Company”) as of December 31, 2021 and 2020, the related
consolidated statements of operations, comprehensive income (loss), shareholders’ equity, and cash flows for each of the three
years in the period ended December 31, 2021, and the related notes (collectively referred to as “the financial statements”) and our
report dated February 28, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s
Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal
control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over
financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
We identified the realizability of deferred tax assets as a critical audit matter. The estimation of the future reversal pattern of
existing temporary tax differences and other assumptions of future taxable income is subjective and may be affected by future
market and economic conditions including changes in tax laws. Auditing these elements was especially challenging due to the
nature and extent of auditor judgment involved in evaluating the Company’s estimation of the reversal of timing items including
through the extent of specialized skill or knowledge needed.
The primary procedures we performed to address this critical audit matter included:
Covetrus, Inc. 2021 Form 10-K
50
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that
(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ BDO USA, LLP
Boston, MA
February 28, 2022
Covetrus, Inc. 2021 Form 10-K
51
COVETRUS, INC.
CONSOLIDATED BALANCE SHEETS
(In millions, except share amounts)
December 31, 2021
December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents
$
183
$
290
Accounts receivable, net of allowance of $4 and $5 (Note 3)
480
507
Inventories, net
583
530
Other receivables
75
67
Prepaid expenses and other
30
26
Total current assets
1,351
1,420
Non-current assets:
Property and equipment, net (Note 11)
144
116
Operating lease right-of-use assets, net (Note 10)
137
117
Goodwill (Note 6)
1,247
1,187
Other intangibles, net (Note 6)
439
555
Investments (Note 5)
49
52
Other non-current assets
43
49
Total assets
$
3,410
$
3,496
LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
442
$
411
Current maturities of long-term debt and other borrowings (Note 7)
32
1
Accrued payroll and related liabilities
63
67
Accrued taxes
24
37
Accrued expenses and other current liabilities (Note 9)
137
175
Total current liabilities
698
691
Non-current liabilities:
Long-term debt and other borrowings, net (Note 7)
1,014
1,068
Deferred income taxes
13
28
Other liabilities
151
136
Total liabilities
1,876
1,923
Commitments and contingencies (Note 8)
Mezzanine equity:
Redeemable non-controlling interests (Note 19)
23
36
Shareholders' equity:
Common stock
1
1
Accumulated other comprehensive loss (Note 16)
(79)
(66)
Additional paid-in capital
2,670
2,629
Accumulated deficit
(1,081)
(1,027)
Total shareholders’ equity
1,511
1,537
Total liabilities, mezzanine equity, and shareholders’ equity
$
3,410
$
3,496
Common shares authorized, par value of $0.01
675,000,000
675,000,000
Common shares issued and outstanding
138,011,969
136,017,964
See notes to consolidated financial statements.
Covetrus, Inc. 2021 Form 10-K
52
COVETRUS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
Years Ended
December 31, 2021
December 31, 2020
December 31, 2019
Net sales (Note 3)
$
4,575 $
4,339 $
3,976
Cost of sales
3,717
3,541
3,227
Gross profit
858
798
749
Operating expenses:
Selling, general and administrative
881
867
808
Goodwill impairment
—
—
938
Operating income (loss)
(23)
(69)
(997)
Other income (expense):
Interest expense, net
(32)
(46)
(54)
Other, net
1
91
22
Income (loss) before taxes
(54)
(24)
(1,029)
Income tax benefit (expense) (Note 13)
—
7
46
Net income (loss)
(54)
(17)
(983)
Net (income) loss attributable to redeemable non-controlling interests
—
(2)
3
Net income (loss) attributable to Covetrus
$
(54) $
(19) $
(980)
Earnings (loss) per share attributable to Covetrus: (Note 17)
Basic
$
(0.39) $
(0.22) $
(9.14)
Diluted
$
(0.39) $
(0.22) $
(9.14)
Weighted-average common shares outstanding:
Basic
137
118
107
Diluted
137
118
107
See notes to consolidated financial statements.
Covetrus, Inc. 2021 Form 10-K
53
COVETRUS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In millions)
Years Ended
December 31, 2021
December 31, 2020
December 31, 2019
Net income (loss)
$
(54) $
(17) $
(983)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)
(16)
23
(3)
Gain (loss) on derivative instruments
3
(3)
(1)
Total other comprehensive income (loss)
(13)
20
(4)
Comprehensive income (loss)
(67)
3
(987)
Comprehensive (income) loss attributable to redeemable non-controlling interests:
Net (income) loss
—
(2)
3
Foreign currency translation (gain) loss
—
(2)
(1)
Comprehensive (income) loss attributable to redeemable non-
controlling interests
—
(4)
2
Comprehensive income (loss) attributable to Covetrus
$
(67) $
(1) $
(985)
See notes to consolidated financial statements.
Covetrus, Inc. 2021 Form 10-K
54
COVETRUS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(In millions, except share amounts)
Common Stock
Accumulated
Other
Comprehensive
Income (Loss)
Additional
Paid-in
Capital
Accumulated
Deficit
Net
Former
Parent
Investment
Total
Shareholders'
Equity
Shares
Amount
December 29, 2018
—
— $
(82) $
— $
— $
1,534 $
1,452
Net income (loss) attributable to Covetrus (a)
—
—
—
—
(1,001)
21
(980)
Dividend to Former Parent
—
—
—
(21)
—
(1,153)
(1,174)
Issuance of shares at Separation (including
Share Sale investors)
71,693,426
1
—
566
—
(567)
—
Issuance of shares in connection with the
Acquisition
39,742,089
—
—
1,772
—
—
1,772
Shares canceled
(700,400)
—
—
(30)
—
—
(30)
Net increase in Former Parent investment
—
—
—
—
—
172
172
Issuance of shares in connection with
share-based compensation plans
885,392
—
—
5
—
—
5
Share-based compensation
—
—
—
46
—
—
46
Deferred tax impact of acquisition of non-
controlling interest
—
—
—
—
—
(7)
(7)
Other
—
—
—
1
—
—
1
Other comprehensive income (loss)
—
—
(4)
—
—
—
(4)
Balance at December 31, 2019
111,620,507
1 $
(86) $
2,339 $
(1,001) $
— $
1,253
Net income (loss) attributable to Covetrus
—
—
—
—
(19)
—
(19)
Redeemable non-controlling interest
redemption value adjustment
—
—
—
(6)
—
—
(6)
Issuance of shares in connection with
share-based compensation plans
1,793,394
—
—
10
—
—
10
Share-based compensation
—
—
—
40
—
—
40
Series A preferred stock dividend
—
—
—
—
(7)
—
(7)
Conversion of Series A preferred stock
22,604,063
—
—
246
—
—
246
Other comprehensive income (loss)
—
—
20
—
—
—
20
Balance at December 31, 2020
136,017,964 $
1 $
(66) $
2,629 $
(1,027) $
— $
1,537
Net income (loss) attributable to Covetrus
—
—
—
—
(54)
—
(54)
Issuance of shares in connection with
acquisitions
146,633
—
—
4
—
—
4
Issuance of shares in connection with share-
based compensation plans, net of shares
withheld for taxes
1,847,372
—
—
(7)
—
—
(7)
Share-based compensation
—
—
—
46
—
—
46
Redeemable non-controlling interest
redemption value adjustment
—
—
—
(2)
—
—
(2)
Other comprehensive income (loss)
—
—
(13)
—
—
—
(13)
Balance at December 31, 2021
138,011,969 $
1 $
(79) $
2,670 $
(1,081) $
— $
1,511
(a) Net income earned from January 1, 2019 through February 7, 2019 is attributed to the Former Parent as it was the sole shareholder prior to February 7,
2019
See notes to consolidated financial statements.
Covetrus, Inc. 2021 Form 10-K
55
COVETRUS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
Years Ended
December 31, 2021
December 31, 2020
December 31, 2019
Cash flows from operating activities:
Net income (loss)
$
(54) $
(17) $
(983)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Depreciation and amortization
171
167
154
Amortization of right-of-use assets
29
24
21
Goodwill impairment
—
—
938
Gain on divestiture of a business
—
(73)
—
Share-based compensation expense
46
40
46
Benefit for deferred income taxes
(22)
(32)
(64)
Amortization of debt issuance costs
6
6
5
Other
18
4
(9)
Changes in operating assets and liabilities, net of acquisitions
Accounts receivable, net
15
(68)
13
Inventories, net
(65)
106
(58)
Other assets and liabilities
(59)
(15)
(52)
Accounts payable and accrued expenses
17
(89)
92
Net cash provided by (used for) operating activities
102
53
103
Cash flows from investing activities:
Investments in property, equipment, and software
(60)
(58)
(39)
Payments related to equity investments and business acquisitions, net of cash
acquired
(81)
(54)
(26)
Proceeds from divestiture of a business, net
—
103
—
Proceeds from sale of property and equipment
1
4
—
Net cash provided by (used for) investing activities
(140)
(5)
(65)
Cash flows from financing activities:
Proceeds from revolving line of credit
—
190
—
Repayment of revolving line of credit
—
(190)
—
Proceeds from issuance of debt
—
—
1,220
Principal payments of debt
(30)
(122)
(43)
Debt issuance and amendment costs
—
(5)
(24)
Dividend paid to Former Parent
—
—
(1,174)
Proceeds from share-based awards
8
12
6
Tax payments related to share-based awards
(15)
(2)
(1)
Net transfers from Former Parent
—
—
165
Proceeds from issuance of Series A preferred stock
—
250
—
Series A preferred stock issuance costs
—
(6)
—
Series A preferred stock dividend
—
(6)
—
Distributions to non-controlling shareholders
(2)
—
—
Deferred payments related to equity investments and business acquisitions
(13)
(17)
(9)
Payments related to the buy-out of non-controlling interests in subsidiaries of
Covetrus
(14)
—
(74)
Net cash provided by (used for) financing activities
(66)
104
66
Effect of exchange rate changes on cash and cash equivalents
(3)
8
3
Net change in cash and cash equivalents
(107)
160
107
Cash and cash equivalents, beginning of period
290
130
23
Cash and cash equivalents, end of period
$
183 $
290 $
130
Covetrus, Inc. 2021 Form 10-K
56
COVETRUS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions) (Continued)
Years Ended
December 31, 2021
December 31, 2020
December 31, 2019
Supplemental disclosures of cash payments:
Interest
$
22 $
40 $
47
Income taxes
$
27 $
24 $
18
Amounts included in the measurement of operating lease liabilities
$
27 $
27 $
25
Supplemental disclosures of noncash investing and financing activities:
Conversion of Series A preferred stock
$
— $
245 $
—
Right-of-use assets obtained in exchange for new operating lease liabilities
$
51 $
56 $
104
Right-of-use assets obtained in exchange for new financing lease liabilities
$
2 $
— $
1
Common stock issued in business acquisition
$
4 $
— $
—
Deconsolidation of a subsidiary
$
— $
15 $
—
See notes to consolidated financial statements.
Covetrus, Inc. 2021 Form 10-K
57
1. BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES
Business Overview
Covetrus, Inc. is a global animal-health technology and services company dedicated to supporting the companion, equine, and
large-animal veterinary markets.
On February 7, 2019, Henry Schein completed the spin-off of its Animal Health Business and transferred the applicable assets,
liabilities, and ownership interests to us and distributed all the shares of our common stock that were then owned by Henry Schein
to its stockholders of record as of January 17, 2019. Also, on February 7, 2019 and prior to the Distribution, we sold $361 million
in shares to accredited institutional investors (the “Share Sale”). The proceeds from the Share Sale were paid to us and distributed
to Henry Schein. Concurrent with the Distribution, we paid a cash dividend of $1.2 billion from loan proceeds from our newly
established credit facility (see Note 7 - Long-Term Debt and Other Borrowings, Net). We then acquired Vets First Choice in an
all-stock transaction (the “Acquisition”).
Immediately following the Share Sale, Distribution, and Acquisition, on a fully diluted basis, (i) approximately 63% of our
outstanding common stock was owned by (a) shareholders of Henry Schein and the Share Sale investors, and (b) specific
employees of the Animal Health Business who held certain equity awards, and (ii) approximately 37% was owned by (a)
shareholders of Vets First Choice, and (b) certain employees of Vets First Choice who held certain equity awards. On February 8,
2019, our common stock began regular-way trading under the symbol “CVET” on the Nasdaq Global Select Market.
Basis of Presentation and Principles of Consolidation
The accompanying consolidated financial statements are prepared in accordance with GAAP. The accompanying consolidated
financial statements include the operations of the Company as well as those of our wholly-owned and majority-owned subsidiaries
from their respective dates of inception or acquisition. Intercompany transactions and balances are eliminated in consolidation.
Investments in unconsolidated affiliates, which are 20% to 50% owned, or investments of less than 20% in which we could
influence the operating or financial decisions, are accounted for under the equity method.
The accompanying consolidated financial statements and notes hereto include the adjustments described below:
Immaterial reclassifications from interim periods in 2021 that were corrected in the fourth quarter of 2021:
During the fourth quarter of 2021, the Company identified and corrected classification errors related certain capitalized software
development costs. Property and equipment, net was understated by $5 million, $7 million and $10 million, respectively as of
March 31, June 30, and September 30 2021. Other non-current assets were overstated by the same amounts. We also reclassified
the cash flows related to these development costs from operating to investing activities on the statements of cash flows.
Immaterial corrections from a previous year:
We identified and corrected our consolidated statements of cash flows for the year ended December 31, 2019 related to the
revision to deferred tax assets associated with investment in partnerships that was identified in our Annual Report on Form 10-K
for the year ended December 31, 2020, which we concluded was not material to any previously issued financial statements. The
benefit for deferred income taxes was understated by $39 million and the change in other assets and liabilities was overstated by
the same amount. Our cash flows from operating activities was unaffected by this reclassification.
During the fourth quarter of 2021, the Company identified a calculation error in the fair value of vested shares presented in Note
18 - Share-based Compensation and Other Employee Benefits to the financial statements in our Annual Report on Form 10-K for
the year ended December 31, 2020. The fair values of RSA/RSU vested shares were understated by $11 million and $22 million
for the years ended December 31, 2020 and 2019, respectively. This error impacted only our footnote disclosures and did not
misstate our financial statements for any period.
We determined the corrections listed above to be immaterial, both individually and in aggregate, in the accompanying
consolidated financial statements and the notes hereto.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Covetrus, Inc. 2021 Form 10-K
58
Use of Estimates
Preparing financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts
reported and disclosed in the financial statements and accompanying notes. Changes in circumstances could cause actual results to
differ materially from these estimates. The most significant estimates include our evaluation of goodwill impairment, deferred
taxes, contingencies, intangible assets acquired, fair value measurements, share-based compensation, and supplier rebates.
Significant Accounting Policies
Cash and Cash Equivalents
We classify all highly liquid short-term instruments with an original maturity of three months or less as cash equivalents. We
maintain cash depository accounts with high-quality banks throughout the world. Our cash on deposit in the U.S. generally
exceeds federally insured limits. We have not incurred any related losses for the years ended December 31, 2021, 2020, and 2019.
Customer Contract Balances
Contract balances represent amounts presented in the consolidated balance sheets when we have either transferred goods or
services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts
receivable, contract assets, and contract liabilities.
Accounts Receivable
The carrying amount of accounts receivable is reduced by an allowance that reflects our best estimate of the amounts that are not
expected to be collected. We estimate and reserve for our expected credit loss exposure based on our experience with past due
accounts, write-off history, the aging of accounts receivable, our analysis of customer data, current economic conditions, and
reasonable and supportable future forecasts. From time to time, we adjust our assumptions for anticipated changes in any of these
or other factors expected to affect collectability. Accounts receivable balances are written off when it is probable that all
contractual payments due will not be collected.
Contract Assets
Contract assets include amounts related to any conditional right to consideration for work completed as of the reporting date and
generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable
when the right becomes unconditional. Current contract assets are included in prepaid expenses and other and non-current
contract assets are included in Investments within the consolidated balance sheets. The contract assets primarily relate to the
bundled arrangements for the sale of equipment and consumables and sales of term software licenses.
Contract Liabilities
The contract liabilities primarily relate to advance payments from customers and upfront payments for service arrangements
provided over time. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current
contract liabilities are included in other current liabilities and non-current contract liabilities are included in other liabilities within
the consolidated balance sheets.
Inventories
Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. When inventory is
adjusted to net realizable value, the corresponding adjustment is included in cost of sales. Cost is determined by the first-in, first-
out method for merchandise or actual cost for large equipment and high-tech equipment. In accordance with our policy for
inventory valuation, we consider many factors, including the condition and salability of the inventory, historical sales, forecasted
sales, and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or
other factors expected to affect the value of inventory.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
59
We record a liability for unconditional purchase commitments with contract suppliers for quantities greater than future demand
forecasts consistent with excess and obsolete inventory valuations. As of December 31, 2021 and 2020, we did not record any
liability related to excess unconditional purchase commitments.
Concentration Risks
We are subject to a concentration of risk with our suppliers, as five suppliers accounted for approximately 48% and 50% of our
purchases for the years ended December 31, 2021 and 2020, respectively.
Property and Equipment
Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is computed primarily
under the straight-line method. Amortization of leasehold improvements is computed using the straight-line method over the
lesser of the useful life of the assets or the lease terms. See Note 11 - Property and Equipment, Net.
Capitalized software costs consist of costs to purchase and develop software for internal use. Costs incurred during the application
development stage for software bought and further customized by outside suppliers, software developed by a supplier for
proprietary use, and costs incurred for our own personnel who are directly associated with software development are capitalized.
Leases
We evaluate whether an arrangement is or contains a lease at contract inception. For all our leases, we determine the classification
as either operating or financing. Leases with an initial term of 12 months or less are not recognized on the consolidated balance
sheets. We have lease agreements with both lease and non-lease components, which are generally accounted for together as a
single lease component. We recognize lease expense for these leases on a straight-line basis over the lease term. For purposes of
calculating operating lease liabilities, lease terms may be deemed to include options to extend or terminate the lease when it is
reasonably certain that we will exercise that option.
Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. As most of our leases do not provide an implicit rate, we use a rate that is based on similarly
secured borrowings available to us at commencement date in determining the present value of future lease payments. We use the
implicit rate when readily determinable. See Note 10 - Leases.
Goodwill
The net assets of businesses acquired are recorded at their fair value at the acquisition date and the consolidated financial
statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of
identifiable net assets acquired is recorded as goodwill. Goodwill is not amortized, but the potential impairment of goodwill is
assessed at least annually (on October 1st) and on an interim basis whenever events or changes in circumstances indicate that the
carrying value of a reporting unit exceeds its fair value. Impairment analysis for goodwill requires a comparison of the fair value
to the carrying value of a reporting unit.
Some important factors that could trigger an interim impairment review include:
•
Significant underperformance relative to expected historical or projected future operating results,
•
Significant changes in the manner of the use of acquired assets or our overall business strategy (e.g., decision to divest a
business),
•
Sustained decline in our share price and a resulting decrease in our market capitalization, or
•
Significant negative industry or economic trends.
See Note 6 - Goodwill and Other Intangibles, Net.
Long-lived Assets
The estimated fair value of identifiable intangible assets is based on critical estimates, judgments, and assumptions derived from
analysis of market conditions, discount rate, discounted cash flows, customer retention rates, and estimated useful lives.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
60
Definite-lived intangible assets consist primarily of non-compete agreements, trademarks, patents, customer relationships, and
product development. Long-lived assets, other than goodwill, are evaluated for impairment whenever events or changes in
circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future
cash flows derived from such assets. The carrying amount of long-lived assets is not recoverable if it exceeds the sum of
undiscounted cash flows expected as a result from use and eventual disposition of the asset. For long-lived assets used in
operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted,
probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount
and the estimated fair value. When impairment exists, the related assets are written down to fair value. See Note 6 - Goodwill and
Other Intangibles, Net.
Equity Method Investments
Equity investments are accounted for using the equity method of accounting if the investment gives us the ability to exercise
significant influence, but not control, over an investee. Equity method investments are included within Investments on our
consolidated balance sheets. Our share of the earnings or losses as reported by equity method investees, amortization of basis
differences, related gains or losses, and impairments, if any, are recognized in equity in earnings of affiliates on our consolidated
statements of operations. Each reporting period, we evaluate whether declines in fair value below carrying value are other-than-
temporary and if so, we write down the investment to its estimated fair value. See Note 5 - Divestitures and Equity Method
Investments.
Fair Value
GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and
liabilities that may be measured at fair value on a non-recurring basis, and certain financial assets and liabilities that are not
measured at fair value in our condensed consolidated balance sheets, but the fair value is disclosed. The fair value disclosures of
these assets and liabilities are based on a three-level hierarchy, which is defined as follows:
•
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities
•
Level 2 - Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for
identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are
observable for the asset or liability
•
Level 3 - Unobservable inputs for the asset or liability
See Note 14 - Fair Value.
Income Taxes
We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and
liabilities for the expected future tax consequences of events that have been recognized in the financial statements or tax returns.
In estimating future tax consequences, we generally consider all expected future events other than proposed changes in tax laws or
rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the
period of the enactment date. We recognize interest accrued and penalties on uncertain income tax positions as components of
income tax (benefit) expense in the consolidated statement of operations. See Note 13 - Income Taxes.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
61
Loss Contingencies
We are subject to loss contingencies, including claims with customers and vendors, pending and potential legal actions for
damages, investigations relating to governmental laws and regulations, and other matters arising out of the normal course of our
business. We record a liability when we believe that it is probable that a loss has been incurred and the amount can be reasonably
estimated. If we determine that a loss is reasonably possible and the loss or range of loss can be estimated, we disclose the
possible loss in the notes to our financial statements. Legal fees are expensed as incurred. See Note 8 - Commitments and
Contingencies.
Redeemable Non-Controlling Interests
Some minority equity owners in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership
interest in those entities. As a result of these redemption features, we record the non-controlling interests as redeemable and
classify them as mezzanine equity on our consolidated balance sheets initially at their acquisition-date fair value. The non-
controlling interests are adjusted each reporting period for income (or loss) attributable to the non-controlling interests. A
measurement period adjustment, if any, is then made to adjust the non-controlling interests to the higher of redemption value or
carrying value each reporting period. These adjustments are recognized through retained earnings and are not reflected in net
income or net income attributable to Covetrus. See Note 19 - Redeemable Non-controlling Interests.
Foreign Currency Translation and Transactions
The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional
currency with the exception of certain foreign holding companies, whose functional currency is USD. Assets and liabilities of our
foreign subsidiaries are translated at the exchange rate in effect at each month of the year. Statement of operations accounts are
translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing
exchange rates from period to period are included in accumulated other comprehensive loss in equity. Gains and losses resulting
from foreign currency transactions are in other, net in our consolidated statements of operations.
Derivatives
Our global business exposes us to risks related to changes in foreign currency exchange rates and interest rates. Our financial risk
management program is designed to manage the exposure arising from cash flow variability and uses derivative financial
instruments to minimize this risk. We do not enter into derivative financial instruments for trading or speculative purposes.
Our derivative instruments consisted of interest rate swap contracts, which matured in July 2021, and foreign currency forward
exchange contracts. We entered into the foreign currency forward exchange contracts in December 2021. The forward exchange
contracts are not designated for hedge accounting. Derivative instruments are recorded in the consolidated balance sheets either as
other current assets/liabilities or other assets/liabilities. The changes in the fair values of these foreign currency forward exchange
contracts and of the underlying hedged exposures are generally offsetting and are recorded immediately in other, net on the
consolidated statement of operations.
For the matured interest rate swap contracts, which were cash flow hedges, the changes in the fair value of the derivative were
recorded as a component of accumulated other comprehensive income (loss) and subsequently reclassified into earnings in the
period(s) during which the hedged transaction affected earnings. We classified the cash flows related to hedging activities in the
same category on the consolidated statements of cash flows as the cash flows related to the hedged item. See Note 15 -
Derivatives.
At inception of the hedging contract, we used statistical regression to assess the effectiveness of the interest rate hedges. The
hedging contracts were deemed highly effective throughout the hedge period. Therefore, we performed a qualitative assessment of
the hedge effectiveness at each subsequent quarterly reporting date. Derivative gains and losses were initially reported as a
component of other comprehensive (loss) income and subsequently recorded in the consolidated statement of operations when the
hedged transaction was recognized in earnings.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
62
Revenue Recognition
We recognize revenue when a customer obtains control of promised goods or services in an amount that reflects the consideration
that we expect to receive for those goods or services. To recognize revenue, we do the following:
•
Identify the contract(s) with a customer
•
Identify the performance obligations in the contract
•
Determine the transaction price
•
Allocate the transaction price to the performance obligations in the contract
•
Recognize revenue when, or as, we satisfy a performance obligation
Our revenue is generated from the following major product categories:
•
Supply Chain Services - primarily includes the sale of animal-health consumable products, including our own
proprietary and Covetrus-branded products, small equipment, laboratory products, large equipment, equipment repair
services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products,
parasiticides, and vitamins and supplements to wholesale and retail customers. Our value-added practice solutions
include equipment repair, inventory management, e-commerce, as well as continuing education services for practitioners.
•
Software Services - includes practice management software systems for veterinary practitioners and animal-health
clinics, client communication services, reminders, data backup services, and hardware sales and support.
•
Prescription Management - includes the distribution of finished goods pharmacy products, specialty pharmaceutical
compounding, e-commerce, shipping, manufacturer incentives, service fees, and data integration and support services.
We estimate the transaction price at contract inception, including any variable consideration, and update the estimate each
reporting period for any changes in circumstances. Variable consideration, including provisions for discounts, rebates to
customers, customer returns, and other contra revenue adjustments is included in the transaction price at contract inception by
estimating the most likely amount based upon historical data and estimates and is recorded in the period in which the related sales
are recognized.
Many of our contracts with customers require us to take possession of the inventory, provide the goods or services, and establish
the price for the goods or services. Revenue and cost of sales from this type of contract are recognized on a gross basis. From time
to time, certain contracts require us to arrange for the procurement of goods or services on behalf of our customer, but we do not
purchase or take title of the product from the supplier before they are transferred to our customer. In this type of contract, we are
acting as an agent, and revenue is recognized on a net basis (revenue less cost of sales is included in net sales) (“Net Agency
Revenue”), as the supplier is the primary obligor, bears the inventory and credit risk, establishes the price, determines the product
specifications, and the amount is fixed. For the years ended December 31, 2021 and 2020, Net Agency Revenue was not material.
Payment terms differ by customer and jurisdiction and generally range from 30 to 60 days.
Supply Chain Services
Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer.
Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the
shipment date is the most appropriate point in time indicating control has transferred to the customer, because we have no post-
shipment obligations, and this is when legal title and risks and rewards of ownership transfer to the customer, and we have an
enforceable right to payment.
Revenue derived from the sale of equipment is recognized when control transfers to the customer. This generally occurs when the
equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service
technicians. Some equipment sales require minimal installation which is typically completed at the time of delivery. Our products
generally carry standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor
services, the warranty costs are accrued in the period the related revenue is recognized.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
63
Software Services
Revenue derived from the sale of software products is recognized when products are shipped to customers or made available
electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its
design. Revenue derived from post-contract customer support for software, including annual support, is generally recognized over
the life of the support period while revenue from training services is recognized over the period the services are provided.
Prescription Management
Revenue under this category is primarily generated from prescription management and pharmacy services (including the
distribution of finished goods products, specialty pharmaceutical compounding, shipping, manufacturer incentives, and service
fees), which is recognized when control transfers to the customer, typically upon shipment or delivery.
Other Revenue
Revenue derived from other sources, including freight charges and equipment repairs, is recognized when the related product
revenue is recognized or when the services are provided. We applied the practical expedient to treat shipping and handling
activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in
the contract.
Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations that are
accounted for separately. When we sell software products together with related services (e.g., training and technical support), we
allocate revenue to software using the residual method, utilizing an estimate of our standalone selling price to estimate the fair
value of the undelivered elements. Bundled arrangements that include elements that are not considered software consist primarily
of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of
the goods or services. If an observable selling price is not available because we do not sell the goods or services separately, we
use one of the following techniques to estimate the standalone selling price: (i) adjusted market approach, (ii) cost-plus approach,
or (iii) the residual method. There is no specific hierarchy for the use of these methods, but the relative selling price reflects our
best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis, taking into
consideration the cost structure of the business, technical skill required, customer location, and other market conditions.
Sales, value-add, and other taxes we collect concurrently with revenue-producing activities are excluded from revenue, and are
recorded as liabilities and included in accrued taxes. See Note 3 - Revenue from Contracts with Customers and Note 2 - Segment
Data for additional disclosures.
Cost of Sales
The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks, and
rebates) and inbound and outbound freight charges. Cost of sales also includes costs directly related to the design and production
of software, distribution of licenses, hardware and costs related to services provided, and amortization of the capitalized costs for
internally generated software for resale.
Our distribution network costs, such as purchasing, receiving, inspections, warehousing, internal inventory transfers, and other
related costs are included in selling, general and administrative along with other operating costs.
We classify the following activities into either cost of sales or SG&A:
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
64
Amortization of intangibles
Cost of Sales
Costs and expenses related to specific class of intangible assets that are directly linked with revenue-generating
activities.
We include the amortization of our product formulas within cost of sales as these formulas are directly tied to the
production of compounded products as alternatives to back-ordered solutions, patient-specific customized
medications, and in-clinic use medications.
SG&A
Amortization expense for intangible assets that are not directly related to sales-generating activities
Shipping and handling
Cost of Sales
Freight and other direct shipping costs including payroll and related benefit costs of employees performing these
activities
SG&A
Direct handling costs, which represent primarily direct payroll costs of employees who pick, pack, and otherwise
prepare, if necessary, merchandise for shipment to customers
Advertising
Cost of Sales
Net amount of reimbursements received from vendors that are more than the cost of advertising
SG&A
Advertising costs are charged to operations when incurred as part of Selling, general and administrative.
Advertising expense was $19 million in 2021, $17 million in 2020, and $17 million in 2019.
We receive reimbursements from certain vendors for advertising costs. Reimbursements for advertising costs are
reported on a net basis within Selling, general and administrative.
Additionally, advertising and promotional costs incurred in connection with direct marketing, including product catalogs and printed
materials, are deferred and amortized on a straight-line basis over the period that is benefited, typically one year. Deferred direct marketing
expenses are included in prepaid expenses and other on the consolidated balance sheets.
Supplier Rebates
Cost of Sales
We receive quarterly and annual performance rebates from suppliers based upon attainment of certain purchase or
sales goals. Supplier rebates are included as a reduction of Cost of sales and are recognized over the period they
are earned.
The factors considered in estimating supplier rebate accruals include forecasted inventory purchases and sales in
conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either
increased purchase or sales volume.
SG&A
not applicable
Share based compensation
Cost of Sales
not applicable
SG&A
Share-based compensation represents the cost related to share-based awards granted to employees and non-
employee directors, which are measured at the grant date fair value.
We recognize share-based compensation expense, net of estimated expected forfeitures, on a straight-line basis
over the requisite service period of the award.
Earnings (loss) per Share
Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted-average number of
shares of common stock outstanding during the period. In addition, the shares of common stock issuable pursuant to restricted
stock awards, restricted stock units, performance stock units, and stock options outstanding under our 2019 Omnibus Incentive
Compensation Plan, and shares issuable under our Employee Stock Purchase Plan are included in the diluted EPS calculation to
the extent they are dilutive. See Note 17 - Earnings (Loss) Per Share.
Accounting Standards Update
•
As of January 1, 2021, we adopted ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes,” which removes specific technical exceptions to general principles found in Topic 740, items that often produce
information that investors have difficulty understanding, and simplifies the accounting for income taxes. The adoption of
this ASU did not have a material impact on the results of our consolidated financial statements.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
65
•
ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial
Reporting,” provides optional guidance for a limited period of time to ease the potential burden in accounting for (or
recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other
transactions that reference LIBOR. The standard is currently effective and upon adoption may be applied prospectively
to contract modifications made on or before December 31, 2022. Our debt agreements that utilize LIBOR have not yet
discontinued the use of LIBOR and, therefore, this ASU is not yet effective for us. The banking syndicate associated
with our Credit Facilities ceased using the 1-week and 2-month USD LIBOR at the end of 2021. The other USD Tenors
to cease June 30, 2023. We will continue to monitor, and, to the extent our Credit Facilities require amendment to reflect
a replacement rate prior to December 31, 2022, we will evaluate the benefits of adopting this ASU.
2. SEGMENT DATA
We are organized based upon geographic region and focus on delivering our platform of products and services to our customers
on a geographical basis which reflect how the CODM reviews financial information and makes operating decisions. We have
three reportable segments are (i) North America, (ii) Europe, and (iii) APAC & Emerging Markets. Our major product groups that
we disaggregate within our reportable segments are (i) supply chain services, (ii) software services, and (iii) prescription
management. See Note 3 - Revenue from Contracts with Customers for our revenue disaggregated by major product category and
reportable segment. We do not allocate expenses managed at the corporate level to our segments, such as corporate wages and
related benefits, corporate occupancy costs, professional services utilized at the corporate level, and non-recurring expenses. All
intersegment balances and transactions have been eliminated in consolidation.
The following table reflects Net sales based on geographic location:
(In millions)
Years Ended
Net Sales
December 31, 2021
December 31, 2020
December 31, 2019
North America
$
2,719 $
2,377 $
2,111
Europe
1,412
1,571
1,509
APAC & Emerging Markets
461
402
368
Eliminations
(17)
(11)
(12)
Total net sales
$
4,575 $
4,339 $
3,976
The following tables reflect depreciation and amortization expense, expenditures, and total assets by geographic location and
Corporate:
(In millions)
Years Ended
Depreciation and amortization
December 31, 2021
December 31, 2020
December 31, 2019
North America
$
148 $
144 $
131
Europe
19
17
18
APAC & Emerging Markets
3
6
5
Corporate
1
—
—
Eliminations
—
—
—
Total depreciation and amortization expense
$
171 $
167 $
154
(In millions)
Years Ended
Expenditures for long-lived assets
December 31, 2021
December 31, 2020
December 31, 2019
North America
$
49 $
41 $
23
Europe
8
11
10
APAC & Emerging Markets
2
3
1
Corporate
1
3
5
Eliminations
—
—
—
Total expenditures for long-lived assets
$
60 $
58 $
39
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
66
(In millions)
Assets
December 31, 2021
December 31, 2020
North America
$
3,095 $
3,077
Europe
576
713
APAC & Emerging Markets
195
188
Corporate
1,432
1,415
Eliminations
(1,888)
(1,897)
Total assets
$
3,410 $
3,496
The following tables reflect Adjusted EBITDA by geographic location and a reconciliation of Net Income (Loss) Attributable to
Covetrus to Non-GAAP Adjusted EBITDA:
(In millions)
Years Ended
Adjusted EBITDA
December 31, 2021
December 31, 2020
December 31, 2019
North America
$
223 $
187 $
153
Europe
71
72
68
APAC & Emerging Markets
40
28
18
Corporate
(90)
(61)
(39)
Eliminations
—
—
—
Total Adjusted EBITDA
$
244 $
226 $
200
Years Ended
(In millions)
December 31, 2021
December 31, 2020
December 31, 2019
Reconciliation of Net Income (Loss) Attributable to Covetrus to Non-GAAP Adjusted EBITDA
Net income (loss) attributable to Covetrus
$
(54)
$
(19)
$
(980)
Plus: Depreciation and amortization
171
167
154
Plus: Interest expense, net
32
46
54
Less: Income tax (benefit) expense
—
(7)
(46)
Earnings (loss) before interest, taxes, depreciation, and amortization
149
187
(818)
Plus: Share-based compensation
46
40
46
Plus: Strategic consulting
20
20
2
Plus: Transaction costs
3
8
2
Plus: Formation of Covetrus
2
19
31
Plus: Separation programs and executive severance
14
17
11
Plus: Equity method investments and non-consolidated affiliates
3
2
(4)
Plus: IT infrastructure
—
4
6
Plus: Carve-out operating expenses
—
—
5
Plus: Goodwill impairment
—
—
938
Plus: Capital structure
—
2
—
Plus: Other impairments
7
8
—
Plus: Other items, net
—
(81)
(19)
Non-GAAP Adjusted EBITDA
$
244
$
226
$
200
Below is a listing of adjustments to EBITDA included in the reconciliation above:
Share-based compensation - Stock-based compensation is a non-cash expense.
Strategic consulting - Related to third-party consulting services. Included within this line item are variable performance fees
earned for services rendered under a third-party consulting agreement. This agreement was amended in April 2021 and, in
connection with such amendment, the services were completed and fees were fully accrued for as of June 30, 2021.
Transaction costs - Includes legal, accounting, tax, and other professional fees incurred in connection with contemplated and
completed acquisitions and divestitures. The completion of acquisitions and divestitures is often dependent on factors that may be
outside of our control and unrelated to us or to the continuing operations of the acquired or divested business. In addition, the
amount of acquisition-related cost is generally driven by the complexity inherent in the transaction and may not necessarily
indicate the future costs of the acquired business. Excluding transaction costs allows for a better comparison of our historical
performance.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
67
Formation of Covetrus - Includes professional and consulting fees, duplicative costs associated with TSAs, and other costs
incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.
Separation programs and executive severance -
•
2021: Includes $8 million related to our organizational rationalization in Germany and the U.K., as well as other
separation and executive severance programs
•
2020: Includes $6 million related to our France managed exit of our distribution business specializing in medicines, pet
food, equipment, and services for veterinary clinics beginning in the third quarter of 2020 as well as executive severance
•
2019: $11 million of executive severance
IT infrastructure - Includes certain IT infrastructure expenses necessary to establish ourselves as a newly public. These IT costs
are distinct from recurring IT infrastructure costs which are included within our Adjusted EBITDA.
Equity method investment and non-consolidated affiliates - Includes the proportionate share of the adjustments to EBITDA of
consolidated and non-consolidated affiliates where Covetrus ownership is less than 100%.
Goodwill impairment - In 2019, we experienced a sustained decline in our share price and a resulting decrease in our market
capitalization. These events triggered an interim impairment review as of August 31, 2019. We tested for goodwill impairment by
quantitatively comparing the fair values of our reporting units to their carrying amounts and determined that the carrying value of
our reporting units exceeded their fair values resulting in an impairment charge of $938 million.
Other impairments -
•
2021: Includes $6 million related to customer relationships intangible impairments as the asset groups were not
recoverable due a significant reduction in cash flows
•
2020: $8 million related to an operating lease right-of-use asset impairment in our North America segment as the asset
group was not recoverable based on COVID-19's effect on the subleasing market as well as other asset group specific
factors
Capital Structure - Includes investment banking, legal, underwriting, and other fees incurred in connection with private
investment and public equity offerings as well as debt issuance fees or debt modification fees to the extent they are not
capitalized.
Carve-out operating expense - Related to Corporate overhead allocation from Former Parent at the time of the merger.
Other items, net -
•
2020: Includes a pre-tax gain of $73 million gain on the divestiture of scil, a $6 million mark-to-market adjustment for
immaterial put and call options, and a $1 million gain on the deconsolidation of SAHS. See Note 5 - Divestitures and
Equity Method Investments
•
2019: Includes $15 million of gains associated with acquisitions in France and Romania, $2 million gain on legacy
investment, and a $1 million government grant income
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
68
3. REVENUE FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue
The tables below presents our revenue disaggregated by major product category and reportable segment:
Year Ended December 31, 2021
(In millions)
Supply Chain Services
Software Services
Prescription Management
Eliminations
Total
North America
$
2,230 $
79 $
503 $
(93) $
2,719
Europe
1,419
11
—
(18)
1,412
APAC & Emerging Markets
452
9
—
—
461
Eliminations
(17)
—
—
—
(17)
Total Net sales
$
4,084 $
99 $
503 $
(111) $
4,575
Year Ended December 31, 2020
(In millions)
Supply Chain Services
Software Services
Prescription Management
Eliminations
Total
North America
$
1,969 $
78 $
406 $
(76) $
2,377
Europe
1,574
10
—
(13)
1,571
APAC & Emerging Markets
394
8
—
—
402
Eliminations
(11)
—
—
—
(11)
Total Net sales
$
3,926 $
96 $
406 $
(89) $
4,339
Year Ended December 31, 2019
(In millions)
Supply Chain Services
Software Services
Prescription Management
Eliminations
Total
North America
$
1,816 $
82 $
246 $
(33) $
2,111
Europe
1,513
10
—
(14)
1,509
APAC & Emerging Markets
361
7
—
—
368
Eliminations
(12)
—
—
—
(12)
Total Net sales
$
3,678 $
99 $
246 $
(47) $
3,976
Contract Balances
The following table presents information about our receivables and contract liabilities from contracts with customers:
(In millions)
Balance Sheet Location
December 31, 2021
December 31, 2020
Accounts receivable:
Accounts receivable, net
Accounts receivable, net
$
480 $
507
Contract liabilities:
Deferred revenue, current
Other current liabilities
$
15 $
22
For the years ended December 31, 2021 and 2020, our contract assets and long-term contract liabilities were determined to be
immaterial. For the year ended December 31, 2021, deferred revenue recognized from performance obligations completed this
period approximates the balance outstanding as of December 31, 2020.
Performance Obligations
Estimated future revenues expected to be generated from long-term contracts with unsatisfied performance obligations as of
December 31, 2021 were not material.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
69
4. BUSINESS ACQUISITIONS
VCP and AppointMaster
During the year ended December 31, 2021, we completed acquisitions of VCP, a leading platform in veterinary wellness plan
administration, and AppointMaster, a provider of integrated communications solutions for veterinary practices, for 100%
ownership in both entities for an aggregate purchase price of $85 million, including $4 million in common stock. These
acquisitions are intended to provide our Customers with new tools to foster stronger relationships with their Animal Owner clients
by delivering better business and healthcare outcomes. The allocation of the aggregate purchase price resulted in goodwill of
$60 million and other intangible assets, including technology, of $31 million. The results of operations have been included in our
North America segment since the acquisition dates. All acquisition expenses incurred were not material. Goodwill generated by
Appointmaster is tax deductible whereas the goodwill generated by our acquisition of VCP is not tax-deductible. The transactions
are not material business combinations or material to our consolidated financial statements individually or in the aggregate.
Goodwill for VCP See Note 6 - Goodwill and Other Intangibles, Net.
Veterinary Study Groups
During the year ended December 31, 2020, we acquired an 80% interest in Veterinary Study Groups, Inc., which manages a
family of more than 50 Veterinary Management Groups in the United States and Canada. The goodwill from this transaction is
not deductible for tax purposes. The results of operations have been included in our North American segment since the acquisition
date. This transaction is not a material business combination. The acquisition expenses incurred were not material. See Note 6 -
Goodwill and Other Intangibles, Net and Note 19 - Redeemable Non-controlling Interests.
Other
We completed certain other acquisitions during the year ended December 31, 2020 which were immaterial to our consolidated
financial statements individually and in the aggregate.
5. DIVESTITURES AND EQUITY METHOD INVESTMENTS
Divestitures
During the year ended December 31, 2020, we completed the divestiture of scil to Heska Corporation for $110 million pursuant to
an amended purchase agreement. We recorded a pre-tax gain of $73 million included in other, net in our consolidated statements
of operations which reflects a $1 million foreign exchange adjustment for the finalization of the purchase price. It was primarily
included within our Europe segment.
Equity Method Investments
On April 30, 2020, we completed the combination of our subsidiary, SAHS, with Distrivet, S.A. to form a leading animal-health
provider on the Iberian Peninsula. We contributed SAHS by means of a in-kind contribution of all the shares of SAHS in
exchange for the transfer of shares from shareholders of Distrivet, S.A. (“Distrivet Shareholders”). During the second quarter of
2020, we deconsolidated SAHS, remeasured our retained investment initially at a fair value of $45 million, which was included in
investments in our consolidated balance sheets, and recognized a gain of $1 million, which was included in other, net in our
consolidated statements of operations. The fair value was measured using third-party valuation models and was determined using
both the market approach and income approach, which includes discounted expected cash flows.
We made a payment to the Distrivet Shareholders of approximately $13 million in cash on the one-year anniversary in April 2021.
We own 50.01% of Distrivet.
Based on Distrivet's governance structure, we do not have power over key financial and operating decisions that are made in the
ordinary course of business. Accordingly, our investment in Distrivet is accounted for under the equity method and Distrivet is
considered a related party. See Note 18 - Related-Party Transactions. As of December 31, 2021, the carrying amount of our
investment in Distrivet was $47 million which was included in Investments in our consolidated balance sheets.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
70
6. GOODWILL AND OTHER INTANGIBLES, NET
Goodwill
The changes in the goodwill balances by segment for the years ended December 31, 2021 and December 31, 2020 were as
follows:
(In millions)
North
America
Europe
APAC &
Emerging
Markets
Total
Balance at January 1, 2020
$
1,154 $
— $
— $
1,154
Goodwill additions (a)
33
—
—
33
Balance at December 31, 2020
1,187
—
—
1,187
Goodwill additions (a)
60
—
—
60
Balance at December 31, 2021
$
1,247 $
— $
— $
1,247
(a) See Note 4 - Business Acquisitions
There were no accumulated impairment losses at December 31, 2021 and December 31, 2020. The accumulated impairment
losses at December 31, 2019 were $938 million.
Other Intangibles, Net
Definite-lived intangible assets consisted of the following as of:
December 31, 2021
(In millions)
Weighted
Average
Useful Life
Cost
Accumulated
Amortization
Net
Customer relationships (a)
10.0 years
$
365 $
(157) $
208
Trademarks
6.0 years
63
(41)
22
Patents
7.0 years
30
(30)
—
Product development
5.4 years
430
(221)
209
Non-compete agreements
4.1 years
2
(2)
—
Total other intangibles
$
890 $
(451) $
439
(a) Includes $6 million of impairment charges. See Note 2 - Segment Data
December 31, 2020
(In millions)
Weighted
Average
Useful Life
Cost (a)
Accumulated
Amortization
Net
Customer relationships
12.5 years
$
526 $
(265) $
261
Trademarks
7.6 years
64
(33)
31
Patents
7.0 years
30
(28)
2
Product development
5.4 years
403
(143)
260
Non-compete agreements
4.1 years
2
(1)
1
Total other intangibles
$
1,025 $
(470) $
555
(a) Includes $45 million primarily related to customer relationships; see Note 4 - Business Acquisitions
The table below sets forth amortization of intangible assets:
(In millions)
Years Ended
Location
December 31, 2021
December 31, 2020
December 31, 2019
Cost of sales
$
7 $
5 $
4
Selling, general and administrative
129
130
123
Total amortization expense
$
136 $
135 $
127
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
71
The estimated future amortization of intangible assets as of December 31, 2021 is as follows:
(In millions)
Amount
2022
$
134
2023
121
2024
67
2025
30
2026
26
Thereafter
61
Total
$
439
7. LONG-TERM DEBT AND OTHER BORROWINGS, NET
Long-term debt and other borrowings consisted of the following as of:
(In millions)
Maturity Date
Rate as of
December 31, 2021
December 31, 2021
December 31, 2020
Credit Facility
Revolving line of credit
February 2024
— % $
— $
—
Term loan
February 2024
1.9 %
1,050
1,080
Other borrowings (a)
8
7
Total debt and other borrowings
1,058
1,087
Less: current maturities
(32)
(1)
Total Long-term debt and other borrowings
$
1,026 $
1,086
Less: unamortized debt discount
(12)
(18)
Total Long-term debt and other borrowings, net
$
1,014 $
1,068
(a) As of December 31, 2021 and 2020, other borrowings include a loan payable of $6 million along with finance lease obligations of $2 million
and $1 million, respectively.
Credit Facility
Our Credit Facility is comprised of the following:
(In millions)
Total Amount
Amount Available as of
December 31, 2021
Term loan facility
$
1,200 $
1,050
Revolving line of credit (a)
300
298
Total Credit Facility (b)
$
1,500 $
1,348
(a) Letters of credit reduce our borrowing capacity under the revolving line of credit. At December 31, 2021, we had $2 million for letters of
credit outstanding against the total $35 million sub-limit available.
(b) For the years ended December 31, 2021, 2020 and 2019, we paid $0 million, $4 million, and $24 million, respectively of debt issuance costs
related to the Credit Facilities, respectively. Debt issuance costs is deferred and amortized on an effective yield basis to interest expense.
On February 7, 2019, we entered into a syndicated credit agreement with a five-year term primarily to pay a dividend to our
Former Parent, as well as provide funding for working capital and general corporate purposes. In February 2020, the Credit
Facility was amended, and the revised terms are reflected below. The term loan facility and revolving line of credit bear interest
on a floating rate basis at our option, according to a leverage-based pricing grid and incur fees as follows:
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
72
•
USD LIBOR (for one-month, two-month, three-month, six-month and potentially nine-month and 12-month tenors)
subject to a floor of 0.00%
◦
plus, an applicable margin ranging from 1.25% to 2.50% annually based on our leverage ratio at the end of the prior
quarter.
•
Alternative base rate determined as 1.00% plus the highest of the Prime Rate, Federal Funds Rate plus 0.50%, or one-
month USD LIBOR
◦
plus, an applicable margin ranging from 0.25% to 1.50% annually based on our leverage ratio at the end of the prior
quarter.
•
Unused capacity under the revolving line of credit loan incurs a fee ranging from 0.175% to 0.400% per annum based on
our leverage ratio at the end of the prior quarter.
•
Additionally, customary letter of credit fees, as well as fronting fees, are incurred for letters of credit outstanding.
Over the past two years, regulators, including the Board of Governors of the Federal Reserve System, OCC, FDIC, and the FCA,
advocated that companies and financial institutions stop using LIBOR as a borrowing basis. Following December 31, 2021, one-
week and two-month USD LIBOR, as well as all non-USD LIBOR tenors, ceased publication immediately, while three-month,
six-month, and one-year USD LIBOR will cease publication after June 30, 2023. As a result, in lieu of amending or waiving any
term of the Credit Facility, we notified the administrative agent to the Credit Facility that non-USD currencies would not be
available to us either as a revolving line of credit or term loan facility borrowing, and further we suspended our rights to borrow at
the two-month USD LIBOR tenor until such time as the Credit Facility is amended with an alternative benchmark rate to USD
LIBOR.
The applicable margins on USD LIBOR and alternative base rate borrowings fluctuated over the course of 2021 dependent on a
pricing grid based on our consolidated net total leverage ratio as defined in the Credit Facility. As of December 31, 2021, the
applicable margins on LIBOR and alternative base rate borrowings were 1.75% and 0.75%, respectively, for both the term loan
facility and revolving line of credit. The commitment fee for the revolving line of credit as of December 31, 2021 was 0.25%.
Starting March 31, 2020, the term loan facility began amortizing in quarterly installments equal to 5.00% per annum of the initial
borrowed amount and requires full payment at maturity of all remaining amounts owed. No amortizing payments are required for
the revolving line of credit, however all amounts owed are due at maturity. We have the option to prepay both the term loan
facility and revolving line of credit without penalty, subject to certain conditions. If the aggregate balance of loans outstanding
exceeds the lender's commitments made to the revolving line of credit at any time, then the amount of such excess is required to
be repaid. Mandatory prepayments of the term loan facility are required in an amount equal to the net cash proceeds of, subject to
specific conditions, (i) certain assets sales, (ii) certain debt offerings, and (iii) certain insurance recovery and condemnation
events.
Additionally, the Credit Facility limits or restricts our ability, subject to certain exceptions, to:
•
Incur additional indebtedness
•
Make dividends and other restricted payments
•
Incur additional liens
•
Consolidate, merge, sell, or otherwise dispose of all or substantially all assets
•
Make investments
•
Transfer or sell assets
•
Enter into restrictive agreements
•
Change the nature of the business
•
Enter certain transactions with affiliates
In December 2021, we prepaid $30 million of our scheduled 2022 term loan facility amortization payments. The next mandatory
quarterly principal amortization term loan facility payment of $15 million is due on September 30, 2022.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
73
Compliance and Covenants
Based on the revised schedule contained in the 2020 amendment to our Credit Facilities, we are required to remain compliant with
a Credit Facilities-defined leverage covenant that is currently set at 4.50x, which will be reduced to 3.75x as of June 30, 2022
through maturity of the Credit Facilities in February 2024. The decrease in this particular financial covenant and our required
compliance may influence our investment decisions.
We continuously monitor our compliance with the terms and conditions of our Credit Facility and take such actions as are
necessary to attain and ensure compliance. We were in compliance with all financial covenants as of and for the year ended
December 31, 2021.
The Credit Facility is guaranteed by Covetrus, the subsidiary borrower, and its subsidiary guarantors. We have pledged
substantially all tangible and intangible assets, as well as our ownership interests in certain subsidiary companies, in support of the
Credit Facility.
Long-term debt maturities and Other borrowings
The following table presents the maturities of our long-term debt and other borrowings, net as of December 31, 2021:
(In millions)
Credit Facility
Other Borrowings
Total Repayments
2022
$
30 $
2 $
32
2023
60
6
66
2024
960
—
960
2025
—
—
—
Total debt maturities
$
1,050 $
8 $
1,058
8. COMMITMENTS AND CONTINGENCIES
We are involved in various legal proceedings that arise in the ordinary course of business. Substantial judgment is required in
predicting the outcome of these legal proceedings, many of which may take years to adjudicate. We accrue estimated costs for a
contingency when we believe that a loss is probable and can be reasonably estimated. No material loss contingencies were
accrued as of December 31, 2021.
Securities Litigation Matter
On September 30, 2019, the City of Hollywood (Florida) Police Officers' Retirement System filed a putative securities class
action lawsuit in the United States District Court for the Eastern District of New York, purportedly on behalf of purchasers of
Covetrus common stock from February 8, 2019 through August 12, 2019, against the Defendants. The complaint alleges that the
Defendants violated Sections 10(b) and 20(a) of the Exchange Act, by making allegedly false and misleading statements and
omissions, primarily regarding the Company’s financial prospects and the integration costs relating to the business combination
involving the Animal Health Business and Vets First Choice. The suit seeks unspecified damages, fees, interest, and costs. On
August 3, 2021, the Court issued an order granting in part and denying in part Defendants’ motions to dismiss. In particular, the
Court dismissed, with prejudice, all claims asserted against our Former Chief Financial Officer, a director, and our Former Parent,
as well as certain claims based on alleged misrepresentations attributed to the Company and our Former Chief Executive Officer.
We intend to continue to defend the remaining claims vigorously. Given the uncertainty of litigation, the preliminary stage of the
case, and the legal standards that must be met for, among other things, class certification and success on the merits, we cannot
estimate the reasonably possible loss or range of loss that may result from this action.
Purchase Obligations
We are party to an exclusive supply agreement with an unconditional commitment to purchase certain products within the U.S.
market until 2025. The agreement operates on a contract year of October 6 through October 5. The unconditional purchase
obligation is approximately $8 million for each remaining contract year. For the years ended December 31, 2021, 2020, and 2019
we purchased products totaling $7 million, $8 million and $9 million, respectively under this agreement.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
74
Our purchases for each contractual year through October 5, 2021 met our purchase obligation for those periods. Our forecasted
sales of these products exceed our purchase obligations under this agreement.
In 2019, we engaged a third party for services over a three-year period ending December 31, 2022. We considered the contract to
be of a “take-or-pay” nature due to the termination fees embedded in the contract: fixed termination fees of $12 million until mid-
November 2020 and $14 million thereafter, plus any variable performance fees through termination. The fixed portion of the
contract was capped at $14 million while the variable portion of the contract was capped at $39 million over the term of the
engagement. In April 2021, we amended this contract with the third-party service provider such that the terms of the original
agreement were deemed fully satisfied by both parties. This amendment resulted in a decrease of $18 million from the remaining
commitments under the original terms of the agreement. In connection with the contract amendment, we agreed to pay the third
party $10 million for specific services, which were completed and fully accrued for as of June 30, 2021.
9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
The following table presents our accrued expenses and other current liabilities as of:
(In millions)
December 31, 2021
December 31, 2020
Customer related liabilities
49
59
Operating lease liabilities - current
22
22
Accrued payables
15
10
Professional fees
10
14
Acquisition related expenses
—
13
Other accrued expenses (a)
41
57
Total
$
137 $
175
(a) Other accrued expenses include expenses related to separation and executive severance programs. See Note 2 - Segment Data
10. LEASES
We have office space, warehouse facilities, vehicles, and equipment under non-cancelable operating leases with third parties. The
leases have remaining lease terms of 1 to 20 years.
Rent expense charged to operations under operating leases during the years ended December 31, 2021, 2020, and 2019 was $29
million, $30 million, and $25 million, respectively. Common Area Maintenance and taxes for the years ended December 31,
2021, 2020, and 2019 was $5 million, $3 million , and $2 million respectively. Short-term lease expense and variable rent expense
for the years ended December 31, 2021, 2020, and 2019 were not material. Our finance leases were not material as of December
31, 2021 and 2020.
The following table presents the lease balances within the consolidated balance sheets and other supplemental information related
to our leases as of:
(In millions)
December 31, 2021
December 31, 2020
Operating Leases:
Operating lease right-of-use assets, net
$
137
$
117
Accrued expenses, other
22
22
Other liabilities
130
107
Total operating lease liabilities
$
152
$
129
Weighted-average remaining lease term:
Operating leases
9.2 years
8.1 years
Weighted-average discount rate:
Operating leases
3.3 %
3.5 %
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
75
The following table presents the maturities of our lease liabilities as of December 31, 2021:
(In millions)
Operating Leases
2022
$
27
2023
25
2024
20
2025
16
2026
14
Thereafter
75
Total minimum lease payments
177
Less: amount representing interest
(25)
Present value of net minimum lease payments
152
Less: current portion of lease obligations
(22)
Long-term lease obligations
$
130
As of December 31, 2021, we had additional operating leases that have not yet commenced which included the following:
Description
Commencing
Lease Term
Total Future Lease Payments
Office space
May 2022
20 years
$
72
Total
$
72
11. PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following as of:
(In millions)
Estimated Useful Life
December 31, 2021
December 31, 2020
Land
N/A
$
1 $
1
Buildings and permanent improvements
10-40 years
7
10
Leasehold improvements
Lesser of the useful life or lease terms
22
21
Machinery and warehouse equipment
2-12 years
52
45
Furniture, fixtures, and other
2-10 years
39
46
Computer equipment and software
2-10 years
100
76
Capital in progress
58
23
Total property and equipment, gross
279
222
Less: accumulated depreciation and amortization
(135)
(106)
Total Property and equipment, net
$
144 $
116
The following table sets forth our depreciation and amortization expense related to property and equipment:
(In millions)
Years Ended
Location
December 31, 2021
December 31, 2020
December 31, 2019
Cost of sales
$
1 $
1 $
3
Selling, general and administrative
32
31
24
Total depreciation and amortization expense
$
33 $
32 $
27
12. SHARE-BASED COMPENSATION AND OTHER EMPLOYEE BENEFITS
Share-based Compensation Plan
In 2019, we adopted the 2019 Omnibus Incentive Compensation Plan (the “Plan”) which authorizes our Compensation Committee
of the Board of Directors to grant stock options, stock awards, stock units, stock appreciation rights, other share-based awards,
and cash awards. Awards may be granted to employees, consultants, advisors, and non-employee directors of Covetrus and our
subsidiaries. Awards issued under the Plan may not have a term greater than 10 years from the date of grant and vesting is subject
to the terms of specific awards made under the Plan.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
76
At December 31, 2021, 16 million shares of our common stock were authorized under the Plan. In addition, to the extent that
awards outstanding under the Plan are cancelled, forfeited, or otherwise terminated without being exercised, the number of shares
underlying such awards will be available for future grant under the Plan.
The following table summarizes the total share-based compensation expense and related tax benefit:
Years Ended
(In millions)
December 31, 2021
December 31, 2020
December 31, 2019
Share-based compensation expense
$
46 $
40 $
46
Tax benefit
$
2 $
8 $
6
As of December 31, 2021, there was $55 million in unrecognized compensation expense related to nonvested share-based awards,
including 100% performance attainment for our PSUs, that is expected to be recognized over a weighted-average period of 1.7
years.
Stock Options
We granted stock options at an exercise price equal to the closing market price of our stock on the grant date. We use the Black-
Scholes pricing model to determine the fair value of options granted and have elected the accrual method for recognizing
compensation costs. The fair value of share-based payment awards calculated using the Black-Scholes model varies based on
share price, award exercise price, stock volatility, expected term, risk free interest rate, expected dividends, and the assumptions
used in determining these variables. No stock options were granted during 2021 and 2020.
The following table summarizes our stock option activity under the Plan for the year ended December 31, 2021:
(In millions, except per share data)
Number
of Shares
Weighted-
average
Exercise
Price
Per Share
Weighted-
average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at beginning of year
2 $
15.58
Granted
—
—
Exercised
(1)
8.00
Forfeited
—
—
Outstanding at end of year
1 $
15.74
5.7
$
11
Exercisable at end of year
1 $
14.12
5.5
$
11
The total intrinsic value of options exercised for the years ended December 31, 2021, 2020, and 2019 was $8 million, $13 million
and $15 million, respectively. Cash received from option exercises for the years ended December 31, 2021, 2020, and 2019 was
$3 million, $7 million, and $4 million, respectively.
The following table provides the weighted-average grant-date fair value and related valuation assumptions for these awards
granted during the year ended December 31, 2019:
Weighted-average grant-date fair value
$12.19
Valuation assumption ranges:
Expected term (years)
6.0
Risk-free interest rate
1.8 % - 2.5%
Expected volatility
29.6 % - 30.0%
RSAs/RSUs
RSAs/RSUs granted generally vest over a one-year to three-year term. We have granted RSUs to certain executive officers which
vest over a three-year term. One-year term RSUs granted exclude our named executive officers and relate to retention. The
following table summarizes our RSA/RSU activity under the Plan for the year ended December 31, 2021:
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
77
(In millions, except per share data)
Number of
Shares
Weighted-
average
Grant-date
Fair Value
Per Share
Weighted-
average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Nonvested at beginning of year
4 $
14.07
Granted
2
27.60
Vested
(2)
14.88
Forfeited
—
—
Nonvested at end of year
4 $
22.47
0.98
$
71
The weighted-average fair value at grant date of the nonvested shares granted for the years ended December 31, 2021, 2020, and
2019 were $27.60, $11.51, and $27.83, respectively. The total fair value of awards vested during the years ended December 31,
2021, 2020, and 2019 was $25 million, $17 million, and $25 million, respectively.
PSUs
PSUs provide meaningful incentives for management to execute on the longer-term financial and strategic growth goals. We
granted PSUs to members of our management team as well as certain key employees. Our 2020 PSU plan design included PSUs
granted subject to specific performance conditions with one-year vesting performance cycles over a three-year term. Our 2021
PSU plan design grants shares subject to annual targets over a three-year period where the annual targets are set at the beginning
of the three-year performance period. The 2021 PSU awards will vest at the end of the three-year performance period.
We recognized $11 million in expense for PSUs in 2021 and $3 million in expense in 2020.
Employee Stock Purchase Plan
In 2019, we adopted the ESPP and approved 2 million shares for issuance under this plan. The ESPP is administered by the
compensation committee.
The ESPP provides for the issuance of shares of our common stock to participating employees. At the end of each designated
offering period, which occurs every six months on May 31 and November 30, employees can elect to purchase shares of our
common stock with contributions up to a maximum of 15% of their base pay or eligible base pay up to the Section 423 of the
Internal Revenue Code limit of $25,000, which is accumulated via payroll deductions, at an amount equal to 85% of the lower of
our stock price on (i) the first day of the offering period, or (ii) the last day of the offering period. For the years ended
December 31, 2021, 2020, and 2019, activity under the ESPP was not material.
Annual Incentive Plan
In 2019, our compensation committee adopted the AIP. The AIP provides pay for performance incentive compensation to our
employees, including our named executive officers, rewarding them for their contributions to us with incentive compensation
based on attainment of predetermined corporate performance goals, as applicable. Compensation expense associated with the AIP
for the years ended December 31, 2021, 2020 and 2019 was $11 million, $16 million, and $7 million, respectively.
401(k) Plan
Covetrus maintains a qualified 401(k) plan covering eligible employees of certain of the U.S. entities as well as certain other
defined contribution plans. Matching contributions and administrative expenses related to these plans for the years ended
December 31, 2021, 2020, and 2019 was $11 million, $11 million, and $9 million, respectively.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
78
13. INCOME TAXES
Income (loss) before taxes were as follows:
Years Ended
(In millions)
December 31, 2021
December 31, 2020
December 31, 2019
Domestic
$
(98) $
(164) $
(809)
Foreign
44
140
(220)
Total income (loss) before taxes
$
(54) $
(24) $
(1,029)
The provisions for income taxes were as follows:
Years Ended
(In millions)
December 31, 2021
December 31, 2020
December 31, 2019
Current income tax (benefit) expense:
U.S. federal
$
(1) $
1 $
—
State and local
1
2
2
Foreign
22
22
16
Total current income tax (benefit) expense
22
25
18
Deferred income tax (benefit) expense:
U.S. federal
(13)
(25)
(46)
State and local
(4)
(1)
(10)
Foreign
(5)
(6)
(8)
Total deferred income tax (benefit) expense:
(22)
(32)
(64)
Total income tax (benefit) expense
$
— $
(7) $
(46)
Significant components of our deferred tax assets and liabilities were as follows:
Years Ended
(In millions)
December 31, 2021
December 31, 2020
Deferred income tax assets:
Net operating losses and other carryforwards
$
57 $
43
Lease liability
27
20
Stock based compensation
8
6
Accrued compensation
7
7
Inventory
4
5
Other assets
11
9
Total deferred income tax assets
114
90
Valuation allowance for deferred tax assets
(27)
(11)
Deferred income tax assets, net of valuation allowance
87
79
Deferred income tax liabilities:
Intangibles amortization
(55)
(74)
Lease asset
(24)
(17)
Accelerated depreciation
(7)
(5)
Other liabilities
(2)
(2)
Total deferred income tax liabilities
(88)
(98)
Deferred income tax assets (liabilities), net of valuation allowance
$
(1) $
(19)
The deferred income tax assets (liabilities) are classified in the consolidated balance sheets as follows:
(In millions)
December 31, 2021
December 31, 2020
Non-current deferred income tax assets, net (a)
$
12 $
9
Non-current deferred income tax liabilities, net
(13)
(28)
Non-current deferred income tax assets (liabilities)
$
(1) $
(19)
(a) Included in other non-current assets
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
79
The valuation allowance was $27 million as of December 31, 2021 and $11 million as of December 31, 2020. In assessing the
realizability of deferred tax assets, management considers whether it is more likely than not that some or all the deferred tax assets
will be realized. The ultimate realization of deferred taxes assets is dependent upon generation of future taxable income during the
period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income, and taxable income in carryback years and tax-planning strategies when making this
assessment. Significant pieces of objective negative evidence evaluated are the U.S. and certain non-U.S. cumulative losses
incurred over the three-year period ended December 31, 2021. Such objective evidence limits the ability to consider other
subjective evidence. The change in valuation allowance for the year ended December 31, 2021 was $16 million and was primarily
attributable to an increase related to the uncertainty regarding the realization of future tax benefits of tax losses and other deferred
tax assets from certain U.S. and non-U.S. jurisdictions. The table below summarizes the change in valuation allowance for the
year.
(In millions)
December 31, 2021
December 31, 2020
Valuation allowance for deferred tax assets, beginning of year
$
11 $
10
Current year expense, net
17
1
Foreign exchange and other
(1)
—
Valuation allowance for deferred tax assets, end of year
$
27 $
11
On December 31, 2021, we had the following tax loss and tax credit carryforwards available to offset taxable income in prior and
future years:
(In millions)
Amount
Expiration Period
U.S. federal tax loss carryforwards
$
26
2030 - unlimited
Non-U.S. tax loss carryforwards
11
2022 - unlimited
U.S. federal and state interest carryforwards
8
unlimited
U.S. state tax loss carryforwards
5
2024 - unlimited
U.S. federal other credit carryforwards
4
2030-2041
Non-U.S. interest carryforwards
3
unlimited
Total tax loss and tax credit carryforwards
$
57
The non-U.S. tax loss carryforwards were incurred in various jurisdictions, predominantly in Germany and France. The U.S. state
tax loss carryforwards were incurred in various jurisdictions.
The tax provision (benefit) differs from the amount computed by applying the federal statutory income tax rate due to the
following:
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
80
Years Ended
December 31, 2021
December 31, 2020
December 31, 2019
Income tax provision at federal statutory rate
21.0 %
21.0 %
21.0 %
Return to Provision impacts
9.0
12.1
—
Foreign income tax (benefit) provision
5.2
15.7
0.3
State income tax provision, net of federal income tax effect
3.9
(3.7)
0.9
Credits
2.3
6.6
—
Reverse Book Gain/(Loss) on Foreign Sales
—
69.2
0.3
Impact of Partnership Inside/Outside Basis Conversion
—
7.5
—
Revaluation of deferred tax assets and liabilities
—
—
(0.9)
Goodwill impairment
—
—
(14.4)
Tax on GILTI
—
(42.6)
(0.9)
Impact of Uncertain Tax Positions
(1.0)
2.2
0.1
Non-deductible foreign exchange gains/(losses)
(1.8)
2.4
—
Non-deductible expenses
(1.9)
(23.6)
(0.6)
Non-deductible interest
(3.4)
(8.1)
—
Excess tax benefits related to share-based compensation
(3.5)
(28.4)
(0.5)
Valuation allowance impacts
(31.7)
(2.2)
(0.5)
Other
3.0
0.8
(0.3)
Effective tax rate
1.1 %
28.9 %
4.5 %
We file U.S. federal and various state and local income tax returns as well as income tax returns in 22 foreign jurisdictions. Tax
returns are generally subject to examination for a period of three to five years after the filing of the respective return. The tax
years subject to examination by major tax jurisdictions include the years 2018 and forward by the U.S. Internal Revenue Service,
the years 2017 and forward for certain state and local jurisdictions, and the years 2014 and forward for certain foreign
jurisdictions.
We elect to recognize the tax on GILTI as a period expense in the period the tax is incurred. There was no tax expense recorded
related to GILTI for the year ended December 31, 2021. We have recorded tax expense for the GILTI provision of $10 million for
the years ended December 31, 2020 and December 31, 2019.
We previously considered the earnings in all of our foreign subsidiaries as indefinitely reinvested. Accordingly, we had not
recorded deferred income taxes with respect to such earnings. However, during the year ended December 31, 2020, we considered
changes in our business and emerging funding needs and determined that certain unremitted earnings of approximately
$135 million existing in the Company’s foreign subsidiaries located in various jurisdictions are no longer indefinitely reinvested.
As a result of U.S. Tax Reform, unremitted earnings can generally be remitted to the U.S. without incurring additional U.S.
federal income taxation. In addition, earnings repatriated from the jurisdictions noted above, based upon our current legal
structure, can generally be repatriated without incurring any withholding tax liability. Accordingly, we determined that the
deferred tax liability associated with the repatriation of the undistributed earnings from the applicable subsidiaries located in these
tax jurisdictions was not material and accrued the liability for the years ended December 31, 2021 and December 31, 2020. The
Company has not provided for deferred taxes on outside basis differences in our investments in our foreign subsidiaries that are
unrelated to unremitted earnings as these basis differences will be indefinitely reinvested. A determination of the unrecognized
deferred taxes related to these other components of our outstanding basis differences is not practicable to calculate.
The accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions
contained within the guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial
statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be
recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount
recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate audit
settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such
examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in
respect to certain tax matters.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
81
The following table provides a reconciliation of unrecognized tax benefits which are included in other liabilities within the
consolidated balance sheets:
(In millions)
December 31, 2021
December 31, 2020
Balance at beginning of period
$
3 $
4
Additions based on prior year tax positions
2
(1)
Reductions from settlements with taxing authorities
(2)
—
Balance at end of period
$
3 $
3
14. FAIR VALUE
Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
The following table presents our financial instruments measured at fair value on a recurring basis and indicates the level within
the fair value hierarchy (in millions):
(In millions)
Level
December 31, 2021
December 31, 2020
Interest rate swap contracts (a)
2
$
— $
5
Total liabilities
$
— $
5
(a) These interest rate swaps matured on July 31, 2021. See Note 15 - Derivatives
Interest Rate Swap Contracts
Our five interest rate swap contracts which were over-the-counter and were not traded through an exchange matured on July 31,
2021. The fair values of our swap contracts were determined based on inputs that are readily available in public markets or can be
derived from information available in publicly quoted markets. See Note 15 - Derivatives.
Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
Certain assets and liabilities may be required to be measured at fair value on a nonrecurring basis. We do not periodically adjust
carrying value to fair value for these assets or liabilities; rather, the carrying value of the asset is reduced to its fair value when
there is evidence of impairment.
During the year ended December 31, 2021, we recorded an impairment of intangible assets of $6 million included in selling,
general and administrative expense in our consolidated statements of operations in our North America segment. The fair value of
the intangible assets was determined to be zero as such assets were deemed to have no future economic benefit based on the
market participant assumptions and no expected future cash flows. See Note 6 - Goodwill and Other Intangibles, Net.
During the year ended December 31, 2020, we recorded an operating lease right-of-use asset impairment of $8 million included in
Selling, general and administrative expense in our consolidated statements of operations in our North America segment as this
asset group was not recoverable based on COVID-19's effect on the subleasing market as well as other asset group specific
factors. The fair value of the operating lease right-of-use asset was $8 million, determined using the discounted expected cash
flow. The significant unobservable inputs utilized in this Level 3 fair value measurement included market rent assumptions and
discount rate.
Assets and Liabilities that are not Measured at Fair Value
Financial Assets and Liabilities
The carrying amounts reported on the consolidated balance sheets for cash and cash equivalents, accounts receivables, other
receivables, accounts payable, and accrued expenses approximate their fair value due to the short maturity of those instruments.
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
82
Long-Term Debt
Our Long-term debt is classified as a Level 2 instrument. The carrying amount of the term loan facility approximates fair value
given the underlying interest rate applied to such amounts outstanding is currently reset to the prevailing monthly market rate. See
Note 7 - Long-Term Debt and Other Borrowings, Net.
15. DERIVATIVES
We are exposed to the impact of changes in foreign currency exchange rates and interest rates in the normal course of business.
Our financial risk management program is designed to manage the exposure arising from this cash flow risk and uses derivative
financial instruments to minimize this risk. We do not enter into derivative financial instruments for trading or speculative
purposes.
In December of 2021, we executed foreign currency exchange rate forward contracts in currency pairs for EUR, AUD, NZD
versus USD. These foreign currency forward agreements related to foreign currency balance sheet exposure resulting from
intercompany loans and provide economic hedges but were not designated as hedges for accounting purposes. The terms of these
forward contracts are approximately one month and are expected to be settled in cash upon maturity.
In 2019, we executed interest rate swaps that were designated as cash flow hedges to manage interest rate risk on our floating rate
debt. These interest rate swap contracts adjusted the amount of our total debt that is subject to variable interest rates by effectively
fixing the borrowing rates on a portion of our floating rate debt discussed in Note 7 - Long-Term Debt and Other Borrowings, Net.
These agreements matured on July 31, 2021.
Our interest rate swap agreements exchanged payment streams based on the notional principal amount. These agreements fixed
our interest rates ranging from 1.63% to 1.70% plus the applicable margin as provided in our debt agreement on an amount of our
debt principal equal to the then-outstanding swap notional amount. On the interest rate swap inception dates, we designated the
swaps as a hedge of the variability in cash flows to be paid on our variable rate borrowings.
The following table discloses the notional amounts and fair value of our derivative instruments included in other current liabilities
or other liabilities on our consolidated balance sheets:
December 31, 2021
December 31, 2020
(In millions)
Notional Amount
Liability
Notional Amount
Liability
Non-Designated Hedging Instruments
Foreign currency exchange rate forward contracts
$
56 $
— $
— $
—
Designated Cash Flow Hedging Instruments
Interest rate swap contracts
—
—
500
5
Total contracts
$
56 $
— $
500 $
5
The following table discloses the effect of our derivative instruments on our consolidated statements of operations:
Years Ended
(In millions)
Location
December 31, 2021
December 31, 2020
December 31, 2019
Interest rate swap contracts
Interest (income) expense
$
5 $
5 $
1
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
83
16. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
The following table presents the changes in accumulated other comprehensive income (loss), net of applicable taxes, by
component:
(In millions)
Derivative
Gain (Loss)
Foreign
Currency
Translation
Gain (Loss)
Total
Balance as of December 29, 2018
$
— $
(82) $
(82)
Other comprehensive income (loss) attributable to Covetrus before reclassifications
(1)
(4)
(5)
Reclassified from Accumulated other comprehensive loss to earnings
1
—
1
Period Change
—
(4)
(4)
Balance as of December 31, 2019
—
(86)
(86)
Other comprehensive income (loss) attributable to Covetrus before reclassifications
(8)
21
13
Reclassified from Accumulated other comprehensive loss to earnings
5
2
7
Period Change
(3)
23
20
Balance as of December 31, 2020
(3)
(63)
(66)
Other comprehensive income (loss) attributable to Covetrus before reclassifications
(2)
(16)
(18)
Reclassified from Accumulated other comprehensive loss to earnings
5
—
5
Period Change
3
(16)
(13)
Balance as of December 31, 2021
$
— $
(79) $
(79)
Comprehensive income (loss) includes certain gains and losses that are excluded from net income (loss) under GAAP as these
amounts are recorded directly as an adjustment to total equity. We recognize foreign currency translation losses as a component of
comprehensive income (loss) due to changes in foreign exchange rates from the beginning of the period to the end of the
period. Fluctuations in the value of foreign currencies as compared to USD may have a significant impact on comprehensive
income (loss). The tax effect on the components comprehensive income (loss) were not material for the periods presented.
17. EARNINGS (LOSS) PER SHARE
The following is a reconciliation of the numerator and denominator of the basic and diluted EPS computation for net (loss)
earnings per share:
(In millions, except per share data)
December 31, 2021
December 31, 2020
December 31, 2019
Numerator:
Net income (loss) attributable to Covetrus
$
(54) $
(19) $
(980)
Adjustment for:
Dividends declared on Series A preferred stock
—
(7)
—
Net income (loss) available to common shareholders
$
(54) $
(26) $
(980)
Denominator:
Basic
Weighted-average common shares outstanding
137
118
107
Diluted
Effect of dilutive shares
—
—
—
Weighted-average common shares outstanding
137
118
107
Earnings (loss) per share:
Basic - EPS
$
(0.39) $
(0.22) $
(9.14)
Diluted - EPS
$
(0.39) $
(0.22) $
(9.14)
Potentially dilutive securities (a)
5
6
6
(a) Potentially dilutive securities include stock options, RSUs, RSAs, PSUs, ESPP, and the Series A Preferred Stock (until converted) which are excluded from
the computation of diluted earnings per share because the securities would have had an antidilutive effect
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
84
18. RELATED-PARTY TRANSACTIONS
Upon closing the transaction with Distrivet, S.A., Distrivet, our equity method investee, became a related party. See Note 5 -
Divestitures and Equity Method Investments). During the year ended December 31, 2021 and 2020, we provided management
services and corporate branding to Distrivet under our agreement, and we provided goods to Distrivet. During the year ended
December 31, 2021, product sales to Distrivet were $1 million. For the year ended December 31, 2020 these services and product
sales were not material.
As of December 31, 2021, CD&R beneficially owns 24.40%, or approximately 33.7 million shares of our outstanding common
stock and are deemed a related party. As part of the terms of the Investment Agreement, CD&R had the right to designate two
members to our Board of Directors, which resulted in increasing the number of directors serving on the board. CD&R's current
designees on our Board of Directors are Ravi Sachdev (investor board member) and Sandra E. Peterson (advisor board member).
CD&R’s right to representation on our board is directly related to their level of share ownership. Should CD&R's beneficial
ownership decrease below 50% of its ownership as of May 19, 2020 or below approximately 16.8 million shares, then its right to
designate an advisor board member terminates. Should CD&R's beneficial ownership decrease below 25% of its ownership as of
May 19, 2020 or below approximately 8.4 million shares, then its right to designate an investor board member is also terminated.
19. REDEEMABLE NON-CONTROLLING INTERESTS
The following table presents the components of change and balances of redeemable non-controlling interests within the
consolidated balance sheets as of:
(In millions)
December 31, 2021
December 31, 2020
December 31, 2019
Balance at beginning of period
$
36 $
10 $
92
Decrease due to redemptions
(13)
(4)
(74)
Increase due to business acquisitions (a)
—
24
—
Net income (loss) attributable to redeemable non-controlling interests
—
2
(3)
Dividends declared
(2)
—
—
Effect of foreign currency translation (gain) loss attributable to
redeemable non-controlling interests
—
(2)
1
Change in redemption value
2
6
(6)
Balance at end of period
$
23 $
36 $
10
(a) See Note 4 - Business Acquisitions
COVETRUS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Covetrus, Inc. 2021 Form 10-K
85
(i)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of our assets,
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in
accordance with authorizations of our management and directors, and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
our assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may change.
Our management, with the participation of our CEO and our CFO, evaluated the effectiveness of our internal control over
financial reporting at December 31, 2021. Based on this evaluation, the CEO and CFO concluded that as of that date, our internal
control over financial reporting was effective, at a reasonable assurance level.
Remediation of Material Weakness
As previously disclosed in our Form 10-K for the year ended December 31, 2020, management identified deficiencies in our
internal control over financial reporting which related to the following (i) accounting for income taxes, and (ii) deferred tax asset
calculation errors and determined that the impact of these deficiencies resulted in a material weakness. This material weakness
stemmed from issues associated with the transition to expanded in-house tax capabilities and utilization of new tax consultants. As
a result of these issues, our controls to review and analyze our income tax provision and deferred income tax balances were not
effective.
We remediated this material weakness by implementing the following:
•
Enhanced the capabilities of the tax accounting team, including the hiring of a new Vice President of Tax
•
Enhanced policies, procedures, and controls relating to significant judgments impacting our income tax accounts
•
Increased management oversight of the calculation and reporting of certain tax balances of our global operations,
including deferred income tax balances and the income tax provision
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
None
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Exchange Act, as of the end of the period covered by this report, we carried out an
evaluation under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness
of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, we recognize that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the
desired control objectives, and our management necessarily applies its judgment in evaluating and implementing possible controls
and procedures. Based upon that evaluation, the CEO and CFO concluded that, as of the end of the period covered by this Report,
our disclosure controls and procedures were effective. Management reviewed the results of its assessment with our Audit
Committee. The attestation report concerning the effectiveness of our internal control over financial reporting as of December 31,
2021issued by BDO USA LLP, an independent registered public accounting firm, appears in Item 8 of this Annual Report on
Form 10-K.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in
Rule 13a-15(f) or 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:
Covetrus, Inc. 2021 Form 10-K
86
•
Increased communication to information providers for tax jurisdiction specific information and
•
Strengthened communication and information flows between the tax department and the finance groups
We have assessed the impact of these remediation efforts and have concluded that our previously identified material weakness has
been remediated as of December 31, 2021 and our internal controls over financial reporting are operating effectively.
Changes in Internal Control over Financial Reporting
Other than the remediation of the material weakness discussed above, there were no changes to our internal control over financial
reporting during 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation
of controls can provide absolute assurance that all control issues, if any, within a company have been detected.
Item 9B. Other Information
Not applicable
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable
PART III
Item 10. Directors, Executive Officers, and Corporate Governance
The information required by this item of Form 10-K is incorporated by reference to our definitive proxy statement (which will be
filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2022 Annual Meeting of Shareholders
(our 2022 Proxy Statement).
Item 11. Executive Compensation
The information required by this item is incorporated by reference to our 2022 Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated by reference to our 2022 Proxy Statement.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated by reference to our 2022 Proxy Statement.
Item 14. Principal Accountant Fees and Services
The information required by this item is incorporated by reference to our 2022 Proxy Statement.
Covetrus, Inc. 2021 Form 10-K
87
PART IV
Item 15. Exhibits and Financial Statement Schedules
Page
(a) (1)
Financial Statements: See “Index to Consolidated Financial Statements”
48
(a) (2)
Financial Statement Schedules: None
We have omitted schedules for which provision is made in the applicable accounting regulations of
the SEC because they are not required under the related instructions, or they do not apply.
(a) (3)
Exhibits:
Exhibit
Number
Exhibit Description
Form
Date
No.
2.1
Contribution and Distribution Agreement, dated as of April 20, 2018, by and among
Henry Schein, Inc., HS Spinco, Inc., Direct Vet Marketing, Inc. and Shareholder
Representative Services LLC
S-4
12/26/2018
2.1
2.2
Agreement and Plan of Merger, dated as of April 20, 2018, by and among Henry
Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc., Direct Vet Marketing, Inc. and
Shareholder Representative Services LLC
S-4
12/26/2018
2.2
2.3
Letter Agreement, Amendment No. 1 to Contribution and Distribution Agreement
and Amendment No. 1 to Agreement and Plan of Merger, dated as of September 14,
2018, by and among Henry Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc.,
Direct Vet Marketing, Inc. and Shareholder Representative Services LLC
S-4
12/26/2018
2.3
2.4
Letter Agreement and Amendment No. 2 to Contribution and Distribution
Agreement, dated as of November 30, 2018, by and among Henry Schein, Inc., HS
Spinco, Inc., Direct Vet Marketing, Inc. and Shareholder Representative Services
LLC
S-4
12/26/2018
2.4
2.5
Letter Agreement, Amendment No. 3 to Contribution and Distribution Agreement
and Amendment No. 2 to Agreement and Plan of Merger, dated as of December 25,
2018, by and among Henry Schein, Inc., HS Spinco, Inc., HS Merger Sub, Inc.,
Direct Vet Marketing, Inc. and Shareholder Representative Services LLC
S-4
12/26/2018
2.5
2.6
Letter Agreement and Amendment No. 4 to Contribution and Distribution
Agreement, dated as of January 15, 2019, by and among Henry Schein, Inc., HS
Spinco, Inc., Direct Vet Marketing, Inc. and Shareholder Representative Services
LLC
S-4/A
1/15/2019
2.6
3.1
Second Amended and Restated Certificate of Incorporation of Covetrus, Inc.
10-Q
5/6/2021
3.1
3.2
Amended and Restated Bylaws of Covetrus, Inc.
S-4/A
1/8/2019
3.5
3.3
Certificate of Designations Classifying Series A Convertible Preferred Stock
8-K
5/19/2020
3.1
4.1
Specimen Common Stock Certificate
S-4/A
1/8/2019
4.1
4.2*
Description of the Registrant’s Securities registered pursuant to Section 12 of the
Securities Exchange Act of 1934
10.1
Credit Agreement, dated as of February 7, 2019, by and among Vet Intermediate
Holdco II, LLC, JP Morgan Chase Bank, N.A., and the several banks and other
financial institutions from time to time party thereto
8-K
2/7/2019
10.1
10.2
Guarantee and Collateral Agreement, dated as of February 7, 2019, by and among
Vet Intermediate Holdco II, LLC and JP Morgan Chase Bank, N.A.
8-K
2/7/2019
10.2
10.3
Employee Matters Agreement, dated as of April 20, 2018, by and among Henry
Schein, Inc., HS Spinco, Inc. and Direct Vet Marketing, Inc.
S-4
12/26/2018
10.1
10.4
Transition Services Agreement, dated as of February 7, 2019, by and between Henry
Schein, Inc. and HS Spinco, Inc.
8-K
2/7/2019
10.4
10.5
Letter Agreement to Transition Services Agreement, dated as of February 7, 2019,
by and between Covetrus, Inc. and Henry Schein, Inc.
8-K
2/7/2019
10.5
Covetrus, Inc. 2021 Form 10-K
88
Exhibit
Number
Exhibit Description
Form
Date
No.
10.6
Tax Matters Agreement, dated as of January 7, 2019, by and among Henry
Schein, Inc., HS Spinco, Inc. and Direct Vet Marketing, Inc.
S-4/A
1/8/2019
10.3
10.7
Escrow Agreement, dated as of February 7, 2019, by and among Henry Schein,
Inc., HS Spinco, Inc., Shareholder Representative Services LLC and Continental
Stock Transfer & Trust Company
8-K
2/7/2019
10.3
10.8†
Form of Indemnification Agreement between HS Spinco, Inc. and each of its
directors and executive officers
S-4
12/26/2018
10.5
10.9†
Direct Vet Marketing, Inc. 2010 Stock Incentive Plan
S-4
12/26/2018
10.6
10.10†
Amendment to Direct Vet Marketing, Inc. 2010 Stock Incentive Plan dated
June 30, 2017
S-4
12/26/2018
10.7
10.11†
Amendment to Direct Vet Marketing, Inc. 2010 Stock Incentive Plan dated
December 6, 2017
S-4
12/26/2018
10.8
10.12†
Covetrus 2019 Omnibus Incentive Compensation Plan, and forms of agreement
thereunder
S-4
12/26/2018
10.9
10.13†
Covetrus Employee Stock Purchase Plan
S-4
12/26/2018
10.10
10.14†
Covetrus Annual Incentive Plan
S-4/A
1/8/2019
10.11
10.15†
Amended and Restated Employment Agreement, effective as of May 4, 2021, by
and between the Company and Michael Ellis
10-Q
5/6/2021
10.1
10.16†
Amended Transformation Performance Stock Unit Agreement
10-Q
5/6/2021
10.2
10.17†
2021 Performance Stock Unit Agreement
10-Q
5/6/2021
10.3
10.18†
2021 Performance Stock Unit Agreement for Non-U.S. Participants
10-Q
5/6/2021
10.4
10.19†
Employment Agreement, dated as of February 7, 2019, by and between HS
Spinco, Inc. and Georgina Wraight
8-K
2/7/2019
10.12
10.20
Lease Agreement, dated as of August 20, 2018, by and between 86 Newbury
Street LLC and Direct Vet Marketing, Inc.
S-4
12/26/2018
10.16
10.21
Lease Agreement, dated as of August 20, 2018, by and between 86 Newbury
Street LLC and VFC Pharmacy #101, LLC
S-4
12/26/2018
10.17
10.22
Lease Agreement, dated as of June 22, 2018, by and between Northgate Office,
LLC and Direct Vet Marketing, Inc.
S-4
12/26/2018
10.18
10.23
Stock Subscription and Purchase Agreement, dated as of December 25, 2018, by
and among Henry Schein, Inc., HS Spinco, Inc. and the purchasers party thereto
S-4
12/26/2018
10.19
10.24
Registration Rights Agreement, dated as of December 25, 2018, by and among
HS Spinco, Inc. and the other parties thereto
S-4
12/26/2018
10.20
10.25†
Non-Employee Director Compensation Policy of Covetrus, Inc.
8-K
3/5/2019
10.7
10.26†
Employment Agreement, dated as of March 30, 2020, by and between Covetrus,
Inc. and Benjamin Wolin
8-K
3/24/2020
10.1
10.27†
Amended and Restated Employment Agreement, effective as of November 9,
2020, by and between the Company and Dustin Finer
10-Q
11/10/2020
10.1
10.28†
Employment Agreement, effective as of June 1, 2020, by and between the
Company and Matthew Foulston
8-K/A
6/30/2020
10.1
10.29†
Form of Performance Stock Unit Agreement
8-K
1/21/2020
10.1
10.30†
Form of Performance Stock Unit Agreement for Non-U.S. Participants
8-K
1/21/2020
10.2
10.31
First Amendment, dated as of February 27, 2020, to the Credit Agreement dated
as of February 7, 2019, by and among Vet Intermediate Holdco II, LLC, JP
Morgan Chase Bank, N.A., and the several banks and other financial institutions
from time to time
10-K
3/3/2020
10.31
Covetrus, Inc. 2021 Form 10-K
89
Exhibit
Number
Exhibit Description
Form
Date
No.
10.32†
Separation and Release Agreement, effective as of February 13, 2020, by and
between the Company and David Christopher Dollar
8-K/A
2/2/2020
10.1
10.33
Investment Agreement, dated as of April 30, 2020, between Covetrus, Inc. and
CD&R VFC Holdings, L.P.
8-K
5/1/2020
10.1
10.34
Registration Rights Agreement, dated as of May 19, 2020, by and between
Covetrus, Inc. and CD&R VFC, L.P.
8-K
5/19/2020
10.1
21.1*
Subsidiaries of the Registrant
23.1*
Consent of BDO USA, LLP, Independent Registered Public Accounting Firm
31.1*
Certification of the Chief Executive Officer, as required by Section 302 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)
31.2*
Certification of the Chief Financial Officer, as required by Section 302 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)
32.1**
Certification of the Chief Executive Officer, as required by Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)
32.2**
Certification of the Chief Financial Officer, as required by Section 906 of the
Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
*
Filed herewith
**
Furnished and not filed herewith
†
Indicates management contract or compensatory plan
Item 16. Form 10-K Summary
None
Covetrus, Inc. 2021 Form 10-K
90
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
COVETRUS, INC.
Date: February 28, 2022
By: /s/ Benjamin Wolin
Benjamin Wolin
President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.
Name
Title
Date
/s/ Benjamin Wolin
President, Chief Executive Officer and Director
(Principal Executive Officer)
February 28, 2022
Benjamin Wolin
/s/ Matthew Foulston
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
February 28, 2022
Matthew Foulston
/s/ Andrew B. Coxhead
Vice President, Corporate Controller and Chief
Accounting Officer (Principal Accounting Officer)
February 28, 2022
Andrew B. Coxhead
/s/ Philip A. Laskawy
Chairman of the Board and Director
February 28, 2022
Philip A. Laskawy
/s/ Paul R. Fonteyne
Director
February 28, 2022
Paul R. Fonteyne
/s/ Deborah G. Ellinger
Director
February 28, 2022
Deborah G. Ellinger
/s/ Sandra L. Helton
Director
February 28, 2022
Sandra L. Helton
/s/ Mark J. Manoff
Director
February 28, 2022
Mark J. Manoff
/s/ Edward M. McNamara
Director
February 28, 2022
Edward M. McNamara
/s/ Steven Paladino
Director
February 28, 2022
Steven Paladino
/s/ Sandra E. Peterson
Director
February 28, 2022
Sandra E. Peterson
/s/ Ravi Sachdev
Director
February 28, 2022
Ravi Sachdev
/s/ Sharon Wienbar
Director
February 28, 2022
Sharon Wienbar
Covetrus, Inc. 2021 Form 10-K
91
Executive Officers
Benjamin Wolin
President and Chief Executive Officer
Matthew Foulston
Executive Vice President
and Chief Financial Officer
Andrew Coxhead
Vice President, Corporate Contoller
and Chief Accounting Officer
Dustin K. Finer
Chief Administrative Officer
Rebecca Kidd
Head of Global Operations
Matthew Malenfant
Chief Commercial Officer
Georgia Wraight
Executive Vice President and
President, Global Technology Solutions
Independent Public
Accountants
BDO USA, LLP
One International Place
Boston, MA 02110
Worldwide Headquarters
Covetrus, Inc.
7 Custom House Street
Portland, ME 04101
888-280-2221
covetrus.com
Annual Meeting
2022 Annual Meeting
of Shareholders
Virtual meeting
May 11, 2022 | 10:00 am EDT
Common Stock Listing
Nasdaq Global Select
Market Symbol:
CVET
Investor Relations
Nicholas Jansen
nicholas.jansen@covetrus.com
Transfer Agent
Continental Stock Transfer
& Trust Company
1 State Street, 30th Floor
New York, NY 10004-1561
Outside Legal Counsel
Weil, Gotshal & Manges
100 Federal Street, 34th Floor
Boston, MA 02110
Board of Directors
Philip A. Laskawy
Chairman of the Board
Deborah G. Ellinger
Paul Fonteyne
Sandra L. Helton
Mark J. Manoff
Edward M. McNamara
Steven Paladino
Sandra Peterson
Ravi Sachdev
Sharon Wienbar
Benjamin Wolin
We are the leading tech-enabled service
company in the animal health industry
Software Services
Client communications &
telemedicine Practice management
software Payment processing
Supply Chain Services
Logistics & distribution
Inventory Management
Proprietary Brands
Prescription Management
Rx services & compounding
E-commerce solutions
Client engagement
Covetrus is a global animal-health company dedicated to empowering veterinary practices. We combine products,
services, and technology in a single platform that connects our customers to the solutions and insights they need to grow.
Our current product and service offerings across our segments:
North America Segment:
In broad categories, we offer supply
chain services, software services, and
prescription management.
Europe Segment:
We offer supply chain services and
software services to our customers
and animal-owners.
Asia-Pacific and Emerging
Markets Segment:
We offer supply chain services and
software services to our customers
and animal-owners.
Our major products and services categories are described below: